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Abstract 
 
Engineered Biosynthesis of Fluorinated Polyketides 
by 
 Benjamin Williams Thuronyi 
Doctor of Philosophy in Chemistry 
University of California, Berkeley 
Professor Michelle C. Y. Chang, Chair 
 
 
Natural products use exquisite structural complexity to tailor a limited repertoire of 
functional groups for different molecular functions. These molecules have been adopted or 
adapted by humans to create a large fraction of current therapeutics. However, those adaptations 
have not always been able to combine the chemical diversity possible for totally synthetic 
compounds with the many advantages of biosynthesis. Extremely rare in nature but ubiquitous in 
synthetic pharmaceuticals, fluorine is a unique tool for molecular design, and an excellent 
candidate for expanding biosynthetic diversity. This dissertation describes our work to enable 
efficient fluorine incorporation into complex biosynthetic pathways, both in vitro and in the 
context of a whole organism, and our progress in enabling fluorinated polyketide biosynthesis. 
We hope to set the stage for a dramatic expansion in polyketide structural diversity via 
engineered biosynthesis, using a design element that could improve bioactive properties and 
furnish new therapeutics. 
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1.1. Natural products and their analogs in medicine 
Antibiotics are a hugely important part of modern medicine. Bacterial infections that would 
once have meant a death sentence have become only an inconvenience. However, resistance to 
antibiotics has posed a problem since the first antibiotic was discovered. There is often a 
relatively short window between the introduction of a new antibiotic to the clinic and emergence 
of bacterial resistance to that antibiotic (Figure 1.1), and resistance mechanisms may be as 
ancient as antibiotics themselves [1,2]. This is at least in part because antibiotic use imposes a 
strong selective pressure on bacteria to either develop resistance de novo or enrich for resistance 
that already exists within a population. Multi-drug resistant bacteria are an increasingly common 
cause of death, and represent a growing public health crisis [3].  
Antibiotic use places us in an arms race with bacteria, requiring us to use existing antibiotics 
judiciously, but also to continue introducing new ones, preferably with novel mechanisms of 
action. However, this process has not proven easy to maintain. Instead, antibiotic resistant strains 
are emerging more rapidly while introduction of new antibiotics has declined. The peak years for 
FDA antibiotic approvals were 1980-1995, followed by a steep drop (Figure 1.2). 
One of the main causes of this decline is the nature of the source for the vast majority of 
antibiotics (and indeed, of a significant fraction of all human therapeutics): natural products and 
their derivatives (Figure 1.2) [2,4]. Screening microbial isolates from soil samples or other 
sources for antibiotic activity has revealed numerous classes of antibiotic natural products. 
However, continued screening efforts suffer from diminishing returns as a higher and higher 
percentage of hits represent known compounds. Both the difficulty and importance of natural 
penicillin
penicillin
tetracycline
tetracycline
erythromycin
erythromycin
methicillin
methicillin
gentamycin
gentamycin
vancomycin
vancomycin
imipenem, ceftazidime
ceftazidime
imipenem
levofloxacin levofloxacin
linezolid linezolid
daptomycin
daptomycin
ceftaroline ceftaroline
1940
1950
1960
1970
1980
1990
2010
Antibiotic
introduced
Resistance
observed
Figure 1.1. Timeline showing the dates of clinical introduction of major antibiotic classes and 
the first observation of resistant bacteria. Adapted from Antibiotic Resistance Threats in the 
United States, 2013, CDC. 
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antibiotic sources are highlighted by the recent 
excitement over an ingenious method to make 
difficult-to-culture organisms accessible to 
screening, resulting in discovery of a new 
antibiotic [5]. Furthermore, considerable 
resources are being devoted to metagenomic 
sequencing and high throughput or in silico 
prediction of natural product biosynthetic 
clusters that may produce leads for new drugs  
[6-8]. 
Along with discovery efforts, another 
critical source of new antibiotics comes from 
derivatization of natural products or generation 
of structural analogs. Strikingly small changes 
to drug structures can improve potency, 
increase effectiveness against drug-resistant 
bacteria, or alter distribution, bioavailability 
and stability of drugs. Therefore, making 
chemical modifications and exploring the structure-activity relationships of existing drugs – and 
natural products – is a rich source of new therapeutics. 
However, methods to carry out such modifications are often limited. A hallmark of natural 
products is their structural complexity, including multiple stereocenters and diverse functional 
groups. These compounds are accessible by total synthesis but usually only at considerable effort 
and expense. The most common method to produce natural product analogs is to chemically 
derivatize the natural product itself, which is obtained from the producing organism (or 
sometimes a heterologous host), in a process known as semisynthesis. This strategy takes 
advantage of the relatively high efficiency and inexpensive feedstocks of native producer 
biosynthetic machinery, but it is constrained by the chemical reactivity of the natural product; 
not every desired transformation can be carried out selectively without unwanted side-reactions 
or degradation. 
A desirable goal, therefore, is a method that combines the fine structural control available to 
total synthesis with the efficiency and selectivity of biosynthetic enzymes. Considerable progress 
has been made to engineer and adapt biosynthetic assembly lines to accomplish this. The natural 
product biosynthesis enzymes that are most amenable to engineering are modular assembly lines, 
where the natural product is a tailored polymer and each monomer unit is added by a distinct 
biosynthetic module. Many polyketides and all non-ribosomal peptides, which together represent 
more than 104 natural products, are made this way. This programmed biosynthesis can then be 
altered to make specific changes to the output structure. 
Figure 1.2. FDA antibiotic approvals over time. Antibiotics that 
are unmodified natural products, are close analogs of natural 
products, or incorporate a natural product pharmacophore are 
shown in red; synthetic antibiotics are in blue. Data is 
compiled from Wikipedia and [2]. 
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Modular polyketide synthases (PKSs) specifically have been engineered in several ways that 
change the chemical composition of the backbone (Figure 1.3). Blocked assembly lines, where 
the initial modules have been inactivated, can be used to extend a completely synthetic precursor 
to a full-length natural product derivative [9,10]. The module that selects the organic acid starter 
unit, the monomer that initiates biosynthesis, is often promiscuous or can be replaced with a 
promiscuous module from another PKS [11]. To some extent, modules can be swapped and 
recombined, or specific tailoring domains inactivated, resulting in different chain tailoring and 
monomer arrangements [12-14]. However, such dramatic changes as module swapping almost 
invariably lead to dramatic reductions in assembly line function, and even blocking tailoring 
steps like ketoreduction or dehydration can interfere with downstream reactions in subtle but 
significant ways. Finally, if a unique chain extension monomer is present in the structure, its 
biosynthesis can be blocked and a chemically similar monomer unit fed as a substitute and 
incorporated into the final product [15,16]. 
However, thus far, replacement or modification of the non-unique extender units that make 
up the bulk of each polyketide’s 
structure has not been feasible. The 
enzymatic domains that select these 
monomer units were until recently 
thought to be extremely selective for 
their native substrates, excluding 
non-native extender units from 
incorporation. However, recent work 
has shown that many extender 
selection domains can exhibit 
substrate promiscuity, particularly 
when presented with extender units 
that are not available in their native 
context [17-20]. 
A general strategy to introduce 
new monomers to natural product 
synthesis, particularly for natural 
product classes such as polyketides that rely on a relatively small native monomer pool, would 
dramatically expand natural product structural space. Furthermore, doing so in a modular, 
minimally perturbative manner could enable generation of large libraries of natural product 
analogs from diverse biosynthetic assembly lines. Monomer replacement has the potential to 
make large changes to the chemical composition of a natural product, but may avoid some of the 
difficulties associated with module rearrangement and modification if it can be accomplished in 
the context of a largely intact, native assembly line. 
1.2. Fluorine in medicinal and biological chemistry 
Fluorine-containing molecules are a rarity in nature, with fewer than 25 known examples 
including structural analogues, most of which stem from a single biosynthetic pathway found in 
Streptomyces cattleya (Figure 1.4) [21]. By contrast, other characterized organohalogens number 
in the tens of thousands. This is probably because fluorine is difficult both to access and to 
activate in an aqueous biological setting. Although environmental fluorine is not uncommon, 
Figure 1.3. Strategies to modify biosynthesis of polyketides. 
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most of its mineral salts are highly 
insoluble, and solvated fluoride ion 
is a very poor nucleophile because 
of its tightly bound solvent shell. 
Unlike other halogens, it is 
extremely difficult to oxidize, 
excluding it from many of the 
pathways used in organohalogen 
biosynthesis. The sole 
characterized organofluorine 
synthetic enzyme, the fluorinase 
FlA, desolvates fluoride ion and 
forms 5'-fluorodeoxyadenosine by 
nucleophilic substitution [22,23]. 
In contrast to natural products, 
anthropogenic molecules make heavy use of fluorine. Its distinctive and dramatic properties 
make it useful in drug design, as well as a unique tool for studying enzyme mechanism and 
metabolism. Fluorine’s small size and high electronegativity confer powerful effects on small 
molecule properties, and drug fluorination can improve bioavailability, reduce clearance, alter 
pKa and lipophilicity, block metabolism, or increase potency. Fluorine is now found in 20-30% 
of therapeutics and agrochemicals. 
Because organofluorines are so rare in biological systems, few enzymes have evolved that 
specifically recognize fluorine-containing substrates. The small organofluorine building blocks 
produced by the S. cattleya pathway, fluoroacetate and fluorothreonine, have not been found to 
be elaborated into more complex molecules, with the exception of omega-fluoro fatty acids, 
where fluoroacetate acts only as a chain initiator. Therefore, although natural products are 
extremely diverse and many are highly bioactive, almost none of them leverage the molecular 
properties that fluorine can confer. This element has been excluded from the evolution of 
biosynthesis, and introducing it to the pool of available design elements may produce new 
molecules with improved characteristics. This makes it an excellent candidate for a natural 
product monomer. 
Organofluorine physical organic properties. The physical organic properties of fluorine 
provide the foundation (and rationale) for expanding its role in biology [24-27]. Fluorine is 
considered a sterically conservative substitution for hydrogen or oxygen; the C–F unit is similar 
in size to C=O [25,27]. This means it can be accommodated by many scaffolds without 
disrupting a molecule’s fit in a binding site, an important qualification for being used to 
derivatize pharmaceuticals and other bioactive compounds. 
The C–F bond is extremely strong, largely because it is so polarized that it has substantial 
ionic character (C∂+–F∂-) [28]. Aliphatic fluorine substituents are therefore fairly inert, with 
substitution reactions uncommon and elimination requiring an E1CB mechanism and full 
carbanion formation [28]. This can be useful for blocking metabolism at specific sites in a drug. 
C–F bonds are impervious to enzymes that oxidize organic compounds by hydrogen abstraction, 
and this can give fluorinated compounds much slower clearance rates. 
Figure 1.4. A selection of naturally occurring organofluorines. 
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Fluorine substitution has strong inductive effects on neighboring functional groups, 
activating electrophiles and increasing acidity. However, α-fluoro carbonyl compounds are a 
special case and are less acidic than would be expected. While a fluoroenolate is stabilized by 
induction, it is concomitantly destabilized because fluorine prefers to be bonded to an sp3 rather 
than an sp2 carbon; this is due to unfavorable overlap between the filled p orbitals on F and C-sp2 
and reduction in σ-electron density that can be polarized toward F [27,28].  A methyl group has 
the opposite hybridization preference, so these two substituents can confer similar acidity. By 
contrast, purely inductive effects make fluoroacetic acid over 2 pKa units more acidic than 
propionic or acetic acid. 
Organofluorines are primarily stabilized by dipolar electrostatic interactions [25,28].  
Fluorine is so nonpolarizable that induced dipole effects are weak, and C–F is a poor hydrogen 
bond acceptor, about half as strong as C–OH [27,28]. However, the C–F dipole does interact 
favorably with centers of positive charge, as with the “fluorophilic” Arg side-chain, where the 
C–F bond adopts either a perpendicular or an out-of-plane parallel orientation to the plane of the 
guanidinium group, rather than the in-plane linear hydrogen bonding geometry [25]. It is also 
favorable to orient the C–F dipole toward the carbonyl carbon of a backbone amide or Asn/Gln 
side-chain (0.2-0.3 kcal/mol) [29], or toward the peptide Cα–H bond. [25] 
Because the C–F dipole can only form strong, favorable interactions within significant 
orientational constraints, organofluorines are naturally suited to be ligands. Macromolecule 
binding reduces ligand entropy in most cases, and this cost can be offset by the enthalpic gain 
from a favorable C–F dipole arrangement [25]. Furthermore, the poor hydrogen-bonding ability 
of C–F and its low polarizability make solvation in water relatively unfavorable [30]. Since C−F 
is a poor replacement for H2O, only a few arrangements of water molecules will have their 
dipoles properly oriented to interact favorably with C–F, leading to entropically unfavorable 
ordering of the solvent. As a result, when the C–F unit is desolvated upon macromolecule 
binding the release of ordered water provides an entropic driving force, even in the absence of 
specific C–F dipolar interactions in the binding site. A very polar C–F unit can therefore bind 
favorably in a nonpolar pocket, leading to the description of organofluorines as “polar 
hydrophobic.” [30] 
Fluorine as biochemical probe. Besides its pronounced and potentially useful effects on 
molecular properties, fluorine makes an excellent biochemical tool, either to elucidate how 
natural systems function or to develop new biochemistry [31]. Fluorine’s small size means that 
many enzymes that accept H, OH, CH3 or C=O substituents can tolerate fluorine as well. 
Fluorine can be used as a stereo- or regiochemical label, one that is much easier to install than 
2H, albeit a less perfect 1H mimic. This approach has been used to investigate enzyme 
stereochemistry, since prochiral methylene units become chiral when one hydrogen is replaced 
by fluorine and otherwise cryptic enzyme stereospecificity can therefore be directly observed  
[32,33]. 
The high natural abundance (100%), sensitivity (γ = 252 rad s-1 T-1, compared to 268 for 1H 
or 67 for 13C) and wide chemical shift range of 19F, along with its virtual absence from natural 
biological systems, makes it a superb tool to probe biochemistry using NMR. Fluorination of the 
input molecule for a complex metabolic pathway makes it possible to track and identify all 
intermediates in that pathway without needing any ab initio information about them, as is often 
necessary when using mass spectrometry for the same purpose. The regiochemistry of 
transformations can be followed and the complete fate of the starting metabolite revealed, even 
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in a complex biological mixture such as cell 
lysate. Fluorine NMR has also been used for 
high-throughput screening in drug discovery. 
Many individual fluorine-tagged compounds 
in a single multiplexed assay mixture can be 
distinguished by chemical shift, and those that 
bind to a protein target identified based on 
perturbations in chemical shift or relaxation 
time [34,35]. Fluorinated amino acids can also 
be used to study protein dynamics or 
conformational change using NMR [36]. 
Reactivity of fluorinated building blocks. Use of fluorinated monomers for polyketide 
synthesis will involve fluorine’s effects on reactivity as well as molecular properties. The 
presence of a fluorine substituent at the carbonyl α-position in a starter or extender unit creates 
unique challenges by altering the chemistry and reactivity of acid activation intermediates, chain 
extension units and the growing polyketide chain itself (Figure 1.5). Fluorine activates 
compounds as electrophiles, which makes thioester-tethered biosynthetic intermediates more 
labile to hydrolysis. For example, fluoroacetyl phosphate hydrolyzes 63-fold faster than the 
already highly activated acetyl phosphate at pH 7 [37]. Fluoroacetyl-CoA is hydrolyzed only 10-
fold faster than acetyl-CoA at pH 7, but is up to 110-fold more susceptible when hydroxide ion is 
readily available at pH 11, a scenario that may mimic enzyme-catalyzed hydrolysis [38]. 
Therefore, the stability of the more labile intermediates in polyketide biosynthesis, particularly 
α-fluoro β-keto thioesters, will need to be addressed. Furthermore, fluorine substitution will 
Figure 1.6. Reactions of enzymes with organofluorine substrates resulting in loss of fluoride or covalent enzyme inhibition. Only the 
key step(s) are shown. (A) Cytochrome P450 enzymes. (B) PLP-dependent enzymes. (C) Thymidylate synthase. (D) Ribonucleotide 
reductase. (E) Aconitase. (F) Serine proteases. (G) Cysteine proteases.  
Figure 1.5. Possible derailment pathways for a fluorinated chain 
extender in polyketide biosynthesis.   
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affect the kinetics and thermodynamics of extender unit decarboxylation, enolate generation and 
C–C bond formation during chain extension (Section 1.3).  
A number of biocatalytic defluorination reactions have been documented, most of which 
form alkylating agents that act as covalent enzyme inhibitors (Figure 1.6) [39]. However, 
specific conditions – usually a source of electrons adjacent to fluorine, directly or via 
conjugation – are required for loss of fluoride, which is a poor leaving group especially in water. 
The α-fluorinated intermediates and reactions in polyketide synthesis should avoid such 
configurations. Cysteine proteases react with fluoromethylketones (FMKs), which resemble 
potential polyketide elongation intermediates, but FMKs are selective for this enzyme class and 
are very slow to alkylate serine proteases, suggesting that a specific configuration of active site 
residues is required for inhibition [40,41]. 
1.3. Polyketide synthases: mechanism and engineering 
Polyketide synthases are powerful biosynthetic enzymes that produce structurally diverse 
natural products. They are classified based on architecture: type I PKSs include at least some 
multidomain, multifunctional proteins, while type II PKSs are complexes of exclusively 
monofunctional proteins. Both operate on thioester substrates that are covalently tethered to the 
enzyme during chain elongation. Type III PKSs have a single active site and operate exclusively 
on freely diffusing substrates. All type II and type III PKSs are iterative, carrying out multiple 
chain extensions using the same active site(s), but biosynthesis may still be programmed, with 
substrate specificities of different domains resulting in different chemical modifications or 
cyclizations at different elongation steps [42,43], and the same can be true of iterative type I 
PKSs (generally fungal PKSs are type I iterative) as well [44-47]. The basis for this substrate-
directed programming provides many enzymological puzzles, but does not lend itself to facile 
reprogramming to generate new products. 
Type I modular PKSs, by contrast, have been the subject of much study in part because they 
seem to present a clear paradigm for biosynthetic engineering. In typical type I modular systems, 
each module carries out a single chain extension event and any associated tailoring steps before 
passing the chain to the next module in the sequence. The biosynthetic outcome can therefore be 
read out of the primary sequence of the PKS, and in many cases it can be reprogrammed by 
changing the order, identity or functionality of domains or entire modules [12,13]. These PKSs 
are attractive platforms for monomer engineering, since individual steps in chain extension and 
the associated chain extender units can be targeted for modification. 
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The best understood type I modular 
PKS is the enzyme that synthesizes the 
structural core of erythromycin, the 
paradigmatic macrolide antibiotic. 
Erythromycin is derived from 
oxidation and glycosylation of 6-
deoxyerythronolide B (6-dEB) (Figure 
1.7), so the producing enzyme is called 
6-deoxyerythronolide B synthase, or 
DEBS (Figure 1.8), a 2 MDa 
homodimeric complex composed of six 
modules (plus a loading didomain) 
spread across three polypeptides. The 
structure and function of DEBS has 
been subject to intensive study [48,49]. 
Biosynthesis begins when a propionyl starter unit is transferred from propionyl-CoA to the 
acyl carrier protein (ACP) of the loading didomain (which lacks a ketosynthase [KS]), a reaction 
catalyzed by the acyl transferase (AT). ACP domains carry biosynthetic intermediates as 
thioesters using the thiol of a phosphopantetheine prosthetic group, a post-translational 
modification to a Ser residue. The starter unit is passed to Module 1, where it is transacylated 
from ACPLDD to KS1 on an active site Cys. 
Figure 1.8. Modular architecture of the type I polyketide synthase DEBS. The biosynthetic intermediates for 6-
dEB synthesis at each stage of chain extension are shown attached to each module’s ACP, representing the 
step after chain extension and β-ketone tailoring steps carried out by that module have taken place. 
Phosphopantetheine groups are shown as wavy lines. Domain abbreviations: KS, ketosynthase. AT, acyl 
transferase. ACP, acyl carrier protein. KR, ketoreductase. DH, dehydratase. ER, enoyl reductase. TE, 
thioesterase. 
Figure 1.7. Erythromycin A and its in vivo precursor, 6-
deoxyerythronolide B (6-dEB). Starter and extender units, all derived 
from propionic acid, are indicated in alternating colors. The module of 
DEBS that encodes each extender and ketone tailoring is shown at the 
lower right. 
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At this point, chain extension begins using a similar series of steps for each module (Figure 
1.9). An extender unit – an α-carboxylated acyl-CoA, most commonly biosynthesized either by 
an acyl-CoA carboxylase or crotonyl CoA reductase [50] – is transacylated from CoA onto the 
ACP by the AT domain, a reaction that proceeds through a covalent extender-AT intermediate. 
The extender-ACP then enters the KS active site, where a decarboxylative Claisen reaction leads 
to a new C–C bond. The growing chain is now attached to the ACP, and interacts with β-ketone 
processing domains, if present, which can carry out ketoreduction (ketoreductase, KR), 
dehydration (dehydratase, DH) and reduction to the alkane (enoyl reductase, ER). After any 
processing events take place, the ACP-linked chain is passed to the KS of the next module, and 
the cycle begins again. The successive reactions in this cycle do not rely on stochastic movement 
of the ACP from active site to active site. Instead, as stunning whole-module cryo-EM studies 
have recently revealed, the entire module is subject to conformational changes at each stage of 
chain elongation and processing [51,52]. These changes bias the ACP toward productive 
interactions, enforce unidirectional synthesis, and ensure that all processing events take place 
before the chain is passed to the next module – and go a long way toward explaining why 
chimeric or domain-inactivated modules do not work as efficiently as native ones. 
Untangling the individual biochemical steps involved in polyketide synthesis, which is a 
concurrent process with many non-rate-limiting steps, has been difficult. DEBS, and other type I 
PKSs, can be dissected into single modules which catalyze one round of chain extension on 
substrates fed as N-acetyl cysteamine (SNAC) thioesters, making characterization easier. New 
tools, including sophisticated mass spectrometry techniques [53,54] and chemical probes [55,56], 
have made it possible to more directly observe intermediates in chain elongation. 
These methods have recently been helping to overturn a long-held dogma in the polyketide 
biosynthesis field, that ATs are extremely specific for their cognate extender units. (The one 
notable exception is the epothilone PKS Module 3 AT, which has relaxed specificity between 
malonyl- and methylmalonyl-CoA [57].) Early studies that compared malonyl-CoA and 
methylmalonyl-CoA use by DEBS ATs showed extremely high levels of discrimination [58,59], 
and for some time no other substrates were tested. However, reports contemporaneous with the 
work presented here show that the observed specificity does not seem to extend to AT substrates 
Figure 1.9. Mechanistic steps in a single chain extension cycle catalyzed by a modular PKS (light gray, upstream module; light blue, 
active module; red, downstream module). 
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that are not natively available to DEBS, such as ethylmalonyl-CoA [19], and that completely 
unnatural extender units are surprisingly well-tolerated in some cases [17,18]. These findings 
may lead to a resurgence of interest in biosynthesis of polyketide analogues, because they 
provide an underexplored route to increasing structural diversity, potentially without 
compromising efficiency.  
Despite these discoveries, prior to the work described here fluorinated extender units had not 
been examined in polyketide biosynthesis (except at specialized extender unit positions, see 
Figure 1.3). However, fluorinated derivatives of natural products have a rich history. Two 
fluorinated analogues of erythromycin, flurithromycin [60] and solithromycin, [61] have 
improved acid stability and potency, respectively, and numerous other fluorinated polyketides 
have been reported [10,62-64]. Other classes of natural product, such as terpenes, [65] non-
ribosomal peptides and alkaloids [66] have been modified with fluorine as well, and fluorinated 
amino acids have made contributions to protein and peptide design [67]. A general route to 
incorporate fluorine into polyketides would expand these efforts. 
1.4 Thesis organization 
The motivation for this work is to build the tools needed for biosynthesis of fluorinated 
polyketides. Eventually, our goal is to enable fluorine incorporation at all possible backbone 
positions by any polyketide synthase, and to make it possible to do so with reasonable efficiency 
in a scalable in vivo system. This will require numerous enzymes from diverse sources, many of 
which will need to be adapted for fluorine tolerance or specificity. Host organism compatibility, 
monomer activation and polyketide synthesis must all be considered. 
These aims are ambitious, and the results reported here represent only the first steps toward 
realizing them. Chapter 2 describes proof of concept studies showing that wild-type enzymes can 
activate fluoroacetate as a biosynthetic building block and that polyketide synthases can 
incorporate a fluorinated chain extender unit. It also presents preliminary evidence that these 
steps are compatible with E. coli metabolism. Chapter 3 expands on this by constructing and 
characterizing a model organofluorine biosynthetic pathway in vivo that closely resembles 
polyketide synthesis. Chapter 4 builds on another strategy introduced in Chapter 2, the use of 
trans-acyl transferase enzymes to introduce fluorinated extender units site-selectively and in a 
polyketide synthase-agnostic manner. 
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2.1 Introduction 
The catalytic diversity of biological systems provides enormous potential for creating new 
chemistry to allow the scalable production of pharmaceuticals, fuels and materials using living 
cells [1-4]. However, the scope of innovation of living organisms is typically limited to functions 
that confer a direct advantage for cell growth, maximizing biomass as the end product rather than 
a molecule or reaction of interest. In contrast, synthetic biology approaches allow us to 
disconnect some of these remarkable biochemical transformations from cell survival and 
reconnect them in new ways for the targeted synthesis of new classes of compounds. One 
particularly interesting area is the development of methods to introduce fluorine into complex 
small molecule scaffolds, which has become a powerful strategy for the design of synthetic 
pharmaceuticals: 20-30% of drugs, including many of the top sellers, contain at least one fluorine 
atom [5-7]. Recent innovations have expanded the scope of synthetic C–F bond forming 
methodologies, but the unusual elemental properties of fluorine that serve as the basis for its 
success also continue to restrict the range of molecular structures that can be accessed [8-11]. As 
such, the invention of new routes for the site-selective introduction of fluorine into structurally 
diverse molecules, particularly under mild conditions, remains an outstanding challenge. 
Despite its effectiveness as a tool in human hands, fluorine has limited distribution in 
naturally occurring molecules. In fact, the only fluorinated natural products characterized to date 
consist of a small set of simple organofluorines related to the fluoroacetate pathway of 
Figure 2.1. Synthetic biology of fluorine. (A) The fluoroacetate pathway and its metabolites represent the known scope of biological 
fluorine chemistry, producing fluoroacetate and fluorothreonine as the end products (grey box). This scope could be greatly 
expanded by engineering downstream pathways and using fluoroacetate as an organofluorine building block for introducing fluorine 
site-selectively into large families of modularly-synthesized natural products constructed from acetate backbones (red box). A red 
dot represents a position that can be fluorinated with the incorporation of a fluoroacetate monomer without altering the carbon 
skeleton, including locations where fluorine would replace a methyl group derived from propionate or where downstream tailoring 
steps have occurred on the final structure. (B) Assembly of acetate units in the biosynthesis of polyketide natural products. 
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Streptomyces cattleya, a soil bacterium that houses the remarkable ability to catalyze the 
formation of C–F bonds from aqueous fluoride (Figure 2.1A) [12, 13]. Although these 
compounds lack the intricacy typically expected of secondary metabolites, they represent a 
potentially rich source of organofluorine building blocks for the production of complex 
fluorinated natural products. The backbones of isoprenoids, steroids, alkaloids, eicosanoids, 
leukotrienes, and others are biosynthesized directly from the assembly and tailoring of simple 
acetate units (Figure 2.1A). Introduction of the fluoroacetate monomer in place of acetate would 
allow us to site-specifically incorporate fluorine into the backbone of these targets, combining 
the medicinal chemistry advantages of fluorine with the structural complexity and bioactivity of 
natural products to create new molecular function. In this Chapter, we show that the enzymatic 
synthesis of fluoromalonyl-CoA, a fluorinated analog of one of nature’s most powerful carbon 
nucleophiles, can be engineered from fluoroacetate and harnessed as an extender unit for the 
production of fluorinated polyketides in vitro and in vivo. 
Many acetate-based natural products, polyketides in particular, are generated through the 
iterative condensation of activated thioesters, resulting in reactive β-keto units that condense 
further to produce a wide range of structures (Figure 2.1B) [14, 15]. The structural diversity of 
these compounds is especially striking given that the vast majority of polyketides draw on only 
two monomers, acetate and propionate, as the extender units that form their carbon skeletons [3, 
14, 16]. Although polyketide synthases have been observed to be promiscuous with regard to 
their starter units [3, 14], the encoding of extender units has been found to be quite selective and 
the large pool of substituted acyl-CoAs inside the cell are excluded from the backbone [14, 16]. 
Thus, while the specificity between the acetate and propionate extender units can be swapped 
using various approaches [3, 14], engineered extenders units have not yet been employed, except 
in cases where unusual extenders are naturally incorporated by a polyketide synthase [17-19]. In 
fact, fluoroacetate can be used as a starter unit to produce highly toxic ω-fluoro fatty acids 
(Figure 2.1A) [13], but fluorine has never been observed to date within the backbone, implying 
that chain extension reactions with the fluorinated acyl-CoA do not occur in these systems. The 
apparent inability of living systems to utilize fluorine for the biosynthesis of complex small 
molecules could arise from several sources, but is likely derived in part from the extreme 
properties of fluorine that affect biological as well as chemical synthesis. For example, the pKa of 
the α-proton, electrophilicity of the carbonyl group, and the stability of the acyl-CoA and 
carbanion are all highly affected by fluorine substitution. Furthermore, the fluoroacetyl group 
bears a clear similarity to the fluoromethyl ketone motif used for the design of covalent enzyme 
inhibitors, which can lead to the irreversible alkylation of active-site nucleophiles [20]. Thus, the 
development of a system to incorporate novel fluorinated extenders could dramatically increase 
the range of complex structures that can be accessed but must also address the challenges 
involved in activating the fluoroacetate monomer for the C–C bond forming chemistry of chain 
extension reactions. 
2.2 Materials and methods 
Commercial materials. Luria-Bertani (LB) Broth Miller, LB Agar Miller, Terrific Broth 
(TB), yeast extract, malt extract, glycerol, and triethylamine (TEA) were purchased from EMD 
Biosciences (Darmstadt, Germany). Carbenicillin (Cb), isopropyl-β-D-thiogalactopyranoside 
(IPTG), phenylmethanesulfonyl fluoride (PMSF), tris(hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl), sodium chloride, dithiothreitol (DTT), 4-(2-hydroxyethyl)-1-
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piperazineethanesulfonic acid (HEPES), magnesium chloride hexahydrate, kanamycin (Km), 
acetonitrile, N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA), dichloromethane, ethyl acetate 
and ethylene diamine tetraacetic acid disodium dihydrate (EDTA), were purchased from Fisher 
Scientific (Pittsburgh, PA). Sodium fluoroacetate, coenzyme A trilithium salt (CoA), acetyl-
CoA, malonyl-CoA, methylmalonyl-CoA, diethylfluoromalonate, malonic acid, methylmalonic 
acid, tris(2-carboxyethyl)phosphine (TCEP) hydrochloride, lithium hexamethyldisilazide 
solution (LiHMDS), phosphoenolpyruvate (PEP), adenosine triphosphate sodium salt (ATP), 
nicotinamide adenine dinucleotide reduced form dipotassium salt (NADH), nicotinamide adenine 
dinucleotide phosphate reduced form (NADPH), myokinase, pyruvate kinase, lactate 
dehydrogenase, poly(ethyleneimine) solution (PEI), 5-fluorouracil, β-mercaptoethanol, sodium 
phosphate dibasic hepthydrate, chlorotrifluoromethane and N,N,N',N'-tetramethyl-ethane-1,2-
diamine (TEMED) were purchased from Sigma-Aldrich (St. Louis, MO). Formic acid was 
purchased from Acros Organics (Morris Plains, NJ). Acrylamide/Bis-acrylamide (30%, 37.5:1), 
electrophoresis grade sodium dodecyl sulfate (SDS), Bio-Rad protein assay dye reagent 
concentrate and ammonium persulfate were purchased from Bio-Rad Laboratories (Hercules, 
CA). Restriction enzymes, T4 DNA ligase, Antarctic phosphatase, Phusion DNA polymerase, T5 
exonuclease, and Taq DNA ligase were purchased from New England Biolabs (Ipswich, MA). 
Deoxynucleotides (dNTPs) and Platinum Taq High-Fidelity polymerase (Pt Taq HF) were 
purchased from Invitrogen (Carlsbad, CA). PageRuler™ Plus prestained protein ladder was 
purchased from Fermentas (Glen Burnie, Maryland). Oligonucleotides were purchased from 
Integrated DNA Technologies (Coralville, IA), resuspended at a stock concentration of 100 µM 
in 10 mM Tris-HCl, pH 8.5, and stored at either 4°C for immediate use or -20°C for longer term 
use. DNA purification kits and Ni-NTA agarose were purchased from Qiagen (Valencia, CA). 
Complete EDTA-free protease inhibitor was purchased from Roche Applied Science (Penzberg, 
Germany). O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
(HATU), Amicon Ultra 3,000 MWCO and 30,000 MWCO centrifugal concentrators, 5,000 
MWCO regenerated cellulose ultrafiltration membranes, and LiChroCART 250-4 Purospher RP-
18e HPLC column were purchased from EMD Millipore (Billerica, MA). Deuterium oxide and 
chloroform-d were purchased from Cambridge Isotope Laboratories (Andover, MA). 19F NMR 
spectra were collected at 25ºC on Bruker AVQ-400 or AV-600 spectrometers at the College of 
Chemistry NMR Facility at the University of California, Berkeley or on a Bruker Biospin 900 
MHz spectrometer at the QB3 Central California 900 MHz NMR Facility or on a Bruker AV-
600 spectrometer equipped with a QCI-CryoProbe at Novartis Institutes for Biomedical Research 
(Emeryville, California). Spectra were referenced to CFCl3 (0 ppm) or 5-fluorouracil (D2O: -
168.33 ppm vs. CFCl3). NMR assignments were made based on COSY, 13C-1H HSQC, 13C-1H 
HMBC and 19F-1H HMBC spectra where appropriate. High-resolution mass spectral analyses 
were carried out at the College of Chemistry Mass Spectrometry Facility.  
Bacterial strains. E. coli DH10B-T1R and BL21(de3)T1R were used for DNA construction 
and heterologous protein production, respectively, except for DEBS modules, which were 
heterologously expressed in E. coli BAP1 [21].  
Gene and plasmid construction. Standard molecular biology techniques were used to carry 
out plasmid construction. All PCR amplifications were carried out with Phusion or Platinum Taq 
High Fidelity DNA polymerases. For amplification of GC-rich sequences from S. coelicolor, 
PCR reactions were supplemented with DMSO (5%) using the standard buffer rather than GC 
buffer with primer annealing temperatures 8-10°C below the Tm. All constructs were verified by 
sequencing (Quintara Biosciences; Berkeley, CA). 
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The synthetic gene encoding NphT7 was optimized for E. coli class II codon usage and 
synthesized using PCR assembly (Appendix Table 1). Gene2Oligo was used to convert the gene 
sequence into primer sets using default optimization settings (Appendix Table 1) [22]. To 
assemble the synthetic gene, each primer was added at a final concentration of 1 µM to the first 
PCR reaction (50 µL) containing 1 × Pt Taq HF buffer (20 mM Tris-HCl, 50 mM KCl, pH 8.4), 
MgSO4 (1.5 mM), dNTPs (250 µM each), and Pt Taq HF (5 U). The following thermocycler 
program was used for the first assembly reaction: 95oC for 5 min; 95oC for 30 s; 55oC for 2 min; 
72oC for 10 s; 40 cycles of 95oC for 15 s, 55oC for 30 s, 72oC for 20 s plus 3 s/cycle; these cycles 
were followed by a final incubation at 72oC for 5 min. The second assembly reaction (50 µL) 
contained 16 µL of the unpurified first PCR reaction with standard reagents for Pt Taq HF. The 
thermocycler program for the second PCR was: 95oC for 30 s; 55oC for 2 min; 72oC for 10 s; 40 
cycles of 95oC for 15 s, 55oC for 30 s, 72oC for 80 s; these cycles were followed by a final 
incubation at 72oC for 5 min. The second PCR reaction (16 µL) was transferred again into fresh 
reagents and run using the same program. Following gene construction, the DNA smear at the 
appropriate size was gel purified and used as a template for the rescue PCR (50 µL) with Pt Taq 
HF and rescue primers under standard conditions. The resulting rescue product was inserted into 
pBAD33 and confirmed by sequencing, then amplified using the nphT7 F1/R1 primer set 
(Appendix Table 1) and inserted into the NdeI site of pET-16b using the Gibson protocol [23].  
pET16b-His10-AckA.EC and pET16b-His10-Pta.EC were constructed by amplification from 
pRSFDuet-ackA.pta using the AckA.EC F/R and Pta.EC F/R primer sets (Appendix Table 1) and 
insertion into the NdeI-XhoI (Pta, Gene ID 12872491) or NdeI-BamHI (AckA, Gene ID 
12874027) sites of pET16b. pET28a-His6-MatB.SCo and pET28a-His6-Epi.SCo were 
constructed by amplification from S. coelicolor A3(2) M145 (ATCC BAA-471) genomic DNA 
using the MatB.SCo F/R and epi.SCo F/R primer sets (Appendix Table 1) and insertion into the 
NdeI-XhoI sites of pET28a. pET16x-His10-THNS was constructed by amplification out of S. 
coelicolor genomic DNA using the THNS F/R primer set (Appendix Table 1) and insertion into 
the NdeI-SpeI sites of pET16x. pCDFDuet-DszsAT.SCe-MatB.SCo and pCDFDuet-ø-MatB.SCo 
were constructed by amplification from pET28a-His6-MatB.SCo and pFW3 (40) using the 
pCDF-MatB.SCo F/R and pCDF-DszsAT.SCe F/R primer sets (Appendix Table 1) and insertion 
of DszsAT.SCe and MatB.SCo into the NcoI-HindIII and NdeI-KpnI sites of pCDFDuet-1 
respectively. pTRC33-NphT7-PhaB was constructed by amplifying NphT7 from pET-16b-
NphT7 using the NphT7 G F/G R primer set (Appendix Table 1) and PhaB from pBT33-PhaABC 
(48) using the PhaB F/R primer set (Appendix Table 1) where each forward primer included the 
RBS from pET16b, then inserting both genes simultaneously into the BamHI-XbaI sites of 
pTRC33 using the Gibson protocol. pSV272-His6-MBP-DEBSMod2 and pSV272-His6-MBP-
DEBSMod2/AT0 (S2652A based on EryAI numbering) were constructed by amplification from 
pBP19 using the MBP-M2 F/R primer set (pSV272-MBP-DEBSMod2-His6) (Appendix Table 1) 
or MBP-M2 F/MBP-M2ATnull R and MBP-M2ATnull F/MBP-M2 R (pSV272-MBP-
DEBSMod2/AT0-His6) (Appendix Table 1) and insertion into the SfoI-HindIII sites of pSV272.1 
using the Gibson protocol. pBAD33.BirA.EC was cloned by the QB3 Macrolab.  
 Expression of His-tagged proteins. TB (1 L) containing carbenicillin, kanamycin, and 
chloramphenicol (50 µg/mL) as appropriate in a 2.8 L Fernbach baffled shake flask was 
inoculated to OD600 = 0.05 with an overnight TB culture of freshly transformed E. coli 
containing the appropriate overexpression plasmid. The cultures were grown at 37°C at 250 rpm 
to OD600 = 0.6 to 0.8 at which point cultures were cooled on ice for 20 min, followed by 
induction of protein expression with IPTG (His10-AckA, His10-Pta: 1 mM; His10-AccA/B/C/D 
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[26], DEBSMod6/AT0+TE-His6 (pAYC138 [24]): 0.4 mM; His10-MatB, His10-Epi, His10-NphT7, 
His6-DszAT (pFW3 [24]), His6-DEBSMod6+TE-His6 (pRSG54 [27]), DEBSMod3+TE-His6 
(pRSG34 [28]), DEBSMod3/AT0+TE-His6 (pAYC136 [24]), MBP-DEBSMod2-His6, MBP-
DEBSMod2/AT0-His6, DEBS1 : 0.2 mM) and overnight growth at 16°C. For His10-AccB 
expression, pBAD33-BirA was co-expressed (L-arabinose, 0.2 %) and the medium was 
supplemented with 20 nM D-(+)-biotin at induction. For MBP-DEBSMod2-His6 and MBP-
DEBSMod2/AT0-His6 pRARE2 was co-expressed. Cell pellets were harvested by centrifugation at 
9,800 × g for 7 min at 4ºC and stored at -80ºC.  
Purification of His10-AckA, His10-Pta, His10-MatB, His10-Epi, His10-AccA/B/C/D, His6-DszAT and 
His10-NphT7. Frozen cell pellets were thawed and resuspended at 5 mL/g cell paste with Buffer A 
(50 mM sodium phosphate, 300 mM sodium chloride, 20% glycerol, 20 mM BME, pH 7.5) 
containing imidazole (10 mM) for His10-AckA, His10-Pta, His10-AccA/B/C/D, and His10-NphT7 
or Buffer B (200 mM sodium phosphate, 200 mM sodium chloride, 30% glycerol, 2.5 mM 
EDTA, 2.5 mM DTT, pH 7.5) for His10-MatB and His10-Epi. Complete EDTA-free protease 
inhibitor cocktail (Roche) was added to the lysis buffer before resuspension. The cell paste was 
homogenized before lysis by passage through a French Pressure cell (Thermo Scientific; 
Waltham, MA) at 14,000 psi. The lysate was centrifuged at 15,300 × g for 20 min at 4°C to 
separate the soluble and insoluble fractions. DNA was precipitated in the soluble fraction by 
addition of 0.15% (w/v) poly(ethyleneimine). The precipitated DNA was removed by 
centrifugation at 15,300 × g for 20 min at 4°C. The remaining soluble lysate was diluted three-
fold with Buffer A containing imidazole (10 mM) and loaded onto a Ni-NTA agarose column 
(Qiagen, 1 mL resin/g cell paste) by gravity flow or on an ÄKTApurifier FPLC (2 mL/min; GE 
Healthcare; Piscataway, NJ). The column was washed with Buffer A until the eluate reached an 
A280 nm < 0.05 or was negative for protein content by Bradford assay (Bio-Rad).  
His10-AckA, His10-Pta, His10-MatB, His10-AccB and His10-AccD. The column was washed 
with 5 to 10 column volumes with Buffer A supplemented with imidazole (His10-AckA, 40 mM; 
His10-Pta, 35 mM; His10-MatB, His10-AccB, and His10-AccD, 20 mM). The protein was then 
eluted with 300 mM imidazole in Buffer A.  
His10-Epi. His10-Epi was eluted using a linear gradient from 0 to 300 mM imidazole in Buffer 
A over 30 column volumes. 
His10-AccA, His10-AccC and His10-NphT7. The column was washed with a linear gradient 
from 10 to 90 mM imidazole in Buffer A over 15 column volumes and then eluted with 300 mM 
imidazole in Buffer A.  
Fractions containing the target protein were pooled by A280 nm and concentrated using either 
an Amicon Ultra spin concentrator (3 kDa MWCO, Millipore) or an Amicon ultrafiltration cell 
under nitrogen flow (65 psi) using a membrane with an appropriate nominal molecular weight 
cutoff (Ultracel-5 or YM10, Millipore). Protein was then exchanged into Buffer C (50 mM 
HEPES, 100 mM sodium chloride, 2.5 mM EDTA, 20% glycerol, pH 7.5) with (His10-AckA, 
His10-Pta, His10-AccA/B/C/D, His10-NphT7) or without (His10-MatB and His10-Epi) DTT (0.5-1 
mM) using a Sephadex G-25 column (Sigma-Aldrich, bead size 50-150 µm, 10 mL resin/mL 
protein solution), then concentrated again before storage.  
Final protein concentrations before storage were estimated using the ε280 nm calculated by 
ExPASY ProtParam as follows: His10-AckA: 14.8 mg/mL (ε280 nm = 24,860 M-1 cm-1), His10-Pta: 
16.5 mg/mL (ε280 nm = 37,360 M-1 cm-1), His10-MatB: 19.8 mg/mL (ε280 nm = 33,920 M-1 cm-1), 
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His10-Epi: 18.5 mg/mL (ε280 nm = 11,460 M-1 cm-1), His10-AccA: 33.2 mg/mL (ε280 nm = 25,900 M-
1 cm-1), His10-AccB: 23.0 mg/mL (ε280 nm = 2,980 M-1 cm-1), His10-AccC: 32.6 mg/mL (ε280 nm = 
27,850 M-1 cm-1), His10-AccD: 4.5 mg/mL (ε280 nm = 16,960 M-1 cm-1), His6-DszAT: 1.7 mg/mL 
(ε280 nm = 17,420 M-1 cm-1), His10-NphT7: 0.4 mg/mL (ε280 nm = 26,930 M-1 cm-1). All proteins 
were aliquoted, flash-frozen in liquid nitrogen, and stored at -80°C. 
Purification of DEBSMod6+TE-His6, DEBSMod6/AT0+TE-His6, DEBSMod3+TE-His6, and 
DEBSMod3/AT0+TE-His6. The His-tagged DEBS module with thioesterase (DEBSMod6+TE) 
construct was heterologously expressed in E. coli BAP1 pRSG54 as previously described and 
purified using a modified literature protocol [29]. Cleared cell lysates were prepared in Buffer B 
as described above, diluted three-fold with Buffer A, and passed over a Ni-NTA agarose column 
(Qiagen, approximately 1 mL/g cell paste) on an ÄKTApurifier FPLC. The column was washed 
with Buffer A until the eluate reached an A280 nm < 0.05. Protein was eluted with Buffer D (50 
mM sodium phosphate, 50 mM sodium chloride, 20 mM BME, 20% glycerol, 100 mM 
imidazole, pH 7.5). The eluate was diluted two-fold with Buffer E  (50 mM HEPES, 2.5 mM 
EDTA, 2.5 mM DTT, 20% glycerol, pH 7.5), loaded onto a HiTrap Q HP column (GE 
Healthcare, 5 mL), and eluted with a linear gradient from 0 to 1 M sodium chloride in Buffer E 
over 30 column volumes (4.5 mL/min). Fractions containing the target protein (eluted at ~350 
mM sodium chloride) were pooled by A280 nm and concentrated under nitrogen flow (65 psi) in an 
Amicon ultrafiltration cell using a YM10 membrane. The protein was flash-frozen in liquid 
nitrogen and stored at -80°C at a final concentration of 6 - 30 mg/mL, which was estimated using 
the calculated ε280 nm (DEBSMod3+TE and DEBSMod3/AT0+TE: 203,280 M-1cm-1; DEBSMod6+TE 
and DEBSMod6/AT0+TE: 206,260 M-1 cm-1).  
Purification of MBP-DEBSMod2-His6 and MBP-DEBSMod2/AT0-His6. Cleared lysates were 
produced as for other DEBS modules, diluted 2-fold with Buffer A + 10 mM imidazole, and 
bound in batch to Ni-NTA resin (2.5 mL resin per g cell paste) for 2h. The slurry was poured 
into a fritted column and washed with Buffer A + 10 mM imidazole until the A280 nm of the eluent 
dropped below 0.05. The protein was then eluted with Buffer A + 300 mM imidazole. The 
protein was then concentrated to approximately 1 mg/mL in an Amicon ultrafiltration cell. The 
protein was then dialyzed overnight against Buffer E + 50 mM NaCl with 1 mg TEV per 100 mg 
protein to remove the MBP tag. The protein was then loaded onto a HiTrap Q HP column and 
eluted by a linear gradient from Buffer E to Buffer E + 500 mM NaCl over 20 column volumes. 
Fractions containing the desired protein were identified by SDS-PAGE (eluting at approximately 
350 mM NaCl), pooled and concentrated in an Amicon Ultra spin concentrator to 20 - 25 mg/mL 
base on the calculated ε280 nm of 158,360 M-1cm-1. Aliquots were flash frozen in liquid nitrogen 
and stored at -80°C. 
ESI-MS screening method for acyl-CoAs. Preparative HPLC fractions were screened on 
an Agilent 1290 HPLC system using a Zorbax Eclipse Plus C-18 column (3.5 µm, 2.1 × 30 mm, 
Agilent) with a linear gradient from 0 to 65% acetonitrile over 2 min with 0.1% formic acid as 
the aqueous mobile phase (0.75 mL/min). Mass spectra were recorded on an Agilent 6130 single 
quadrupole MS with ESI source, operating in negative and positive ion scan mode.  
Fluoromalonate. Diethylfluoromalonate (0.5 mL, 3.2 mmol) was saponified with 
methanolic sodium hydroxide (2 M, 3.5 mL) in dichloromethane and methanol (9:1 v/v, 32 mL) 
and the sodium salt isolated by filtration through a Büchner funnel with a fine porosity glass frit 
[30]. 19F NMR (565 MHz, D2O, 5-fluorouracil = -168.3 ppm): δ -176.43 (d, J=53 Hz). 
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Fluoromalonyl-CoA. Fluoromalonyl-CoA was prepared enzymatically from fluoromalonate 
and CoA using MatB and ATP. A myokinase/pyruvate kinase/PEP system was also used to 
regenerate ATP in order to avoid high concentrations of AMP that might inhibit MatB. The 
reaction mixture (10 mL) contained 100 mM sodium phosphate, pH 7.5, phosphoenolpyruvate (5 
mM), TCEP (2.5 mM), magnesium chloride (5 mM), fluoromalonate (2.5 mM), ATP (2.5 mM), 
pyruvate kinase (36 U), myokinase (20 U), CoA (2 mM) and MatB (5 µM). The mixture was 
incubated at 37°C for 6 h and then at room temperature for 16 h before lyophilizing overnight. 
The residue was dissolved in water (1.6 mL) and acidified to pH ~2 by addition of 70% 
perchloric acid (160 µL). Insoluble material was removed by centrifugation at 18,000 × g for 10 
min. The supernatant was adjusted to pH 6 by addition of 10 M sodium hydroxide (100 µL) and 
desalted on an Agilent 1200 HPLC system using a Zorbax Eclipse XDB C-18 column (5 µm, 9.4 
× 250 mm, Agilent) with a linear gradient from 0 to 10% methanol over 9 min with 50 mM 
sodium phosphate, 25 mM trifluoroacetic acid, pH 4.5 as the aqueous mobile phase (3 mL/min). 
Fractions eluting near the void volume, containing both fluoromalonyl-CoA and CoA, were 
lyophilized overnight, dissolved in water (1 mL), and purified using a Zorbax Eclipse XDB C-18 
column (5 µm, 9.4 × 250 mm) with a linear gradient from 0 to 50% methanol over 45 min with 
50 mM sodium phosphate, pH 4.5 as the aqueous mobile phase (3 mL/min). Fractions were 
screened by ESI-MS and those containing pure fluoromalonyl-CoA were lyophilized overnight, 
dissolved in water (1 mL), and desalted using a Zorbax Eclipse XDB C-18 column (5 µm, 9.4 × 
250 mm) with a linear gradient from 0 to 15% acetonitrile over 30 min with water as the mobile 
phase (3 mL/min). The desalted fluoromalonyl-CoA was lyophilized and redissolved in water or 
D2O. The fluoromalonyl-CoA solutions were stored at -20°C but are stable for at least 24 h at 
room temperature. During NMR measurements in D2O, complete H-D exchange occurred at the 
fluorine-substituted carbon over the course of 48 h. 1H NMR (600 MHz, D2O, MeOH = 3.34 
ppm): δ 8.55 (s, 1H, H8), 8.27 (s, 1H, H2), 6.17 (d, J=6.6 Hz, 1H, H1´), 5.23 (d, J=50.3 Hz, 1H, 
O2C-CHF-C=O), 4.89 – 4.79 (m, 2H, H2' and H3'), 4.59 (m, 1H, H4'), 4.23 (m, 2H, H5'), 4.00 (s, 
1H, H3''), 3.82 (dd, J=10.2, 4.6 Hz, 1H, pro-R-H1''), 3.54 (dd, J=10.0, 4.4 Hz, 1H, pro-S- H1''), 
3.49 – 3.39 (m, 2H, H5''), 3.38 – 3.29 (m, 2H, H8''), 3.11-3.02 (m, 2H, H9''), 2.42 (t, J=6.7 Hz, 3H, 
H6''), 0.88 (s, 3H, H10''), 0.74 (s, 3H, H11''). 13C NMR (226 MHz, D2O, CH3OH = 49.15 ppm): δ 
196.92, 196.85 (d, J=27.5 Hz, CO2), 175.02 (C4"), 174.32 (C7"), 169.52 (d, J=21.0 Hz, O2C-CDF-
C=O), 155.37 (C6), 152.40 (C2), 149.57 (C4), 140.37 (C8), 118.91 (C5), 93.32 (td, J=25 Hz, 197 
Hz, O2C-CDF-C=O), 86.61 (C1'), 83.81 (d, J=9 Hz, C4'), 74.56 (d, J=5 Hz, C3' or C1''), 74.35 
(C3''), 74.00 (d, J=5 Hz, C2'), 72.16 (d, J=6 Hz, C3' or C1''), 65.56 (C5'), 38.66 (C5" or C6"), 38.58 
(d, J=8 Hz, C8'') 35.58 (d, J=30 Hz, C9"), 27.60 (d, J=3 Hz, C5" or C6"), 21.16 (C10''), 18.22 (C11''). 
19F NMR (565 MHz, D2O, CF3CO2H = -76.20 ppm): δ -182.11 (dd, J=7.8, 50.4 Hz, O2C-CHF-
C=O), -182.72 (m, O2C-CDF-C=O). HR-ESI-MS [M-H]-: calculated for C24H36FN7O19P3S, m/z, 
870.0989, found m/z 870.0991.  
Enzyme assays. Kinetic parameters (kcat, KM) were determined by fitting the data using 
Microcal Origin to the equation: vo = vmax [S] / (KM + [S]), where v is the initial rate and [S] is the 
substrate concentration. Data are reported as mean ± s.e. (n = 3) unless otherwise noted with 
standard error derived from the nonlinear curve fitting. Error bars on graphs represent mean ± 
s.d. (n = 3). Error in kcat/KM is calculated by propagation of error from the individual kinetic 
parameters. 
Acetyl-CoA carboxylase. ACCase activity was measured using a discontinuous HPLC assay. 
Assays were performed at 30°C in a total volume of 200 µL containing 50 mM HEPES, pH 7.5, 
TCEP (10 mM), bovine serum albumin (3 mg/mL), CoA (0.5 mM), ATP (2.5 mM), magnesium 
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chloride (10 mM), sodium bicarbonate (75 mM), acetate or fluoroacetate (10 mM), 
phosphoenolpyruvate (10 mM), pyruvate kinase (4 U), AckA (0.1 µM), Pta (10 µM) and 
ACCase (15 µM). The pH of the buffer remained unchanged after addition of sodium 
bicarbonate. ACCase stock solution was prepared by pre-mixing the protein subunits at 
equimolar ratio (85 µM) except for AccB, which was added at 1.5-fold molar excess. The 
reaction was initiated with addition of ATP. Aliquots (20 µL) were removed and quenched by 
the addition of 70% perchloric acid (1 µL). Insoluble material was removed by centrifugation 
and the supernatant was analyzed on an Agilent 1200 or 1290 HPLC system on a LiChroCART 
250-4 Purospher RP-18e column (5 µm, 4.6 × 250 mm, Millipore) and monitored at A260 nm. For 
reactions with acetate, a linear gradient from 2 to 20% acetonitrile over 10 min with 5 mM 
sodium phosphate and 5 mM sodium citrate with 0.1% trifluoroacetic acid, pH 4.6 as the 
aqueous mobile phase (1 mL/min) was used to analyze the reaction. For reactions with 
fluoroacetate, a linear gradient from 2 to 15% acetonitrile containing 0.1% TEA over 15 min 
with 10 mM Tris, pH 8.0 containing 0.1% TEA as the aqueous mobile phase (1 mL/min) was 
used. Buffers containing TEA were made fresh daily and could be used for at least 6 h before 
significant change in chromatography was observed. 
Malonyl-CoA synthetase. MatB activity was measured using a modified literature method 
[31]. The production of AMP was coupled to pyruvate formation by myokinase and pyruvate 
kinase, which in turn was coupled to NADH oxidation by lactate dehydrogenase. Assays were 
performed at 30°C in a total volume of 200 µL containing 100 mM HEPES, pH 7.5, TCEP (1 
mM), ATP (2.5 mM), magnesium chloride (5 mM), phosphoenolpyruvate (1 mM), NADH (0.3 
mM), myokinase (0.5 U), pyruvate kinase (3.6 U), lactate dehydrogenase (2.6 U), dicarboxylic 
acid (25 µM – 1 mM malonate, 50 µM – 10 mM fluoromalonate or 25 µM – 1.5 mM 
methylmalonate) and MatB (26 nM for malonate, 1 µM for fluoromalonate and 200 nM for 
methylmalonate). The reaction was initiated with addition of CoA (0.5 mM) and monitored at 
340 nm in a Beckman Coulter DU-800 spectrophotometer.  
Acetoacetyl-CoA synthase. NphT7 activity was measured using a NADPH-coupled assay 
with PhaB. Assays were performed at 30°C in a total volume of 500 µL containing 50 mM 
HEPES, pH 7.5, NADPH (160 µM), acetyl-CoA (200 µM), PhaB (0.05 mg/mL), NphT7 (0.2 
µM for malonyl-CoA; 0.5µM for fluoromalonyl-CoA) and malonyl-CoA (5 – 150 µM) or 
fluoromalonyl-CoA (5 – 200 µM). Reactions were initiated with the addition of malonyl- or 
fluoromalonyl-CoA and monitored at 340 nm in an Agilent 8453 diode array spectrophotometer. 
The PhaB-coupled assay was tested both by doubling NphT7, which doubled the initial velocity 
with both the fluorinated and non-fluorinated substrates, and also by doubling the amount of 
PhaB, which led to no difference in initial velocity. 
Acyl-CoA hydrolysis by DEBS. Hydrolytic activity of DEBSMod6+TE was measured by 
monitoring the reaction of free CoA with DTNB as described previously [32]. Assays were 
performed at 37°C in a total volume of 200 µL containing 400 mM sodium phosphate, pH 7.5, 
500 µM DTNB, and DEBSMod6+TE (1 µM). Reactions were initiated by addition of acyl-CoA 
(0.5 mM) and monitored at 412 nm in a Beckman Coulter DU-800 spectrophotometer. Release 
of CoA was quantified by comparison to a standard curve (5–100 µM). 
2-fluoro-3-hydroxybutyryl-CoA production using NphT7. As acetofluoroacetyl-CoA 
proved to degrade fairly rapidly under the assay conditions, 2-fluoro-3-hydroxybutyryl-CoA was 
isolated from a 10 mL reaction containing 100 mM HEPES, pH 7.5, fluoromalonate (10 mM), 
CoA (500 µM), NADPH (1 mM), ATP (1 mM), magnesium chloride (5 mM), 
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phosphoenolpyruvate (10 mM), pyruvate kinase (180 U), myokinase (100 U), MatB (40 µM), 
PhaB (7 µM) and NphT7 (2 µM) that was initiated by the addition of acetyl-CoA (0.5 mM, 
limiting reagent). The reaction was incubated at 30°C overnight followed by quenching by the 
addition of 70% perchloric acid (50 µL). 2-fluoro-3-hydroxybutryl-CoA was purified using a 
Zorbax Eclipse XDB C-8 column (5 µm, 9.4 × 250 mm, Agilent) with a linear gradient from 0 to 
5% acetonitrile over 30 min (3 mL/min) with 50 mM sodium phosphate with 0.1% 
trifluoroacetic acid (pH 4.5) as the aqueous mobile phase. Fractions containing 2-fluoro-3-
hydroxybutryl-CoA were identified by ESI-MS and lyophilized. The remaining solid was 
dissolved in water (1 mL) and purified a second time a Zorbax Eclipse XDB C-8 column (5 µm, 
9.4 × 250 mm, Agilent) with a linear gradient from 0 to 5% acetonitrile over 30 min (3 mL/min) 
with 0.1% formic acid as the aqueous mobile phase. Fractions containing 2-fluoro-3-
hydroxybutryl-CoA were identified by ESI-MS and lyophilized. Two diastereomers were 
observed by NMR in an approximately 2.5:1 ratio. 1H NMR (600 MHz, D2O, acetonitrile = 2.06 
ppm): δ 8.54 (s, 1H, H8), 8.30 (s, 1H, H2), 6.08 (d, J=5.9 Hz, 1H, H1´), 4.93 (dd, J=47.8, 2.6 Hz, 
0.2H, HOCH-CHF-C=O minor diastereomer), 4.85 (dd, J=46.9, 2.2 Hz, 0.8H, HOCH-CHF-C=O 
major diastereomer), 4.77 – 4.77 (m, 2H, H2' and H3'), 4.46 (m, 1H, H4'), 4.16-4.04 (m, 3H, 
HOCH-CHF-C=O, H5'), 3.89 (s, 1H, H3''), 3.72 (d, J=7.1 Hz, 1H, H1'' pro-R), 3.46 (d, J=9.7 Hz, 
1H, pro-S- H1'' pro-S), 3.31 (t, J=6.5 Hz, 2H, H5''), 3.26 – 3.20 (m, 2H, H8''), 2.95 (m, 2H, H9''), 
2.30 (t, J=6.5 Hz, 2H, H6''), 1.15 (d, J=6.7 Hz, 2H, H3C-HOCH-CHF major diastereomer), 1.05 
(d, J=6.4 Hz, 1H, H3C-HOCH-CHF minor diastereomer), 0.79 (s, 3H, H10''), 0.67 (s, 3H, H11''). 
19F NMR (565 MHz, D2O, CF3CO2H = -76.20 ppm): δ -198.62 (dd, J=48.24, 23.3 Hz, HOCH-
CHF-C=O), -206.85 (dd, J=46.9, 27.5, HOCH-CHF-C=O). ESI-MS [M+H]+: calculated for 
C25H42FN7O18P3S, m/z, 872.2, found m/z 872.0.  
Triketide lactone production using DEBSMod6+TE and MatB. Assay and preparative 
mixtures contained 400 mM sodium phosphate, pH 7.5, phosphoenolpyruvate (50 mM), TCEP (5 
mM), magnesium chloride (10 mM), ATP (2.5 mM), pyruvate kinase (27 U/mL), myokinase (10 
U/mL), CoA (0.5 mM), methylmalonyl-CoA epimerase (5 µM), MatB (40 µM or as specified) 
and fluoro- or methylmalonate (10 – 20 mM). Including NADPH resulted in only trace yields of 
reduced triketide product, even with the native methylmalonyl-CoA extender, so the cofactor 
was omitted. This mixture was incubated at 37°C for 30-45 min and then initiated by addition of 
the N-acetylcysteamine thioester of (2S,3R)-2-methyl-3-hydroxypentanoic acid (NDK-SNAC, 1 
– 10 mM) [33] and DEBSMod6+TE (10 µM). Aliquots (35 µL) were removed and quenched by 
addition of 70% perchloric acid (1.75 µL). Samples were centrifuged at 18,000 × g to pellet the 
precipitated protein. The supernatant (33 µL) was removed and added to 1 M sodium bicarbonate 
(6.6 µL) bringing the final pH to 4-5. Excess salts were precipitated by freezing in liquid 
nitrogen and centrifuging at 18,000 × g until thawed. The supernatant was removed and analyzed 
on a Zorbax Eclipse XDB C-18 column (3.5 µm, 3 × 150 mm, 35°C, Agilent) using a linear 
gradient from 0 to 40% acetonitrile over 14 min with 0.1% formic acid as the aqueous mobile 
phase after an initial hold at 0% acetonitrile for 30 s (0.8 mL/min). Products were monitored 
using an Agilent G1315D diode array detector (TKL, A260 nm or A275 nm; F-TKL, A247 nm; NDK-
SNAC; A260 nm). The identity of each compound was verified using an Agilent 6130 single 
quadruple mass spectrometer in negative ion mode. For absolute quantification, each analyte was 
compared to an external standard curve. The concentration of the 2-fluoro-2-desmethyltriketide 
lactone (F-TKL) synthetic standard was determined by 19F NMR using the ERETIC method [34] 
against an external standard of 5.00 mM 5-fluorouracil. The triketide lactone (TKL) standard 
was prepared enzymatically, and the 2-desmethyltriketide lactone (H-TKL) standard was 
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synthesized as described [35]. The concentrations of TKL and H-TKL were determined by 1H 
NMR in D2O using the ERETIC method against an external standard of 75 mM 
diethylfluoromalonate.  
Enzymatic preparation of methyl- and fluorotriketide lactones from methylmalonate 
and fluoromalonate. Reaction mixtures (TKL, 4 mL; F-TKL, 8 mL) containing NDK-SNAC 
(10 mM) were prepared as described above and incubated for 18 h. Protein was removed by the 
addition of 70% perchloric acid (0.05 volumes) and centrifuged at 18,000 × g for 10 min. The 
supernatant was removed and extracted extensively with dichloromethane (TKL, 5 × 15 mL; F-
TKL, 5 × 30 mL) and the organic layers concentrated to 5-10 mL by rotary evaporation. The 
residue was transferred to a silanized glass vial (Sigmacote®, Sigma-Aldrich) and 50 mM sodium 
bicarbonate was added (1 mL). The dichloromethane was removed from the biphasic mixture by 
rotary evaporation to transfer the triketide into the aqueous phase. The aqueous solution of 
triketide was purified on a Zorbax Eclipse XDB C-18 column (5 µm, 9.4 × 250 mm, Agilent) 
using a linear gradient from 0 to 27.5% methanol with 50 mM sodium phosphate, pH 4.5 over 45 
min as the aqueous mobile phase (3 mL/min). Fractions containing triketide were pooled and 
extracted with dichloromethane (4 × 3 volumes), and the combined organic layers were dried 
over magnesium sulfate and concentrated.  
The TKL was purified further on a Zorbax Eclipse XDB C-18 (5 µm, 9.4 × 250 mm, Agilent) 
using a linear gradient from to 0 to 30% acetonitrile with 0.1% formic acid as the aqueous 
mobile phase over 45 min (3 mL/min) after transferring back into bicarbonate buffer as described 
above. Fractions containing TKL were combined and lyophilized for analysis. Due to the 
presence of a β-keto moiety, TKL was expected to be produced as a diastereomeric mixture, and 
was in fact isolated as a 100:7 mixture of (2R,4S,5R)-2,4-Dimethyl-3-oxo-5-hydroxy-n-heptanoic 
acid δ-lactone and its 2S-epimer. The observed NMR spectra are in agreement with the literature 
[36]. 1H NMR (500 MHz, CDCl3): δ 4.66 (ddd, J=8.4, 5.4, 2.9 Hz, 2R H5), 4.48 – 4.42 (m, 2S 
H5), 3.62 (q, J=6.6 Hz, 2R H2), 3.25 (d, J=7.5 Hz, 2S H2), 2.83 (dd, J=7.2, 4.7 Hz, 2S H4), 2.63 
(qd, J=7.6, 2.9 Hz, 2R H4), 1.93 – 1.82 (m, 2R H6a), 1.65 (dqd, J=14.8, 7.6, 5.4 Hz, 2R H6b), 1.48 
(d, J=7.5 Hz, 2S C2-CH3), 1.37 (d, J=6.7 Hz, 2R C2-CH3), 1.16 (d, J=6.4 Hz, 2S C4-CH3), 1.12 (d, 
J=7.5 Hz, 2R C4-CH3), 1.08 (t, J=7.5 Hz, 2R H7), 1.01 (t, J=7.5 Hz, 2S H7). 13C NMR (226 MHz, 
CDCl3, only the 2R epimer was detected): δ 205.59 (C3), 170.21 (C1), 78.68 (C5), 50.56 (C2), 
44.52 (C4), 24.19 (C6), 10.09 (C7), 9.90 (C4-CH3), 8.40 (C2-CH3). HR-ESI-MS [M-H]-: 
calculated for C9H13O3, m/z 169.0870, found m/z 169.0871. 
The enzymatic F-TKL was compared against an authentic synthetic standard by LC-MS, HR-
ESI-MS, 19F-NMR, and GC-MS. 19F-NMR (565 MHz, CDCl3, CFCl3 = 0 ppm): -171.95 (broad 
singlet), -210.32 (d, J = 45.8 Hz). HR-ESI-MS [M-H]-: calculated for C8H10FO3, m/z 173.0619, 
found m/z 173.0623.  
Enzymatic preparation of F-TKL from fluoroacetate. One-pot reaction mixtures 
containing 200 mM HEPES, pH 7.5, TCEP (2 mM), bovine serum albumin (3 mg/mL), 
magnesium chloride (5 mM), fluoroacetate (10 mM), NDK–SNAC (10 mM), coenzyme A (2 
mM), sodium bicarbonate (75 mM), ATP (2.5 mM), phosphoenolpyruvate (50 mM), pyruvate 
kinase (18 U/mL), myokinase (10 U/mL), AckA (10 µM), Pta (1 µM), ACCase (15 µM), MatB 
(40 µM), methylmalonyl-CoA epimerase (5 µM) and DEBSMod6+TE (10 µM) in a total volume 
of 1000 µL were incubated at 37°C for 1.5 hrs at which time sodium phosphate pH 7.5 (400 
mM) was added to the reaction. The reaction was incubated at 37°C for a further 24 hrs. An 
aliquot (200 µL) was removed and prior to analysis, the aliquot was quenched by the addition of 
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70% perchloric acid (10 µL). F-TKL production was analyzed by LC-MS as described above 
using single ion monitoring at m/z 173 in negative ion mode. Telescope reaction mixtures 
containing 200 mM HEPES, pH 7.5, TCEP (2 mM), bovine serum albumin (3 mg/mL), 
magnesium chloride (5 mM), fluoroacetate (10 mM), coenzyme A (1 mM), sodium bicarbonate 
(75 mM), ATP (2.5 mM), phosphoenolpyruvate (50 mM), pyruvate kinase (18 U/mL), AckA (10 
µM), Pta (1 µM) and ACCase (15 µM) in a total volume of 1000 µL were incubated at 37°C for 
1.5 hrs. The reaction was then spun through an Amicon spin concentrator (MWCO 3 kDa) to 
remove proteins. 792 µL of the flow through was used to prepare a reaction with 400 mM 
sodium phosphate, pH 7.5, TCEP (2 mM), magnesium chloride (10 mM), NDK-SNAC (10 mM), 
phosphoenolpyruvate (50 mM), pyruvate kinase (18U/mL), myokinase (10 U/mL), MatB (40 
µM), methylmalonyl-CoA epimerase (5 µM) and DEBSMod6+TE (10 µM) in a total volume of 
1000 µL. The reactions were allowed to proceed for 24 h and were assayed as described for the 
one-pot reactions.  
(2S,3R)-1-((S)-4-Benzyl-2-oxooxazolidin-3-yl)-2-methyl-1-oxopentan-3-yl 2-
fluoroacetate (1). (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methylpentanoyl)oxazolidin-2-one (171 
mg, 0.585 mmol) was prepared as previously described [33] and combined with sodium 
fluoroacetate (70 mg, 0.703 mmol, 1.2 eq) and HATU (267 mg, 0.702 mmol, 1.2 eq) in a flame-
dried round-bottom flask under a nitrogen atmosphere. Anhydrous THF (5.9 mL) and 
diisopropylethylamine (306 µL, 1.76 mmol, 3 eq) were added and the reaction was capped and 
stirred vigorously at room temperature for 44 h, during which time the white suspension turned 
orange-brown. The mixture was diluted with ethyl acetate and washed with saturated sodium 
bicarbonate, resulting in two clear layers. The orange-brown organic layer was washed again 
with saturated sodium bicarbonate, dried over MgSO4, filtered through a plug of silica, and 
concentrated to give an orange-brown oil. The residue was purified by flash chromatography on 
silica (30 g) using a step gradient from 100% heptane to 25% ethyl acetate in heptane with the 
desired compound beginning to elute in 20% ethyl acetate. Fractions were concentrated to yield 
the product (173 mg, 84%) as a clear, colorless oil, Rf 0.35 (25% ethyl acetate/hexanes). 1H 
NMR (500 MHz, CDCl3): δ 7.39 – 7.16 (m, Ph-H), 5.31 (ddd, J=7.9, 5.9, 3.2 Hz, H3'), 4.87 (d, 
J=47.0, CH2F-C=O), 4.60 (dddd, J=9.8, 7.7, 3.5, 2.3 Hz, H4), 4.31 (ddd, J=8.7, 7.7, 0.8 Hz, H5 
pro-R), 4.19 (dd, J=8.9, 2.3 Hz, H5 pro-S), 4.09 (qd, J=6.9, 3.2 Hz, H2'), 3.28 (dd, J=13.4, 3.5 Hz, 
H6a), 2.78 (dd, J=13.4, 9.8 Hz, H6b), 1.79 – 1.64 (m, H4'), 1.22 (d, J=6.9 Hz, C2-CH3), 0.95 (t, 
J=7.4 Hz, H5'). 13C NMR (151 MHz, CDCl3): δ 173.95 (C1'), 168.04 (d, J=22.0 Hz, CH2F-C=O), 
153.83 (N-C=O-O), 135.41 (Caryl), 129.56 (Caryl), 129.07 (Caryl), 127.48 (Caryl), 77.44 (d, J=182.3 
Hz, CH2F-C=O) , 76.40 (C3'), 66.58 (C5), 55.94 (C4), 41.00 (C2'), 38.05 (C6), 25.16 (C4'), 10.15 
(C2'-CH3), 10.04 (C5'). 19F NMR (565 MHz, CDCl3, CFCl3 = 0 ppm): δ -230.44 (t, J=47.0 Hz). 
HR-ESI-MS [M+Na]+: calculated for C18H22FNO5Na, m/z 374.1374, found m/z 374.1381.    
Preparation of (2S,4S,5R)-2-fluoro-4-methyl-3-oxo-5-hydroxy-n-heptanoic acid δ-
lactone (F-TKL). Lactonization of 1 was carried out using literature methods [35]. 1 (160 mg, 
0.455 mmol) was dried under vacuum in a pear-shaped flask then placed under nitrogen. In a 
flame-dried round-bottom flask, anhydrous THF (4.5 mL) and LiHMDS (1.0 M in THF, 1.366 
mL, 3 eq) were combined, stirred and cooled to -78°C under nitrogen. The starting material was 
dissolved in anhydrous THF (3.5 mL), cooled to -78°C, and cannulated dropwise into the 
solution of base over 20 min. A rinse of anhydrous THF (1.5 mL) was also transferred by 
cannula. The reaction mixture was stirred for 3 h at -78°C and quenched by addition of saturated 
ammonium chloride/methanol/water (1:1:1 v/v/v, 13 mL). The mixture was then allowed to 
warm to room temperature while stirring. The pH of the quenched mixture was adjusted to 9 
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using 10 M NaOH and extracted with 3 × 40 mL ethyl acetate to remove the oxazolidinone 
auxiliary. The aqueous layer was adjusted to pH 2 using 12 M HCl and then extracted with 5 × 
20 mL dichloromethane. The combined organic layers were concentrated to give a clear, 
colorless oil, which contained approximately 1 mol% starting material by 1H NMR (36 mg, 
45%). The product was further purified by flash chromatography on silica by washing 
extensively with dichloromethane (Rf < 0.05) then eluting with ethyl acetate (Rf ~ 0.4), and 
concentrated to yield a white, crystalline solid (13 mg, 16%). A mixture of enol (53%) and keto 
(47%) tautomers was observed in CDCl3. The keto form was almost exclusively the 2S 
diastereomer as determined by 1H NOESY and molecular modeling (Figure 2.17). The doublet 
in the 19F NMR spectrum in CDCl3 at -205.96 ppm was assigned to the 2R keto diastereomer 
based on 1H-19F HMBC. 1H NMR (500 MHz, CDCl3): δ 5.83 (d, J=45.7 Hz, keto H2), 4.71 (ddd, 
J=8.4, 5.2, 3.0 Hz, keto H5), 4.26 (ddd, J=8.8, 6.0, 3.3 Hz, enol H5), 2.68 (qd, J=7.5, 3.0 Hz, keto 
H4), 2.45 (qt, J=7.2, 3.8 Hz, enol H4), 1.88 – 1.78 (m, keto H6a), 1.75 (m, enol H6a), 1.60 (m, keto 
H6b), 1.55 – 1.44 (m, enol H6b), 1.14 (d, J=7.5 Hz, keto H8), 1.11 (d, J=7.1 Hz, enol H8), 1.00 (t, 
J=7.4 Hz, keto H7), 0.92 (t, J=7.5 Hz, enol H7). 13C NMR (151 MHz, CDCl3): δ 198.58 (d, 
J=13.4 Hz, keto C3), 164.15 (d, J=20.0 Hz, keto C1), 162.67 (d, J=24 Hz, enol C1), 156.94 (d, 
J=6.5 Hz, enol C3), 130.00 (d, J=232.3 Hz, enol C2), 89.82 (d, J=206.9 Hz, keto C2), 80.27 (enol 
C5), 77.89 (d, J=1.7 Hz, keto C5), 43.97 (keto C4), 35.84 (enol C4), 24.15 (keto C6), 23.96 (enol 
C6), 10.38 (d, J=2.7 Hz, enol C8), 10.11 (keto C8), 9.93 (keto C7), 9.72 (enol C7). 19F NMR (565 
MHz, CDCl3, CFCl3 = 0 ppm): δ -172.36 (d, J=4.3 Hz, enol), -205.96 (d, J=44.9 Hz, 2S keto), -
210.40 (d, J=45.6 Hz, 2R keto). 19F NMR (565 MHz, 10% D2O, 50 mM sodium phosphate pH 
4.5): δ -178.66. 19F NMR (565 MHz, 15% D2O, 85 mM Tris pH 7.5, 5-fluorouracil = -168.3 
ppm): δ -190.20. HR-ESI-MS [M-H]-: calculated for C8H10FO3, m/z 173.0619, found m/z 
173.0617. 
GC-MS analysis of F-TKL. Samples were dissolved in dichloromethane and BSTFA 
containing 1% trimethylsilyl chloride (Sigma-Aldrich, 0.1 volumes) was added. Samples were 
analyzed on a Trace GC Ultra (Thermo Scientific) coupled to a DSQII single-quadrupole mass 
spectrometer using an HP-5MS column (0.25 mm × 30 m, 0.25 µM film thickness, J & W 
Scientific). The injection volume was 1 µL and the oven program was as follows: 75°C for 3 
min, ramp to 25°C at 25°C min-1, ramp to 300°C at 50 °C min-1, hold for 1 min.  
Covalent inhibition assay for DEBSMod6+TE. Two triketide reaction mixtures (200 µL) 
were prepared as described above, one containing fluoromalonate (10 mM) and the other 
methylmalonate (10 mM). DEBSMod6+TE (10 µM) and NDK-SNAC (2.5 mM) were added to 
each and the reactions were incubated at 37°C for 18 h. The protein fraction was isolated from 
each mixture at room temperature by desalting on a Sephadex G-25 column (3 mL) using 400 
mM sodium phosphate, pH 7.5. Fractions were pooled by Bradford assay and concentrated to 
200 µL using Amicon Ultra spin concentrators (3 kDa MWCO). The isolated DEBSMod6+TE was 
assayed by adding TCEP (2.5 mM), methylmalonyl-CoA (1 mM) and NDK-SNAC (1 mM) to 
this mixture to give a final volume of 210 µL and incubating at 37°C for 3 h, then analyzed by 
HPLC as described above.  
Triketide lactone production using AT0 constructs. All assay mixtures contained 400 
mM sodium phosphate, pH 7.5, phosphoenolpyruvate (50 mM), TCEP (5 mM), magnesium 
chloride (10 mM), ATP (2.5 mM), pyruvate kinase (27 U/mL), myokinase (10 U/mL), 
methylmalonyl-CoA epimerase (5 µM) and NDK-SNAC (5 mM). Where appropriate, 
fluoromalonyl-CoA (1 mM), methylmalonyl-CoA (1 mM) or MatB (40 µM), fluoromalonate or 
 30 
methylmalonate or malonate (20 mM), CoA (1 mM) and DszAT (5 µM) were added. Reactions 
were initiated by addition of the appropriate DEBS+TE construct (Mod6 and Mod6/AT0, 10 µM; 
Mod3 and Mod3/AT0, 5 µM in reactions containing DszAT and 8 µM otherwise) and incubated 
at 37°C for 18-20 h. Aliquots were removed, quenched, processed and analyzed as described 
above. 
Tetraketide lactone production. All reactions contained 400 mM sodium phosphate (pH 
7.5 for the 2,4-dimethyl- and 2-fluoro-4-methyl-tetraketide lactone reactions and pH 6 for the 2-
methyl-4-fluoro-tetraketide lactone reaction), glycerol (20%), phosphoenolpyruvate (20 mM), 
TCEP (10 mM), magnesium chloride (5 mM), ATP (2.5 mM), pyruvate kinase (18 U/mL), 
myokinase (10 U/mL), methylmalonyl-CoA epimerase (5 µM), MatB (20 µM), CoA (1 mM), 
methylmalonyl-CoA (100 µM), NDK-SNAC (1 mM) and reduced nicotinamide adenine 
dinucleotide phosphate (NADPH; 5 mM). 
The reaction to produce 2,4-dimethyl-tetraketide lactone also contained methylmalonate (5 
mM), DEBSMod2 (10 µM) and DEBSMod3+TE (2 µM). The reaction to produce 2-fluoro-4-
methyl-tetraketide lactone also contained fluoromalonate (5 mM), DEBSMod2 (10 µM), 
DEBSMod3/AT0 (2 µM) and DszAT (2 µM). The reaction to produce 2-methyl-4-fluoro-
tetraketide lactone also contained fluoromalonate (5 mM), DEBSMod2/AT0 (10 µM) and 
DEBSMod3 (2 µM). 
All reactions were initialized by the addition of DEBSMod2 or DEBSMod2/AT0 and incubated 
at 37°C overnight. Reactions were then saturated with sodium chloride and the aqueous layer 
was acidified by the addition of 0.1 volumes of 70% perchloric acid and extracted four times into 
2 volumes of chloroform. The chloroform layer was concentrated by vacuum centrifugation and 
the tetraketide lactones were resuspended in water for analysis. Tetraketide lactones were 
analyzed by LC-MS using a Phenomenex Kinetex XB-C18 1.7 µm 150 x 2.1 mm column with a 
mobile phase of ammonium acetate (50 mM) with a gradient from 0 to 60% acetonitrile over 15 
min and detected on an Agilent single quadruple mass spectrometer in negative ion mode.  
ESI-MS/MS analysis of tetraketide lactones. ESI LC/MS/MS spectra were collected using 
an LTQ FT (Thermo Scientific). Negative ions analyzed in linear ion trap mode. MS/MS spectra 
were collected with the following normalized collision energies: TKL 26, F-TKL 35, all 
tetraketides 26. 
2.3 Results and Discussion 
Chain elongation in polyketides and related fatty acid-based natural products relies on a 
separate pool of extender units formed by carboxylation of acyl-CoAs at the α-position. These 
malonyl-CoA derivatives are then used as masked enolates for C–C bond formation following 
decarboxylation. The fluorinated extender, fluoromalonyl-CoA, can be made through two routes: 
either a two-step activation of biogenic fluoroacetate or by a direct ligation of CoA to 
fluoromalonate.  
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We reasoned that the acetate kinase 
(AckA)–phosphotransacetylase (Pta) 
pair would be effective at fluoroacetate 
activation, as mutations in this gene 
locus have been shown to lead to 
fluoroacetate resistance in Escherichia 
coli [37]. The enzymes from E. coli 
were therefore overexpressed and 
characterized biochemically, confirm-
ing that AckA and Pta serve as an 
effective activation system to rapidly 
produce both acetyl- and fluoroacetyl-
CoA at near quantitative yield (Figures 
2.2 and 2.3).  
Analysis of the kinetic parameters for these enzymes with respect to fluorinated substrates 
indicate that neither appears to be affected by the fluorine substituent beyond inductive effects 
that alter the nucleophilicity of the carboxylic acid (AckA) or electrophilicity of the carbonyl 
Figure 2.2. Enzymes used in extender unit biosynthesis. (1, AckA; 2, Pta; 
3, AccA; 4, AccB; 5, AccC; 6, AccD; 7, MatB; 8, methylmalonyl-CoA  
epimerase). 
Figure 2.3. Enzymatic synthesis of extender units from acetate and fluoroacetate. (A) Formation of 
fluoroacetyl-CoA (left) fluoromalonyl-CoA (right) monitored by RP-HPLC. (B) Extent of reaction from 
500 µM CoA and either acetate (left) or fluoroacetate (right), utilizing AckA, Pta and ACCase. 
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(Pta) [38].  
Next, we purified the 
individual AccABCD subunits 
that make up the acetyl-CoA 
carboxylase (ACCase) from E. 
coli (Figure 2.2) and added these 
enzymes to the AckA–Pta 
system in order to carry out the 
carboxylation of fluoroacetate in 
a one-pot reaction to generate the 
fluoromalonyl-CoA extender 
unit (Figure 2.3). Under these conditions, the ligation of CoA with AckA–Pta to produce the 
acyl-CoA is rapid and production of the carboxylated product is limited by the ACCase. 
Although the rate of conversion is 2.5-fold slower for fluoroacetate compared to acetate, the 
overall extent of reaction is similar for both congeners and suggests that covalent inactivation of 
the ACCase by fluoroacetyl-CoA is not significant (Figure 2.3). In addition to the route from 
fluoroacetate, we also tested a malonyl-CoA 
synthetase (MatB) [39] for 
coupling CoA directly to 
fluoromalonate (Figure 2.2). 
Although MatB greatly prefers 
malonate over the fluorinated 
congener, fluoromalonyl-CoA 
is still produced at reasonable 
efficiency (Figure 2.4). Both 
of these systems also provide 
in situ regeneration capacity 
that can amplify product yields 
from polyketide synthases, and 
we found that either system 
increased polyketide production by 
tetrahydroxynaphthalene synthase compared with 
simple addition of malonyl-CoA (Figure 2.5). 
We next turned our attention to utilizing the 
fluoromalonyl-CoA monomer for downstream chain 
elongation reactions. To start, we examined the 
behavior of a simple polyketide synthase system 
with regard to one cycle of chain extension and 
ketoreduction. These steps are key to the function of 
larger multimodular systems because they often 
control downstream cyclization and rearrangements 
within the polyketide backbone [3, 14]. We 
constructed a synthetic gene encoding NphT7 from 
Streptomyces sp. CL190 [40] and isolated the 
heterologously-expressed enzyme for biochemical 
characterization (Figures 2.6 and 2.7). NphT7 
Figure 2.4. Kinetic parameters for malonate activation (MatB, malonyl-CoA 
synthetase). 
Figure 2.6. Heterologous 
expression of NphT7. 
Figure 2.5. Efficiency of polyketide production with 
tetrahydroxynaphthalene synthase (THNS) [Izumikawa 
et al. J Ind Microbiol Biotechnol (2003) 30, 510–515] 
using different extender regeneration systems. THNS 
uses only malonyl-CoA as both starter and extender unit. 
All samples contained a fixed amount of malonyl- or 
acetyl-CoA (0.5 mM), and relative THN production was 
monitored at A510 nm. Samples with no regeneration 
system (1, 2) were compared to those containing 
regeneration systems related to non-productive 
decarboxylation (3, 4) and hydrolysis (5), while also 
providing additional substrate (5-9) in situ. Values are 
reported as the mean ± s.d. (n = 3). 
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appears to be a free-standing ketosynthase that is 
related at the structural level to the ketosynthase 
domain of more complex polyketide synthases 
(Figure 2.8).  
Using a coupled assay with an R-specific 
acetoacetyl-CoA reductase (PhaB), we found that 
NphT7 is competent to catalyze the formation of 
acetofluoroacetyl-CoA using an acetyl-CoA starter 
and fluoromalonyl-CoA extender with only a five-
fold defect in catalytic efficiency (kcat/KM) derived 
from a drop in kcat with the fluorinated substrate 
(Figure 2.7D). This lower turnover rate observed 
with the fluorinated substrate may be related to the 
reduced reactivity of the enolate species, which 
could be stabilized by the fluorine substituent. 
However, the overall yield was comparable for 
both fluorinated and nonfluorinated substrates, 
which shows that a decarboxylative Claisen 
condensation with fluoromalonyl-CoA can take 
place with a similar extent of conversion 
Figure 2.7. Chain extension and keto reduction with a fluorinated extender. (A) Reactions catalyzed 
by NphT7 and PhaB. (B) Steady-state kinetic parameters for NphT7-catalyzed C–C bond formation 
measured using a coupled assay with PhaB. (C) HPLC trace of 2-fluoro-3-hydroxybutyryl-CoA 
isolated from enzymatic reaction mixtures (m/z = 872). (D) 19F NMR of the product shows that both 
diastereomers are produced. 
Figure 2.8. Structural alignment of NphT7 and a DEBS 
ketosynthase domain. The NphT7 structure was predicted 
using Phyre2 [42] and based on a type III 3-oxoacyl-(acyl-
carrier protein) synthase from Burkholderia xenovorans 
(PDB ID 4EFI). Despite low sequence identity (<20%), the 
predicted structure overlays well with the KS domain from 
DEBSMod5 [43]. Active site residues (C119, H334 H374 (N in 
NphT7); DEBS numbering) are highlighted.  
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compared to malonyl-CoA. Furthermore, these experiments also show that the 2-fluoro-3-keto 
motif produced with the fluoromalonyl-CoA extender can be accepted by ketoreductases, as 
PhaB is capable of efficiently reducing the acetofluoroacetyl-CoA substrate (Figure 2.7B). The 
1H and 19F NMR spectra of the reduced product indicate that both diastereomers are produced in 
this reaction (Figures 2.6C and 2.9), which may result either from lack of stereochemical 
preference of NphT7 with respect to the fluorine substituent or to racemization of the product 
prior to reduction by PhaB. Although PhaB does not appear to show diastereoselectivity with 
respect to the fluorine group, polyketide synthase ketoreductases are known to be selective with 
regard to their native α-substituent and could potentially carry out the stereochemical resolution 
of the fluorine modification upon reduction [41].  
 
Figure 2.9. 1H-19F HMBC NMR analysis of enzymatically synthesized 2-fluoro-3-hydroxybutyryl-CoA. 
Based on data from other α-fluoroalcohols [44], the 19F resonance for the anti configuration of the 
fluorine and hydroxyl groups should be found upfield of the syn and was assigned as the major product. If 
PhaB maintains is native selectivity as an R-specific acetoacetyl-CoA reductase, the anti product is (2S, 
3R)-2-fluoro-3-hydroxybutyryl-CoA. 
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With this information in hand, we sought to extend our biosynthetic method for fluorine 
introduction to more complex polyketide synthase systems, which use the chain elongation 
reaction for the biosynthesis of many bioactive and clinically important natural products, such as 
erythromycin and rapamycin [3, 14]. Of these, the 6-deoxyerythronolide B synthase (DEBS), a 
multimodular polyketide synthase responsible for production of the erythromycin precursor, is 
likely the most well understood [45]. We therefore focused on studying chain extension by the 
sixth module of DEBS, including the terminal 
thioesterase (DEBSMod6+TE) (Figure 2.10) [28]. 
Using a diketide substrate (NDK-SNAC), 
DEBSMod6+TE can elongate the chain with its native 
methylmalonyl-CoA extender unit and cleave the 
tethered product to form methyltriketide lactone 
(TKL) (Figure 2.11, R= CH3, and Figure 2.12) [27].  
  
Figure 2.10. Enzymes used in the production of model 
polyketides. (1, DEBSMod2; 2, DEBSMod2AT0; 3, 
DEBSMod3+TE; 4, DEBSMod3AT0+TE; 5, DEBSMod6+TE; 6, 
DEBSMod6AT0+TE; 7, DszAT). 
Figure 2.11. Production of a fluorinated polyketide using DEBSMod6+TE. Chain extension by 
DEBSMod6+TE to form triketide lactones monitored by HPLC (TKL, m/z = 169; F-TKL, m/z = 
173). CoA, ATP, and ATP regeneration system are included in all in vitro reactions. Data are 
normalized with respect to the TKL peak. Methylmalonate and MatB (1), synthetic F-TKL 
standard (2), fluoromalonate and MatB (3), co-injection of 2 and 3 (4), fluoroacetate, AckA–Pta, 
ACCase, and MatB were incubated before filtering through a 3 kDa MWCO membrane and 
adding DEBSMod6+TE and NDK-SNAC (5), co-injection of 5 and 2 (6), one-pot reaction using 
conditions from 5 (7), co-injection of 7 and 2 (8), (9), E. coli cells (see below).  
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Scheme 2.1. Hydrolysis and regeneration reactions for F-TKL synthesis. Reaction scheme showing 
enzymes present in F-TKL forming reactions including observed non-productive hydrolysis reactions (red) 
and the ATP regenerating system (blue). 
Figure 2.12. Amplification of TKL formation using MatB. All reactions contained 400 mM sodium 
phosphate, pH 7.5, phosphoenolpyruvate (50 mM), TCEP (5 mM), magnesium chloride (10 mM), 
ATP (2.5 mM), pyruvate kinase (27 U/mL), myokinase (10 U/mL), methylmalonyl- CoA epimerase 
(5 µM), methylmalonate (20 mM), NDK-SNAC (1 mM) and DEBSMod6+TE (10 µM). The source 
of extender unit was either methylmalonyl-CoA (0.5 – 10 mM) or MatB (40 µM) and CoA (0.5 
mM). (A) Dependence of TKL formation on methylmalonyl-CoA. Data are average ± s.d. (n = 3) 
(B) Comparison of TKL yield with and without MatB regeneration. Values are reported as the 
mean ± s.d. (n = 3). 
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Figure 2.13. 1D-NMR spectra of synthetic F-TKL standard in CDCl3. (A) 1H NMR. (B) 13C NMR. (C) 
19F NMR. The relative keto:enol ratio in CDCl3 depends on concentration and increases with 
decreasing concentration.   
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Figure 2.14. 2D-NMR spectra of synthetic F-TKL standard in CDCl3. (A) COSY. (B) 1H-13C HSQC.  
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Figure 2.14. 2D-NMR spectra of synthetic F-TKL standard in CDCl3, cont’d. (C) 1H-13C HMBC. (D) 1H-19F HMBC.  
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Figure 2.15. 1H-19F HMBC of keto isomer region of synthetic F-TKL standard in CDCl3, showing crosspeaks for the 
major and minor epimers. 
 41 
 
 
  
Figure 2.17. Stereochemical analysis for F-TKL. (A) 1H NOESY spectrum of synthetic F-TKL standard in CDCl3. The same 
ratio between epimers is observed for enzymatically produced F-TKL. (B) Molecular modeling results for F-TKL. The lowest 
energy conformations of the two F-TKL keto diastereomers were selected based on a conformational search (Macromodel) 
using Maestro 9.3 (Schrödinger, Inc). Only the 2S epimer would be expected to show a single NOE coupling between H2 and 
H5, as observed.  
 42 
 
 
We found that DEBSMod6+TE is also able to accept the fluorinated monomer to catalyze 
chain extension to form the 2-fluoro-2-desmethyltriketide lactone (F-TKL) and incorporate 
fluorine into the polyketide backbone (Figure 2.11, 1-4). The identity of the F-TKL was 
established by comparison to an authentic synthetic standard by reverse-phase HPLC monitored 
by ESI-MS and further confirmed by characterization of the isolated compound by high 
resolution MS, GC-MS, and 19F NMR spectroscopy (Figure 2.13-2.16). Although the 2-S keto 
tautomer is generated in >94% diastereomeric excess (Figure 2.15, Figure 2.17), this ratio 
appears to be set by the compound’s stereoelectronic factors rather than by the stereochemical 
preferences of DEBSMod6+TE, since the F-TKL is fully enolized in aqueous solution. The F-TKL 
can also be produced directly from fluoroacetate using the AckA–Pta/ACCase activation system 
in either a telescoped (Figure 2.11, 5-6) or single-pot reaction (Figure 2.11, 7-8) with 
DEBSMod6+TE at a similar yield to the MatB reaction, which allows us to connect fluorinated 
polyketide production directly to the biosynthetically available fluorinated building block 
(Figure 2.1A, Scheme 2.1). 
  
Figure 2.18. Time-course for TKL and F-TKL formation by DEBSMod6+TE with substrate regeneration. (A) LC/MS traces 
monitoring TKL formation (m/z 169) from 2.5 mM NDK- SNAC. (B) Plot of NDK-SNAC and TKL concentrations. Initial rate: 1.5 min-1. 
(C) LC/MS traces monitoring F-TKL formation (m/z 173) from 10 mM NDK-SNAC. (D) Plot of NDK-SNAC and F-TKL concentrations. 
Initial rate: 0.14 h-1. (■, NDK-SNAC; ■, TKL; ■, F-TKL)  
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Figure 2.16. GC-MS and 19F NMR analysis of F-TKL. (A) Comparison of EI mass spectra of the standard (tR = 8.51 min) 
compared to the enzymatic product (tR = 8.56 min). (B) Comparison of 19F NMR spectra in CDCl3. The keto form is 
dominant at this concentration. 
 44 
In contrast to the chain extension reaction catalyzed by 
NphT7, DEBSMod6+TE does not incorporate the fluorinated 
extender unit into triketide lactone product as efficiently as its 
native methylmalonyl-CoA extender (Figure 2.18). 
Preliminary studies indicate that the reduced efficiency of 
DEBSMod6+TE with the fluorinated extender is not due to 
covalent inactivation of the enzyme (Figure 2.19), but rather to 
the more complex biochemistry of polyketide synthases with 
regard to monomer selection [46]. In fact, the acyltransferase 
domains of DEBS have been shown to be extremely selective 
for methylmalonyl-CoA, exhibiting a 100- to 1000-fold 
selectivity for their native substrate over malonyl-CoA [47]. 
The molecular mechanism underlying this selectivity remains 
an outstanding question, however, hydrolysis of incorrect 
extender units has been implicated as being involved [46]. 
Indeed, we observe extender unit hydrolysis even for the native 
substrate at a rate comparable to that of product formation (Table 2.1). This hydrolysis appears to 
limit fluoromalonyl-CoA incorporation, since substantially less F-TKL is observed using 
fluoromalonyl-CoA in the absence of MatB and ATP, and fluoromalonate remains the major 
Figure 2.20. 19F NMR analysis of F-TKL forming reaction with DEBSMod6TE. 19F NMR analysis of the reaction mixture of 
DEBSMod6+TE with MatB indicates that the major pathway for loss of fluoromalonyl-CoA appears to be hydrolysis rather than 
unproductive decarboxylation. In addition, no detectable defluorination was observed. (IS, 5-fluorouracil, 50 µM)  
Figure 2.19. Test for covalent inhibition 
of DEBSMod6+TE by fluoromalonyl-CoA. 
DEBSMod6+TE was incubated for 18 h in 
a F-TKL or TKL reaction. The enzyme 
was then isolated by Sephadex G-25 
and tested for its ability to produce TKL. 
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organofluorine species even in 
their presence (Figure 2.20). 
However, it is interesting to note 
that the fluoromalonyl-CoA 
extender is incorporated at higher 
efficiency than malonyl-CoA (R = 
H), which is reported to be 
naturally excluded by DEBS [47]. 
In fact, DEBSMod6+TE produces at 
least 10 times more F-TKL than H-
TKL in a direct competition experiment with equimolar amounts (1 mM) of fluoromalonyl-CoA 
and malonyl-CoA (Table 2.2). 
To address the issue of site- or regioselective fluorine incorporation, we turned our attention 
to replacing the enzyme activity most likely associated with low fluoromalonyl extender 
incorporation, the AT. It was previously shown that an inactivated AT domain could be 
complemented in trans by another AT [48], and we hypothesized that a malonyl-specific AT 
might be more accommodating toward the fluoromalonyl extender than the methylmalonyl-
specific ATs of DEBS. Therefore we set out to complement an AT-inactivated module with the 
trans-AT from the disorazole PKS, DszsAT [49, 50]. When we prepared the catalytically 
compromised DEBSMod6+TE mutant (S2107A), we were surprised to find that F-TKL yield 
increased even in the absence of a complementing AT, while TKL yield dropped considerably as 
expected, but not to zero (Figure 2.21). Formation of these triketides must take place via an AT-
independent mechanism that has not yet been characterized. We found that DszsAT did indeed 
accept fluoromalonyl-CoA and considerably enhanced F-TKL formation by the AT-null mutant 
(Figure 2.21). 
  
 v0 (µM min-1) Relative rate 
Methylmalonyl-CoA 1.36 ± 0.05 1.0 
Fluoromalonyl-CoA 3.5 ± 0.3 2.6 
Malonyl-CoA 6.1 ± 0.4 4.5 
 
Table 2.1. Rates of acyl-CoA hydrolysis by DEBSMod6+TE. 
Steady-state hydrolysis rates were measured using 1 µM 
DEBSMod6+TE and 500 µM acyl-CoA. Values are reported 
as the mean ± s.d. (n = 4). 
 
Figure 2.21. Selectivity of DEBSMod6+TE and DEBSMod3+TE for the methylmalonyl-CoA versus fluoromalonyl-CoA extender unit, as 
monitored by TKL (m/z = 169) and F-TKL (m/z = 173) formation. Conditions include wild-type modules, AT0 modules, and AT0 
modules in conjunction with the trans-AT from the disorazole PKS (DszsAT). Values are reported as the mean ± SD (n = 3). KR* 
denotes that the KR domain of Mod3 is inactive. 
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Figure 2.23. Production of fluorinated tetraketide lactones. Production of 2,4-dimethyl tetraketide lactone (m/z-H: 
227), 2-fluoro-4-methyl tetraketide lactone (m/z-H: 231), and 2-methyl-4-fluoro tetraketide lactone (m/z-H: 231). 
Chromatograms were collect by LC/MS by single ion monitoring in the negative channel. Mass spectra of the 
tetraketide lactones were obtained using LC/MS/MS on a LTQ-FT instrument in negative mode. Fragments that 
differ by 4 AMU, corresponding to a fluorine for methyl substitution, are labeled A – D. 
Table 2.2. F-TKL and H-TKL production under competitive conditions. 
DEBSMod6+TE was incubated with equimolar amounts of malonyl-CoA 
and fluoromalonyl-CoA (1 mM). Without substrate regeneration, no 
detectable H-TKL was formed (<50 nM). MatB and regeneration enzymes 
were then included to amplify and quantify H-TKL formation. Values are 
reported as the mean ± s.d. (n = 3).  
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Using this approach, we began to explore the possibility of site-selective fluorine 
incorporation with a mini-PKS model system, consisting of DEBSMod2 and DEBSMod3+TE, that 
was designed to carry out two chain-extension reactions from the NDK-SNAC substrate [25]. 
Using the appropriate AT-null constructs, we were able to observe preferential production of 
either regioisomer of the fluoro-methyl tetraketide lactone (tetraKL) (Figure 2.22). The identity 
of the 2-fluoro-4-methyl tetraKL and 2-methyl-4-fluoro tetraKL was established by both high-
resolution ESI-MS and LC-MS on the basis of their different retention times, as well as their 
mass fragmentation patterns, which are consistent with the incorporation of fluorine at the 
expected sites (Figure 2.23). These studies also indicate that further chain extension after 
fluorine insertion can be achieved and that fluorinated intermediates could potentially be 
tolerated in downstream reactions. This observation is consistent with previous work that has 
shown that intermediates with non-native substituents, including fluorine, can be extended and 
tailored to the final structure [3, 14, 17-18, 51] and gives promise that larger fluorinated 
polyketide targets may be accessible through this approach. 
The observed selectivity for fluoromalonyl- over malonyl-CoA extender units suggests that 
polyketide chain extension reactions with fluoromalonyl-CoA could possibly be catalyzed in 
vivo in E. coli, which contains a sizable malonyl-CoA pool (~35 mM) [52] but almost no 
methylmalonyl-CoA [21, 53]. We carried out preliminary 19F NMR studies of cells expressing 
MatB, NphT7, and PhaB and fed with nontoxic levels of fluoromalonate. Analysis of the media 
and cell extracts indicated that flux through fluoromalonyl-CoA could reach 100 µM to 1 mM, 
which is sufficient for use by PKSs in live cells (data not shown).  
Next, we tested the ability of DEBSMod6+TE to catalyze chain elongation in cell lysates 
prepared from E. coli BAP1 coexpressing DEBSMod6+TE and MatB. Under these conditions, F-
TKL is produced with no observable H-TKL (< 1 µM) upon addition of only NDK-SNAC, 
fluoromalonate, CoA, ATP, and the ATP regeneration system (Figure 2.24A). Negative controls 
with either no DEBSMod6+TE/MatB expressed or no NDK-SNAC substrate show no production 
of F-TKL (Figure 2.24A). These results demonstrate that the level of expression of the 
Figure 2.22. LC-MS traces showing regioselective tetraketide lactone formation using the DEBS mini-PKS consisting of DEBSMod2 
and DEBSMod3+TE (Me/Me, 2-methyl-4-methyl-tetraketide lactone, m/z = 227; Me/F, 2-fluoro-4- methyl-tetraketide lactone, m/z = 
231; F/Me, 2-methyl-4-fluoro-tetraketide lactone, m/z = 231). Me/Me was produced using DEBSMod2/DEBSMod3+TE and methyl- 
malonate (1). Me/F was produced using DEBSMod2/DEBSMod3AT0+TE, DszsAT, methylmalonyl-CoA, and fluoromalonate (2). F/Me 
was produced using DEBSMod2AT0/DEBSMod3+TE, methylmalonyl-CoA, and fluoromalonate (3). Data are normalized with respect to 
the Me/Me peak. All reactions contained MatB and the ATP regeneration system.  
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DEBSMod6+TE and MatB enzymes is sufficient for the incorporation of the fluorinated extender 
unit. They also further imply that fluorine could be introduced into the polyketide backbone 
inside living cells, which are capable of generating ATP for monomer activation through normal 
metabolic processes.  
Therefore, we cultured E. coli BAP1 coexpressing DEBSMod6+TE and MatB and harvested 
the intact cells after induction. These cells were then fed with the fluoromalonate precursor, 
which resulted in the production of F-TKL upon addition of NDK-SNAC (Figure 2.11, Figure 
2.24). The identity of the F-TKL under these conditions was established by LC-MS, co-injection 
with an authentic standard, and high-resolution MS. Moreover, F-TKL can also be produced 
directly in cell culture with the simple addition of a mixture of both substrates to the media after 
induction of DEBSMod6+TE and MatB (Figure 2.24C), though in lower yield. Taken together, 
these studies show that the natural selectivity of the polyketide synthase allows for the site-
selective introduction of fluorine over hydrogen into the polyketide backbone inside living cells. 
  
Figure 2.24. F-TKL production in vivo. (A) LC/MS traces showing F-TKL formation (m/z 173) in E. coli cell lysate. (B) In vivo 
selectivity data showing F-TKL production compared to H-TKL and TKL in fluoromalonate-fed E. coli resting cells expressing either 
DEBSMod6+TE or DEBSMod6+TE/AT0 and MatB. Bars represent mean ± s.d. (n = 3) with individual samples marked (■▲●). (C) 
LC/MS traces showing F-TKL formation (m/z 173) by E. coli cell culture upon feeding with NDK-SNAC.  
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2.4 Conclusions 
We have demonstrated that we can expand the fluorine chemistry of living systems with 
engineered pathways that use simple biogenic organofluorine building blocks to construct more 
complex fluorinated small molecule targets. To our knowledge, nature has not devised a strategy 
for generation of the fluoromalonyl building block or its utilization as a metabolic precursor for 
biosynthesis of complex natural products. Here, we show that the fluorinated extender unit, 
fluoromalonyl-CoA, can be produced enzymatically and used for downstream chain elongation 
reactions by polyketide synthases and that, at least in one case, subsequent α-ketoreduction is not 
inhibited by incorporation of a fluoroacetyl unit. Because of the modular nature of the 
biosynthetic pathways used to produce polyketides and related acetate-derived natural products, 
these findings open the door to general strategies for exploring the fluorine synthetic biology of 
complex natural products. 
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3.1. Introduction 
Natural products and organofluorines have each been important to the development of small 
molecule therapeutics, but they rarely intersect in structural space. Fluorine’s small size and high 
electronegativity confer powerful effects on small molecule properties, and drug fluorination can 
improve bioavailability, reduce clearance, alter pKa and lipophilicity, block metabolism, or 
increase potency [1,2]. As a result, fluorine is now found in 20−30% of therapeutics and 
agrochemicals, and methods for generating diverse organofluorine structures continue to serve a 
growing number of applications [5]. Despite these advantages, fluorine is rarely observed in 
naturally occurring compounds. Using synthetic biology approaches to incorporate fluorine into 
natural product biosynthesis would combine some of the strengths of organic and biological 
chemistry and expand the structural space of natural products, which have provided the source 
for many human therapeutics. 
We have previously shown that polyketide synthesis can accommodate fluorinated 
monomers as chain extenders in vitro, potentially leading to an enormous increase in natural 
product analogue diversity and new bioactive compounds [3]. However, polyketide synthesis, 
like all biosynthesis, is valuable mostly because it occurs in vivo using self-assembling, self-
replicating catalysts, making it scalable and relatively inexpensive. By contrast, purified enzymes 
are not a practical commercial source of natural products. Several additional challenges arise 
from the transition between an in vitro and an in vivo pathway (Figure 3.1). Fluorinated building 
blocks must be either taken up by the cell from an exogenous supply, or biosynthesized from 
fluoride as in the natural Streptomyces cattleya pathway. The chemistry to convert building 
blocks to activated polyketide monomers must occur within the context of the thousands of 
reactions of native cellular metabolism. Likewise, pathway reactions must now select fluorinated 
substrates out of the pool of all other endogenous metabolites. Diversion of fluorinated 
intermediates from the synthetic pathway must be avoided, since this could waste flux by 
Figure 3.1. Challenges associated with in vivo organofluorine metabolism. 
 56 
producing dead-end metabolites that cannot be reintroduced to the pathway, or interfere with 
background host metabolism resulting in toxicity. Finally, the synthetic pathway and fluorinated 
building block activation must be balanced with native energy and carbon resources needed to 
maintain the cell, produce necessary enzymes, and construct the non-fluorinated portions of the 
target natural product. 
To investigate these issues, we aimed to construct a synthetic organofluorine metabolic 
pathway that would enable both high-flux biosynthesis and in vivo screening and evolution of 
biosynthesis-associated enzymes. Although native polyketide synthase modules can accept 
fluorinated monomers, their low activity and selectivity towards fluorine, as well as the necessity 
of supplying a synthetic diketide precursor to initiate chain extension, lead us to look elsewhere 
for a model system. We had previously characterized two enzymes, the acetoacetyl-CoA 
synthase NphT7 [6], which is essentially a stand-alone polyketide ketosynthase domain, and the 
acetoacetyl-CoA reductase PhaB, which mimics a polyketide ketoreductase. These enzymes 
effectively carry out a single round of polyketide chain extension and ketoreduction but use 
CoA-linked substrates, side-stepping any issues with extender loading onto an acyl carrier 
protein (Chapter 2). We planned to use this high-efficiency pathway to establish that a sufficient 
intracellular fluoromalonyl-CoA pool can be made available, that potentially labile intermediates 
and derailment products do not divert flux from the desired product or cause toxicity for the host, 
and that titers of the pathway product can be achieved that are relevant to natural product 
biosynthesis.  
We selected E. coli as a chassis. Although it is not a host that is particularly amenable to 
polyketide synthase expression (with some exceptions [7]), its ease of genetic manipulation, fast 
growth and relatively well-characterized metabolism make it a useful platform. We hope to use 
E. coli to find generalizable principles for organofluorine metabolism that we can later transfer to 
natural product producing organisms such Streptomyces or Saccharopolyspora. 
We selected the relatively advanced fluoromalonate as the organofluorine input for our 
pathway. It has the advantage of being activated in one step by an enzyme, malonate:CoA ligase, 
that is not native to E. coli. Malonyl-CoA is a committed metabolite in E. coli, used only for fatty 
acid synthesis, and preliminary investigations have shown that fluoromalonyl-CoA does not 
enter that pathway (Xingye Yu, Ben Thuronyi, Chaitan Khosla & Michelle Chang, unpublished 
results), suggesting that it will be orthogonal to host metabolism and participate only in the 
synthetic pathway.  
Perhaps most importantly, fluoromalonate use avoids the need for fluoroacetyl-CoA as a 
pathway intermediate. Formation of this metabolite is key to fluoroacetate toxicity, since its 
entry into the tricarboxylic acid cycle leads to aconitase inhibition [8]. Use of fluoroacetate and 
fluoroacetyl-CoA is an achievable goal, but will likely require acyl-CoA carboxylase engineering 
to ensure that fluoroacetyl-CoA is carboxylated efficiently and cannot build up. Alternatively, 
careful growth-phase-based regulation of fluoroacetyl-CoA use, a strategy used in the native 
fluoroacetate producer S. cattleya [9], could avoid concurrent TCA cycle and fluoroacetyl-CoA 
use and therefore prevent toxicity. These approaches could eventually allow relatively 
inexpensive fluoroacetate, or extremely inexpensive fluoride (via the S. cattleya fluorinase 
pathway [10]), to be used as the input. 
The reduced diketidyl-CoA produced by our pathway is an α-fluorinated derivative of 3-
hydroxybutyryl-CoA, which is the primary feedstock for a class of biopolymers called 
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poly(hydroxyalkanoates) (PHAs) [11-13]. These polyesters can accumulate at high levels (up to 
~80% of dry cell weight) in native producers or transgenic E. coli. When an appropriate 
monomer composition is used, PHAs have materials properties similar to poly(propylene), and 
unlike petroleum-derived polymers they can be easily produced by fermentation of renewable 
feedstocks [12]. Naturally occurring PHAs derive their monomers either from fatty acid 
synthesis intermediates or from short-chain thiolases that are not known to produce 2-substituted 
acyl-CoAs. PHA biosynthesis can be engineered to derive monomers from exogenous fatty 
acids, but fatty acid catabolism is also not known to efficiently accept internally branched fatty 
acid chains that would result in 2-substituted 3-hydroxyacyl CoAs. Therefore, although the 
diversity of PHA monomers is enormous, it draws heavily on variable 3-position substituents; 
polymers with 2-substituents are an underexplored class. PHAs with some 2-methyl substituents 
have been reported, but incorporation by native producers is usually very low [14-17] except in 
one notable case, where fed 3-hydroxypivalic acid could be homopolymerized under specific 
growth conditions [18]. 
NphT7 has previously been shown to be capable of providing 3-hydroxybutyryl-CoA 
monomers for poly(hydroxybutyrate) [19]. We wondered whether, as we had found to be the 
case for polyketide biosynthesis, a 2-fluoro substituent might be acceptable to wild-type PHA 
synthases due to its small size, while simultaneously creating significant changes in PHA 
materials properties because of its electronegativity and unique physical properties. Because α-
fluorinated thioesters are considerably more labile to hydrolysis and presumably also to retro-
aldol decomposition than most other analogues would be, and off-pathway intermediates can 
easily be detected and characterized using 19F NMR, the organofluorine-based pathway would 
also serve as a stringent test case for identifying side-reactions and bottlenecks that might impede 
PHA derivative engineering. Therefore the organofluorine-based pathway could serve as a 
starting point for enzyme and pathway modifications to develop diverse 2-substituted PHAs. 
Accordingly, we investigated pathways that incorporated a poly(hydroxyalkanoate) synthase to 
attempt to produce poly(3-hydroxybutyrate-co-2-fluoro-3-hydroxybutyrate). 
3.2 Materials and methods 
Commercial materials. Luria-Bertani (LB) Broth Miller, LB Agar Miller, Terrific Broth 
(TB) and glycerol were purchased from EMD Biosciences (Darmstadt, Germany). Carbenicillin 
(Cb), isopropyl-β-D-thiogalactopyranoside (IPTG), tris(hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl), sodium chloride, dithiothreitol (DTT), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), magnesium chloride hexahydrate, kanamycin (Km), 
acetonitrile, dichloromethane, ethyl acetate and ethylene diamine tetraacetic acid disodium 
dihydrate (EDTA) were purchased from Fisher Scientific (Pittsburgh, PA). Coenzyme A 
trilithium salt (CoA), acetyl-CoA, malonic acid, methylmalonic acid, tris(2-
carboxyethyl)phosphine (TCEP) hydrochloride, phosphoenolpyruvate (PEP), adenosine 
triphosphate sodium salt (ATP), myokinase, pyruvate kinase, β-mercaptoethanol, sodium 
phosphate dibasic heptahydrate and N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) were 
purchased from Sigma-Aldrich (St. Louis, MO). Diethylfluoromalonate was purchased from 
Sigma-Aldrich (St. Louis, MO) or from Oakwood Chemical (West Columbia, SC). Formic acid 
was purchased from Acros Organics (Morris Plains, NJ). Acrylamide/Bis-acrylamide (30%, 
37.5:1), electrophoresis grade sodium dodecyl sulfate (SDS), Bio-Rad protein assay dye reagent 
concentrate and ammonium persulfate were purchased from Bio-Rad Laboratories (Hercules, 
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CA). Restriction enzymes, T4 DNA ligase, Phusion DNA polymerase, T5 exonuclease, and Taq 
DNA ligase were purchased from New England Biolabs (Ipswich, MA). Deoxynucleotides 
(dNTPs) and Platinum Taq High-Fidelity polymerase (Pt Taq HF) were purchased from 
Invitrogen (Carlsbad, CA). PageRuler™ Plus prestained protein ladder was purchased from 
Fermentas (Glen Burnie, Maryland). Oligonucleotides were purchased from Integrated DNA 
Technologies (Coralville, IA), resuspended at a stock concentration of 100 µM in 10 mM Tris-
HCl, pH 8.5, and stored at 4°C. DNA purification kits and Ni-NTA agarose were purchased from 
Qiagen (Valencia, CA). 10,000 MWCO regenerated cellulose ultrafiltration membranes were 
purchased from EMD Millipore (Billerica, MA). The Rezex ROA-Organic Acid H+ (8%) HPLC 
column was purchased from Phenomenex (Torrance, CA). Deuterium oxide and chloroform-d 
were purchased from Cambridge Isotope Laboratories (Andover, MA). 
Bacterial strains. E. coli DH10B-T1R was used for DNA construction. Except where 
otherwise noted, production and polymer formation experiments were conducted in 
BL21(de3)T1R. Strains DH5α(de3), BW25113, W3110(de3), DH10B-T1R and DH1(de3) were 
also tested in production experiments. Strains from the Keio collection [20] derived from 
BW25113 were used to test the influence of native genes on the pathway. 
Gene and plasmid construction. Plasmids were constructed using the isothermal Gibson 
assembly method [21]. All PCR amplifications were carried out with Phusion or Platinum Taq 
High Fidelity DNA polymerases. For amplification of GC-rich sequences, PCR reactions were 
supplemented with DMSO (5%). All constructs were verified by sequencing (Quintara 
Biosciences; Berkeley, CA).  
The synthetic gene encoding Rhodopseudomonas palustris MatB was reverse translated 
using E. coli class II codon usage and synthesized using PCR assembly. Gene2Oligo was used to 
convert the gene sequence into primer sets using default optimization settings (Appendix Table 
2) [22]. To assemble the synthetic gene, each primer was added at a final concentration of 1 μM 
to the first PCR reaction (50 μL) containing 1 × Pt Taq HF buffer (20 mM Tris-HCl, 50 mM 
KCl, pH 8.4), MgSO4 (1.5 mM), dNTPs (250 μM each), and Pt Taq HF (5 U). The following 
thermocycler program was used for the first assembly reaction: 95oC for 5 min; 95oC for 30 s; 
55oC for 2 min; 72oC for 10 s; 40 cycles of 95oC for 15 s, 55oC for 30 s, 72oC for 20 s plus 3 
s/cycle; these cycles were followed by a final incubation at 72oC for 5 min. The second assembly 
reaction (50 μL) contained 16.5 μL of the unpurified first PCR reaction with standard reagents 
for Pt Taq HF. The thermocycler program for the second PCR was: 95oC for 30 s; 55oC for 2 
min; 72oC for 10 s; 40 cycles of 95oC for 15 s, 55oC for 30 s, 72oC for 80 s; these cycles were 
followed by a final incubation at 72oC for 10 min. The second PCR reaction (16.5 μL) was 
transferred again into fresh reagents and run using the same program. Following gene 
construction, the DNA smear at the appropriate size (1.5 kb) was gel purified and used as a 
template for the rescue PCR (50 μL) with Pt Taq HF and rescue primers r_palu matB F1/R1 
under standard conditions. The resulting rescue product was inserted into the NdeI site of 
pET16b and confirmed by sequencing, then amplified using primers pCDFDuet R.p_matB 
F1/R1 and inserted between the NdeI and KpnI sites of pCDF-Duet1 to yield pCDF-
Duet1.RpamatB.  
pET23c.His6-TEV-NphT7 was constructed by PCR amplifying NphT7 from pET16b.nphT7 
[3]  using primers NphT7 23a F2/R1 and inserting into EcoRI-digested pET23a-His-TEV-SfoI. 
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pXHB vectors. The ribosome binding site and spacing from pET16b was inserted into 
pBAD33 by Gibson insertion of the overlapping primers pBAD33-pET.RBS GF1/GR1 between 
the KpnI and XbaI sites, removing KpnI in the process, to yield pBAD33.pET-RBS. To construct 
pXHB.ø.RpamatB, the following fragments were combined in a one-pot Gibson assembly: 1) An 
araC/pBAD/rrnB fragment was PCR amplified from pBAD33-pET.RBS using primers pBAD 
GF1 and pBAD-pCDF GR1; 2) A lacI fragment was PCR amplified from pCDF-Duet1 using 
primers lacI GF1 and lacI-pBAD GR1; 3) plasmid pCDF-Duet1.RpamatB was digested with 
XbaI and HindIII, removing lacI and one of the T7 promoters. This assembly yielded 
pXHB.ø.RpamatB. 
pXHB.ø.RpamatB was used to construct variants as follows: Transporters were inserted after 
the pBAD promoter into XbaI/HindIII-digested plasmid by Gibson assembly. Ligases were 
inserted after RpamatB into KpnI/XhoI-digested plasmid. 
Transporters: MadLM (gene IDs 3480185 and 3480184) was PCR amplified using a colony 
of Pseudomonas fluorescens Pf-5 as template with primers Pfl.madLM GF1/GR1. MatC (gene 
ID 1097877) was PCR amplified from pBAD18-Cb.500ScomatC (which was obtained from by 
PCR amplifying matC from a neighborhood PCR of Streptomyces coelicolor A3(2) M145 
genomic DNA) using primers pCDF-ara-ScoMatC GF1/R1. MdcF was reverse translated based 
on the protein sequence from Klebsiella pneumoniae 342 (gene ID 6935833) using the Integrated 
DNA Technologies E. coli codon optimization algorithm and purchased as two overlapping 
gBlocks (Appendix Table 2) which were inserted into pXHB.ø.RpamatB in a 3-piece Gibson 
assembly. 
Ligases: EcoACS was PCR amplified from pCDF.P(Tet)-acs.accBC.dtsR1 (acs having been 
originally PCR amplified from E. coli K-12 DNA) using primers pCDF-ACS GF1/GR1. 
EcoPrpE was PCR amplified from pET16b.prpE (prpE having been originally PCR amplified 
from E. coli DH10b DNA) using primers PrpE GF1/GR1. ScoAlkK was PCR amplified from 
Streptomyces coelicolor genomic DNA using primers Sco.AlkK GF1/GR1. PolAlkK was PCR 
amplified from pCDF3-sPhaZ.alKk (which contains a synthetic, E. coli codon optimized gene 
for the protein from Pseudomonas oleovorans, ) using primers Spol.alkK GF1/GR1. 
pXHB.PflmadLM.ø was constructed by digesting pXHB1 with KpnI/NdeI, gel purifying the 
vector backbone and incubating with Gibson isothermal assembly mix without an insert. The 
selected clone had a deletion beginning 13 nt before the T7 promoter and extending to 13 nt after 
the XhoI site as compared to pXHB1. 
pXHB3 was constructed by digesting pXHB1 with NdeI/NotI (which removes the T7 
promoter). pT5 was PCR amplified from pT5T33-Bu2 using primers pXHB3.GF1/GR1 and 
inserted by Gibson assembly. 
pPOL vectors. To construct pPOL1, NphT7 was PCR amplified from pET16b.nphT7 using 
primers FPHB-NphT7 F1/R1, and PhaB.PhaC was PCR amplified using primers FPHB-PHAB 
F1/PHAC R1 from pBT33-PhaABC [23] (PhaB was a synthetic gene [23] corresponding to 
PhaB1 from Ralstonia eutropha H16, gene ID 4249784, and PhaC was originally PCR amplified 
from Ralstonia eutropha H16 genomic DNA, phaC1, Gene ID 4250156). The two fragments 
were inserted between the NcoI and XbaI sites of pTRC99a in a 3-piece Gibson assembly, 
yielding pPOL1. To construct pPOL1-nb, NphT7.PhaB was PCR amplified from pPOL1 using 
primers NphT7 G F3/PhaB G R1, and inserted between the NcoI and XbaI sites of pTRC99a by 
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Gibson assembly. To construct pPOL1-n, pPOL1-nb was digested with EcoRI/XbaI and the gap 
repaired by insertion of the oligos pPOL1-n GF1/GR1. 
To construct pPOL4.1 and 4.2, Rhodococcus ruber PhaC (locus ID WP_017681423) (4.1) 
and Rhodococcus opacus PD630 PhaC (locus ID WP_005237952) (4.2) were reverse translated 
using the Integrated DNA Technologies E. coli codon optimization algorithm and purchased as 
two overlapping gBlocks (Appendix Table 2) which included the ribosome binding site from 
pET16b. pPOL1-nb was digested with XbaI and HindIII and the PhaC gene was inserted by 
Gibson assembly. The final clone selected for pPOL4.2 had a silent mutation at V254 (GTG > 
GTA). 
FlK vectors. pET28a.flK and pET28a.flk-H76A were constructed by PCR amplification of 
flK from pET16b-His-sFlK or pET23a-His-Tev-sFlK-H76A using primers pET28a flK 
GF1/GR1 and insertion into XbaI/NcoI-digested pET28a. To construct pET28a.pTet.flK and 
pET28a.pTet.flK(H76A), these vectors were digested with XbaI and BglI (which removes lacI 
and pT7. TetR and pTet were amplified from pCDF.P(Tet)-acs.accBC.dtsR1 using primers pTet-
pET28a.flk GF1/GR1 and inserted into the digested vectors. 
Expression of His-tagged proteins. TB (3x1 L) containing carbenicillin (50 µg/mL) in 2.5 
L Ultrayield baffled shake flasks (Thomson Instrument Company, ) was inoculated to OD600 = 
0.05 with an overnight TB culture of freshly transformed E. coli BL21(de3)T1R containing the 
appropriate plasmid. The cultures were grown at 37°C at 200 rpm to OD600 = 0.6 to 0.8 at which 
point cultures were cooled on ice for 20 min, followed by induction of protein expression with 
IPTG (1 mM) and overnight growth at 16°C. Cell pellets were harvested by centrifugation at 
10,000 × g for 5 min at 4ºC and stored at -80ºC.  
Purification of His10-RpaMatB. RpaMatB was purified as described [3] for ScoMatB. 
Purification of His6-TEV-NphT7. Frozen cell pellets (20 g) were thawed and resuspended at 
5 mL/g cell paste with Buffer A (50 mM sodium phosphate, 500 mM sodium chloride, 20% 
glycerol, 20 mM BME, pH 7.5) containing imidazole (10 mM) and Tween 20 (1%). Complete 
EDTA-free protease inhibitor cocktail (Roche) was added to the lysis buffer before resuspension 
(1 pellet/100 mL lysis buffer). The cell paste was lysed by sonication (5 s on, 25 s off, 10 min 
processing time). The lysate was centrifuged at 15,300 × g for 40 min at 4°C to separate the 
soluble and insoluble fractions. The soluble lysate was applied to Ni-NTA Agarose (Qiagen, 1 
mL/7 g cell paste) pre-equilibrated with Buffer A and allowed to batch bind for 1 h at 4°C on a 
rocking agitator. The resin was transferred to a column by gravity flow. The column was washed 
with Buffer A + 10 mM imidazole, then Buffer A + 20 mM imidazole, each time until the eluate 
was negative for protein content by Bradford assay (Bio-Rad), then eluted with Buffer A + 250 
mM imidazole. The eluate was diluted 7-fold with Buffer B (50 mM HEPES, 2.5 mM EDTA, 1 
mM DTT, 20% glycerol, pH 7.5) and loaded onto a HiTrap Q HP column (GE Healthcare, 5 mL) 
using an ÄKTApurifier FPLC (GE Healthcare Life Sciences; Piscataway, NJ). Protein was 
eluted with a linear gradient from 0 to 1 M sodium chloride in Buffer E over 50 column volumes 
(4 mL/min). Fractions containing the target protein (eluted at ~100 mM sodium chloride) were 
pooled by A280 nm and concentrated under nitrogen flow (60 psi) in an Amicon ultrafiltration cell 
using a YM10 membrane. The protein (~0.3 mg) was flash-frozen in liquid nitrogen and stored 
at -80°C at a final concentration of 0.3 mg/mL, which was estimated using the calculated ε280 nm 
(26,930 M-1 cm-1). 
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Preparation of sodium fluoromalonate. Fluoromalonate was prepared either as described 
[3] or as follows. Diethylfluoromalonate (19 mmol) was hydrolyzed using sodium hydroxide (38 
mmol, 2.1 eq) in water (40 mL). The mixture was stirred at room temperature (without 
controlling the moderate exotherm) for 15 min until the pH was basic and no organic phase was 
visible. The resulting solution was transferred to a round-bottom flask with water and 
concentrated by rotary evaporation in a 65 °C water bath to dryness (to remove ethanol). The 
resulting white, waxy solid was redissolved in deionized water to a final volume of 20 mL (1 M 
sodium fluoromalonate) and frozen in 2 mL aliquots at -20 °C. The exact concentration was 
determined by quantitative 19F NMR as described below. 
In vitro NphT7 assay. Organofluorine products of NphT7 were observed by 19F NMR. The 
reaction mixture (600 µL) contained 50 mM HEPES, pH 7.5, trifluoroacetate (2 mM), D2O 
(15%), phosphoenol pyruvate (10 mM), pyruvate kinase (18 U/mL), myokinase (2.5 U/mL), 
ATP (2.5 mM), magnesium chloride (2.5 mM), coenzyme A (1 mM), acetyl-CoA (1 mM), 
fluoromalonate (5 mM) and RpaMatB (10 µM). The mixture was preincubated at 298 K and 
formation of fluoromalonyl-CoA verified by NMR. The reaction was initiated by addition of 
NphT7 (5 µM) and observed by 19F NMR at intervals essentially as described below (high-
throughput NMR analysis). 
In vivo production of 2-fluoro-3-hydroxybutyrate and poly(2-fluoro-3-hydroxybutyrate-
co-3-hydroxybutyrate). Chemically competent cells of the appropriate strain were transformed 
with either pXHB or pPOL. A colony was picked, grown in LB with 1% glucose and the 
appropriate antibiotic (carbenicillin and streptomycin, or spectinomycin for SmR strains), and 
cells were harvested at OD600 0.3-0.5 and made chemically competent. These cells were freshly 
transformed with the second plasmid, pXHB or pPOL. Colonies were picked and grown for 12-
18h at 37°C in LB (5 mL) with 1% glucose, carbenicillin (50 µg/mL) and streptomycin (50 
µg/mL) or spectinomycin (25 µg/mL). Overnight cultures were diluted 50-fold into fresh 
medium (50 mL in a 250 mL baffled flask) and grown at 37°C until either OD600 0.2-0.4 (early 
induction) or OD600 0.7-0.9 (late induction). Culture (5 mL) was transferred to 40 mL culture 
tubes containing IPTG (1 mM final), arabinose (0.2% final) and sodium fluoromalonate (5 mM 
final unless otherwise noted). Cultures were grown at 30°C for approximately 48h before 
sampling. 2 mL culture was removed in duplicate and centrifuged at 23,000 × g for 5 minutes in 
plastic 2 mL screw-top tubes with O-ring seals (Thomas Scientific, Swedesboro, NJ). The 
supernatant was decanted and saved for 19F NMR and LC-MS analysis. For polymer-producing 
strains, the tubes were centrifuged again and the remaining medium removed by aspiration; cell 
pellets were frozen at -20°C. For polymer isolation, polymer-producing strains were induced in 
50 mL medium in 250 mL baffled flasks, the entire culture was collected by centrifugation at 
10,000 × g. 
Growth curves. Cultures prepared as above for production experiments were grown at 37°C 
to OD600 0.8-1.2, then used to inoculate fresh medium (25 mL) to OD600 0.10. Cultures were 
grown at 37°C and ODs monitored until they reached 0.25-0.3 (1-2 h). Culture was transferred to 
40 mL tubes (5 mL per condition) containing inducing agents and fluoromalonate as appropriate, 
and 200 µL was removed from each tube and transferred to a 96-well plate. The plate was 
incubated with continuous shaking uncovered at 30°C in a SpectraMax M2 plate reader 
(Molecular Devices, Sunnyvale, CA) and OD600 measurements taken every 5 min for 10 h. An 
internal blank of uninoculated medium containing 200 µg/mL chloramphenicol was included. 
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The tubes were incubated at 30°C at 200 rpm and sampled as described above after 48 h. OD600 
data were corrected for the path length of 200 µL liquid (0.6 cm). 
Large-scale polymer production. Overnight cultures of E. coli BL21(de3)T1R containing 
pXHB1 and pPOL1 were prepared as described above and diluted 50-fold into LB (1L) 
containing 1% glucose, carbenicillin (50 µg/mL) and streptomycin (50 µg/mL). Cultures were 
grown to OD600 0.7-0.9 and induced with 1 mM IPTG and 0.2% arabinose, and sodium 
fluoromalonate or sodium malonate (1 mM) was added. Cultures were grown for 48h at 30°C, 
then cell pellets were harvested by centrifugation (10,000 × g). 
Polymer purification from cell pellets. Polymer was isolated by hypochlorite/sodium 
dodecyl sulfate (SDS) lysis of cells and oxidation of cell debris. This procedure is known to have 
a modest effect on the molecular weight of isolated polymer, since poly(3-hydroxybutyrate) is 
not completely resistant to hypochlorite oxidation [4]. Cell pellets were resuspended at room 
temperature in a solution of 5% sodium hypochlorite (from household bleach) and 1% SDS 
(from a 10% stock solution solubilized at 55°C) at approximately 20 mL/g cell paste. Polymer 
was pelleted by centrifugation at 10,000 × g and the supernatant was discarded. The polymer 
pellet was resuspended in water, then pelleted again; this was repeated a total of four times. 
Polymer was then washed 2x with methanol, 1x with ethyl acetate and 1x with hexanes. The 
polymer was resuspended in hexanes and transferred as a suspension to a tared 10 mL screw-top 
tube with a rubber seal. Residual hexanes were evaporated under a stream of nitrogen and 
chloroform (or chloroform-d) was added at ~1 mL/20 mg polymer. The mixture was heated in a 
sand bath at 90°C overnight and vortexed periodically until the polymer dissolved. The resulting 
solution was used for NMR characterization. For determination of materials properties, polymer 
was precipitated from chloroform by dropwise addition into >100 volumes of rapidly stirring 
methanol. The precipitated polymer was collected manually and dried under vacuum. 
Analysis of polymer properties. SEC was performed using a Hewlett-Packard series 1100 
liquid chromatography system (CHCl3, 35 °C, 1 mL/min), equipped with a Hewlett-Packard 
1047A RI detector and three PLgel 5 µm MIXED-C columns. Apparent molar masses were 
reported versus polystyrene standards (Polymer Laboratories). Thermogravimetric analysis 
(TGA) was performed on a Perkin Elmer Diamond TGA/DTA. Samples were heated in 
aluminum pans under air at a rate of 10°C min-1. 
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Analysis of organofluorines in culture media by high-throughput 19F NMR analysis. 
Culture medium samples for NMR analysis were prepared as described above. Culture medium 
(595 µL) was mixed with TFA internal standard (140. mM, 10 µL) and D2O (95 µL) and 
approximately 600 µL of the solution were transferred to a 7” Grade 2, 5 mM NMR tube 
(Kimble Chase Life Science, Vineland NJ). 19F NMR spectra were collected at 298 K on a 
Bruker AV-600 spectrometer at the College of Chemistry NMR Facility at the University of 
California. Tuning, shimming and 90° pulse time were optimized for each sample. The typical 
90º pulse was ~16 µs at -3 dB power. Two spectra per sample (Figure 3.8) were collected 
consecutively using the zg30 pulse program as follows: Spectrum 1 observed TFA (referenced to 
-76.4 ppm) and fluoride (-121 ppm; not observed except as a contaminant in media) and used the 
following parameters: rg = 512, o1p = -100 ppm, sw = 60 ppm, td = 11750 (aq = 0.34 s), d1 = 0 
s, ds = 20, ns = 100; Spectrum 2 observed fluoromalonate (-178.4 ppm), both diastereomers of 2-
fluoro-(R)-3-hydroxybutyrate (-197.4 and -199.9 ppm; tentatively assigned as 2-(R)-3-(R) and 2-
(S)-3-(R) respectively) and fluoroacetate (-217.9 ppm) and used the following parameters: rg = 
512, o1p = -198 ppm, sw = 79 ppm, td = 15360 (aq = 0.34 s), d1 = 0 s, ds = 20, ns = 1000 (for 
quantitation to ~50 µM). Background signal from fluoropolymer in the probe was removed by 
backward linear prediction (ME_mod = LPbc, ncoef = 32, tdoff = 64) and the spectrum was 
phased and baseline-corrected automatically (apk, abs). Peaks were manually integrated and 
absolute integrals were normalized to TFA. To account for incomplete relaxation between scans 
(Figure 3.2), a standard curve was prepared for each analyte by collecting spectra of dilutions of 
a single sample in culture medium (Figure 3.3) and a linear scaling factor was applied to the 
normalized integrals. The concentrations of analytes in the 1x sample were determined by 
Figure 3.2. Diagram showing how incomplete relaxation affects NMR integrations. Top panel: 
quantitative integrals result from complete relaxation. Middle panel: short relaxation times reduce signal. 
Bottom panel: species with different relaxation times give disproportionate amounts of signal under 
incomplete relaxation conditions. 
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comparison to the 2 mM TFA standard under quantitative conditions (d1 > 5 × the largest T1). 
Analysis of 2-fluoro-3-hydroxybutyrate and 3-hydroxybutyrate in culture medium by 
LC-MS. Culture medium samples were diluted 100x into a solution of 10 µM adipic acid 
(internal standard) in water. Samples were analyzed using an Agilent 1290 HPLC system 
equipped with a needle wash system (50% methanol/water) on a Rezex ROA-Organic Acid H+ 
(8%) column (5 µm, 4 × 150 mm, Phenomenex) maintained at 55°C using 0.5% formic acid as 
the mobile phase and an isocratic method (0.6 mL/min) for 10.5 minutes. The injection volume 
was 2 µL. Products were monitored using a triple quadrupole mass spectrometer (Agilent 5130) 
operating in multiple reaction monitoring mode. 2-fluoro-3-hydroxybutyric acid (m/z 121 > 101), 
3-hydroxybutyric acid (103 > 59) and adipic acid (145 > 83) were detected in negative ion mode 
using the following parameters: ΔEMV 400, fragmentor voltage 70, collision energy 10 (adipic 
acid) or 5 (hydroxybutyric acids), cell accelerator voltage 7, dwell time 120 ms. Crotonic acid 
(87 > 69), resulting from polymer acidolysis (see below), was detected in positive ion mode 
using the following parameters: ΔEMV 400, fragmentor voltage 20, collision energy 8, cell 
accelerator voltage 4, dwell time 200 ms. The ESI source with Jetstream sheath gas was 
configured as follows: gas temperature 285 °C, gas flow 10 L/min, nebulizer 35 psi, sheath gas 
temperature 300 °C, sheath gas flow 12 L/min. 2-Fluorocrotonate was not observed by MS, and 
only a trace amount was detected by 19F NMR (as a doublet with J = 36 Hz, about -127 ppm) 
even when polymer was acidolyzed in neat concentrated sulfuric acid and diluted with basic D2O 
at room temperature, presumably because the equilibrium constant for hydration of this species 
to 2-fluoro-3-hydroxybutyrate is large. Figure 3.4 shows an example chromatogram. 
Analysis of poly(2-fluoro-3-hydroxybutyrate-co-3-hydroxybutyrate) in whole cell 
acidolysate by LC-MS. Cell pellets, collected in 2 mL screw-top tubes as described above, were 
resuspended in 50 µL 16 mM adipic acid (internal standard) by adding ~20-30 glass beads (1 
mm diameter) and vortexing vigorously. Concentrated sulfuric acid (150 µL) was added and the 
mixture incubated at 95 °C in a heat block for ~15 h, resulting in a uniform dark brown 
Figure 3.3. 19F NMR standard curves for organofluorine analytes. 
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suspension. Samples were vortexed and diluted with water (1.4 mL), then heated at 95 °C again 
for 2-6 h to allow partial hydration of crotonic acids formed during the depolymerization. Tubes 
were centrifuged at 21,850 × g to remove insoluble debris and supernatant was removed and 
diluted 50-fold for LC-MS analysis as described above for media samples. The final 
concentration of adipic acid after dilution was 10 µM. 
For analyte quantitation, a standard solution of poly(2-fluoro-3-hydroxybutyrate-co-3-
hydroxybutyrate) acidolysate was prepared by acidolysis of pure, isolated polymer (7.8 mg) as 
described above. The monomer ratio was determined by 1H NMR before acidolysis. The 
concentration of compounds derived from 3-hydroxybutyrate was determined using independent 
standard curves of sodium hydroxybutyrate and crotonic acid, and these values were used along 
with the previously determined monomer ratio to calculate the concentration of 2-fluoro-3-
hydroxybutyrate. Serial dilutions of this acidolysate solution were used as calibration standards; 
analyte responses were normalized to the internal standard. 
  
Figure 3.4. Example MRM chromatogram for media/polymer analytes. 
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3.3 Results and discussion 
Design of a fluorodiketide biosynthetic pathway. We constructed a four-gene, two-
plasmid system for biosynthesis of 2-fluoro-3-hydroxybutyryl-CoA from exogenous 
fluoromalonate (Figure 3.5). Plasmid pXHB encodes enzymes for formation of fluoromalonyl-
CoA, while pPOL encodes ketosynthase, ketoreductase and polymerase enzymes.  
We chose to express MatB using a T7 promoter from pXHB, which has a CloDF13 origin, 
giving a copy number approximately twice that of pPOL (ColE1 origin). We expected this 
combination to emphasize fluoromalonyl-CoA formation over diketide synthesis, since if 
fluoromalonyl-CoA is indeed a committed metabolite in E. coli, its accumulation would drive 
flux through the pathway without resulting in 
toxicity or off-pathway reactions. We previously 
found that the MatB enzyme from Streptomyces 
coelicolor was able to catalyze the ATP-dependent 
ligation of fluoromalonate to CoA with a catalytic 
efficiency of 530 ± 40 M-1s-1 [3]. However, a 
recently reported homolog from 
Rhodopseudomonas palustris was reported to have 
greater promiscuity toward alternative substrates, 
e.g. methylmalonate [24]. We tested the activity of 
this homolog on fluoromalonate and found a larger 
catalytic efficiency of 1,250 ± 80 M-1s-1 (Figure 
3.6), including a 7-fold higher kcat parameter, and 
accordingly used it for fluoromalonate activation in 
the current study. 
To provide MatB with fluoromalonate, we 
incorporated a malonate transporter (see below) 
Figure 3.6. Dose response curve for Rhodopseudomonas 
palustris MatB activation of fluoromalonate, fit to the 
Michaelis-Menten equation. 
Figure 3.5. Plasmids and pathway for 2-fluoro-3-hydroxybutyrate and poly(2-fluoro-3-hydroxybutyrate) synthesis from 
fluoromalonate. Formation of possible derailment products is shown with dotted arrows. 
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into pXHB on a separate promoter. Although previous work in our group found that fed 
fluoromalonate could be converted to fluoro-triketide using a polyketide synthase module in E. 
coli cell culture, the optimal conditions required very high cell density (OD ~100) and high (up 
to 50 mM) fluoromalonate concentrations to obtain product titers on the order of 1 µM [3]. We 
hypothesized that because of its two ionizable groups and low pKa values, diffusion of 
fluoromalonate across the cell membrane might be difficult, and that a malonate transporter 
might provide a solution if it had activity on fluoromalonate as well. 
We ordered the NphT7 and PhaB genes as shown in pPOL in part because NphT7 catalyzes 
an effectively irreversible step (energetically equivalent to hydrolysis of ATP and producing 
CO2), and would therefore be expected to have a larger flux control coefficient in the pathway 
than PhaB, making higher expression advantageous. In addition, the phaCAB operon in 
Ralstonia eutropha has a similar arrangement. We did not expect PhaB activity to limit pathway 
flux: Although it has not been characterized with respect to activity on acetofluoroacetyl-CoA, 
its activity on its native substrate acetoacetyl-CoA 
is high (kcat/KM 1.80 x 107) [25] and reduction of an 
α-fluoro ketone would be more energetically 
favorable. 
A fluoromalonate transporter allows mM 
pathway flux. E. coli BL21(de3) cells harboring 
pXHB.ø.RpamatB, which does not contain a 
malonate transporter, and pPOL1-nb did not 
convert fed fluoromalonate (5 mM) to any other 
fluorinated species within the limit of detection (50 
µM, 1%) of our 19F NMR assay (Figure 3.7). We 
therefore tested one representative of each of three 
classes of architecturally distinct prokaryotic 
malonate transporters that we identified using the 
Transporter Classification Database [26]. MadLM 
is a characterized two-component sodium: 
malonate symporter [27] from Malonomonas 
rubra; we used a homolog from Pseudomonas 
fluorescens. MatC and MdcF, from Streptomyces 
coelicolor and Klebsiella pneumoniae respectively, 
are putative malonate symporters found in operons with malonate:CoA ligase and malonyl-CoA 
decarboxylase genes involved in exploitation of malonate as a carbon source. None of these 
proteins share significant sequence identity (except minor similarity between MdcF and MadM, 
26% identical over 80 amino acids, blastp expect value 0.013). 
Figure 3.7. Organofluorine levels observed by 19F NMR in 
the absence of a malonate transporter. Following induction, 
cultures were incubated for 48 hrs at 30°C, then 
supernatant samples analyzed by NMR. Error bars show 
sample standard deviation, n=3 biological replicates, except 
for the no cell condition where n=1. 
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Surprisingly, we observed little 
toxicity (data not shown) when 
expressing any of the transporters at full 
induction (0.2% arabinose) even with a 
strong canonical RBS, suggesting that 
either translation or membrane insertion 
is not very efficient for these proteins. 
We found that all  three transporters 
were able to accept fluoromalonate, 
leading to formation of two new 
organofluorines in the culture medium: 
2-fluoro-3-hydroxybutyrate and 
fluoroacetate (Figure 3.8). Both MatC 
and the two-component transporter 
MadLM enabled mM levels of flux to 
fluorohydroxybutyrate (Figure 3.9). The 
maximal flux observed in this 
experiment was 30 µM/hr for MatC and 
50 µM/hr for MadLM.  
We evaluated the response of each 
transporter to fed fluoromalonate 
concentration at low and high induction 
ODs (Figure 3.10) and found that MadLM achieved titer saturation at lower fluoromalonate 
levels and also was more versatile in that it performed similarly with early or late induction, 
whereas MatC required early induction to achieve high titers. We carried out the remaining 
studies using the MadLM-containing plasmid pXHB1. 
Figure 3.9. Organofluorine levels observed by 19F NMR with expression of malonate transporters at early or late 
induction times. Performance of MadLM was somewhat higher in this experiment than was typical. Error bars show 
sample standard deviation, n=3 biological replicates. 
Figure 3.8. Organofluorines in culture medium detected from full pathway 
expression. Diastereomers of 2-fluoro-3-hydroxybutyrate are tentatively 
assigned based on chemical shift (as in [3]). 2 mM TFA is used as an 
internal standard.  
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We compared pathway flux in 6 E. coli host strains, B-type strain BL21(de3) and K-12-type 
strains BW25113, W3110, DH1, DH5α(de3) and DH10b. Because not all strains were readily 
available as de3 lysogens, we used pXHB3 for this comparison, in which MatB is expressed 
from a T5 promoter rather than T7. Although the pathway was functional in all strains, only 
BL21(de3) and DH5α(de3) produced significant titers of fluorohydroxybutyrate (Figure 3.11). 
BL21(de3) is a common strain for protein overexpression and lacks the Lon and OmpT 
proteases, which may be important to express sufficient levels of some or all of the pathway 
enzymes. However, DH5α produces even higher titers with those proteases intact. The 
performance of DH5α is surprising given its genotypic similarity to DH1 and DH10b, which are 
far less effective. Unfortunately, its growth rate with the pathway plasmids was slow and lag 
times after inoculation were 5–8 hours, so 
BL21(de3) was selected as a production strain.  
Only fluoroacetate and 
fluorohydroxybutyrate accumulate. 
Irrespective of pathway variant, strain, growth 
and induction conditions, we observed only 
fluoromalonate, fluorohydroxybutyrate and 
fluoroacetate in the growth medium (Figure 3.8). 
Fluorohydroxybutyrate presumably originates 
from hydrolysis of fluorohydroxybutyryl-CoA. 
To evaluate whether this reaction might be 
catalyzed by an endogenous thioesterase, we 
compared organofluorine production by tesA and 
tesB knockout strains from the Keio collection 
[20] to their parent (again using pXHB3), but 
found no difference in production (data not 
shown), albeit in a background of very low 
pathway performance (Figure 3.11). Another 
Figure 3.10. Fluorohydroxybutyrate titers resulting from varying fluoromalonate feeding levels. Error bars show sample standard 
deviation. Three replicate cultures for each transporter and induction OD condition were grown and induced, then each culture was 
split and portions were incubated with various concentrations of fluoromalonate. Large variability with MadLM cultures at late 
induction OD appears to be due to culture-to-culture variation independent of fluoromalonate concentrations (that is, production was 
consistently high or low from a given culture) rather than variable responses to fluoromalonate level. 
Figure 3.11. Comparison of pXHB3/pPOL1-nb pathway 
organofluorines from six E. coli strains. Error bars show 
sample standard deviation, n=3 biological replicates. 
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enzyme may play a role, or the 
relative lability of these α-
fluorinated acyl-CoAs may result in 
facile non-catalyzed hydrolysis. No 
organofluorines were detected by 19F 
NMR in lysate from washed cells 
(intracellular concentrations < 60 
µM) after 48h of growth, consistent 
with relatively low steady-state 
concentrations of fluoroacyl-CoA 
intermediates including 
fluorohydroxybutyryl-CoA.  
 We did not observe 
acetofluoroacetate, the hydrolysis 
product of acetofluoroacetyl-CoA, 
from the full pathway, suggesting 
that PhaB activity meets or exceeds 
NphT7 activity. Only in a PhaB-deleted pathway, pXHB1 pPOL1-n, did we observe peaks in the 
19F NMR tentatively attributed to acetofluoroacetate and fluoroacetone, its decarboxylation 
product, along with another unidentified organofluorine (Figure 3.12). This strain still produced 
a modest amount of fluorohydroxybutyrate, presumably by action of an endogenous 
ketoreductase (Figure 3.13). 
Fluoroacetate originates from off-pathway reactions and leads to minor toxicity. Toxic 
fluoroacetyl-CoA, and its hydrolysis product fluoroacetate, could potentially arise from several 
pathway intermediates. We found that fluoromalonate itself is stable in culture medium for >2 
weeks and is not transformed by cells carrying empty vector, lacking a transporter, or lacking 
MatB (Figure 3.7). However, fluoromalonyl-CoA 
appears to be subject to decarboxylation at a low 
level even in the absence of downstream pathway 
enzymes, and expressing NphT7 further increases 
fluoroacetate formation (Figure 3.13). The cause 
of non-NphT7-catalyzed fluoromalonyl-CoA 
decarboxylation in E. coli remains to be 
determined. 
Like other ketosynthases, NphT7 has been 
shown [6] to decarboxylate extender units 
nonproductively, i.e. without chain extension. To 
verify this activity, we purified His6-NphT7 and 
examined its activity condensing acetyl-CoA with 
fluoromalonyl-CoA (generated in situ using 
MatB) using 19F NMR (Figure 3.14). New peaks 
tentatively assigned to acetofluoroacetate and 
acetofluoroacetyl-CoA formed rapidly, along with 
a small amount of fluoroacetyl-CoA. Non-
quantitative NMR parameters were used to 
Figure 3.12. 19F NMR spectrum of organofluorines produced using plasmids 
pXHB1 and pPOL1-n. 5-fold more scans were collected than for typical 
organofluorine quantitation spectra. Tentative assignments are based on 
chemical shift, multiplicity and by comparison with in vitro NphT7 products 
(Figure 3.14). 
Figure 3.13. Organofluorines produced by truncated 
pathway variants. Error bars show sample standard 
deviation, n=3 biological replicates. 
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achieve acceptable signal-to-noise, 
but the data allow an estimate of the 
ratio of productive (bond-forming) 
to nonproductive decarboxylation 
events at between 8 : 1 and 14 : 1. 
This ratio is roughly consistent with 
the increase in fluoroacetate 
production observed with NphT7 
expression (Figure 3.13). 
Fluoroacetyl-CoA is toxic to E. 
coli and many other organisms 
because of mechanism-based 
inhibition of aconitase and TCA 
cycle shutdown [8]. This toxicity 
could be a roadblock to achieving 
sustainable, high titers of 
fluoropolyketides. To evaluate 
toxicity, we compared the growth 
rates of pathway variants after induction in either the presence or absence of 5 mM 
fluoromalonate (Figure 3.15). Fluoromalonate-dependent toxicity was observed and tracked with 
48 hr fluoroacetate production (except in the case of pXHB.ScomatC.RpamatB, which showed 
Figure 3.15. Growth curves for indicated pathway variants after pathway induction in the presence (red) and absence (black) of 5 
mM fluoromalonate. Cultures were grown in a 96-well plate with shaking at 30°C. Error bars show sample standard deviation, n as 
indicated. 
Figure 3.14. NphT7-catalyzed condensation between fluoromalonyl-CoA and 
acetyl-CoA observed by 19F NMR. Peaks with a prime are deuterated species 
arising from exchange with the solvent (15% D2O/H2O). Tentative assignments: 
a. fluoromalonate b. fluoromalonyl-CoA c. acetofluoroacetate 
d. acetofluoroacetyl-CoA e. unknown f. fluoroacetyl-CoA g. fluoroacetone 
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no fluoromalonate-dependent 
toxicity for reasons that are 
unclear, perhaps related to 
slower fluoromalonate uptake 
during log phase). However, 
the growth inhibition was 
relatively minor, resulting in 
saturation culture densities 
lower by at most 2 OD units 
(data not shown), possibly 
because the majority of 
fluorometabolite production 
occurs after the onset of 
stationary phase even when 
induction is during log phase 
growth. 
To verify that fluoroacetyl-CoA was responsible 
for the observed growth defects, we expressed the 
fluoroacetyl-CoA specific thioesterase from 
Streptomyces cattleya, FlK [28-30], along with 
pathway enzymes (a three-plasmid system). Wild-
type FlK, but not a catalytically compromised mutant 
(H76A, catalytic efficiency reduced by a factor of 3 × 
105) [29], rescued the fluoromalonate-dependent 
growth reduction when the full pathway was 
expressed (Figure 3.16), although expression of FlK 
from a T7 promoter was associated with a 
fluoromalonate-independent growth defect. 
We also observed an increased titer of 
fluoroacetate after 48 hrs in the active, but not an 
inactive FlK expression strain (n=3, 286 ± 80 µM for 
FlK vs. 219 ± 11 µM for FlK-H76A). This increase 
in titer is notable because it suggests that without a thioesterase, metabolism of fluoroacetyl-CoA 
is slow under these conditions, since it represents an apparent bottleneck in fluoroacetate 
formation. If E. coli can indeed maintain a pool of fluoroacetyl-CoA without severe toxicity or 
hydrolysis, expression of an appropriate acyl-CoA carboxylase could allow this off-pathway 
intermediate to be redirected to fluoromalonyl-CoA and desired downstream products. 
Figure 3.17. Monomer content of polymer and growth 
medium for full pathway (+phaC) in the presence or 
absence of 5 mM fluoromalonate. Polymer was 
acidolyzed before LC-MS and medium assayed directly. 
The y-axis represents concentration in mM for media 
samples, and mmol per L culture for intracellular 
polymer. Error bars show sample standard deviation, 
n=3. 
Figure 3.16. Growth curves for strains expressing active or inactive FlK, a 
fluoroacetyl-CoA-specific thioesterase, from a T7 promoter in the presence (red) and 
absence (black) of 5 mM fluoromalonate. Cultures were grown in a 96-well plate with 
shaking at 30°C. Error bars show sample standard deviation, n=3 biological replicates. 
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Fluorohydroxybutyrate can be incorporated into bioplastic. We next investigated 
whether expression of PhaC, a 3-hydroxyalkanoyl-CoA polymerase, would lead to formation of 
a novel 2-fluorinated polyester. To analyze intracellular polymer content, we carried out either 
Figure 3.18. 1D NMRs of poly(2-fluoro-(R)-3-hydroxybutyrate-co-(R)-3-hydroxybutyrate). Diastereomers of the fluorinated monomer 
are assigned tentatively based on chemical shift. Red labels correspond to fluorinated monomers; black labels to non-fluorinated 
monomers. The 19F and 19F-1H decoupled spectra were collected using different instruments. 
Figure 3.19. 1H NMR spectrum of poly((R)-3-hydroxybutyrate) produced by the NphT7 pathway (without fluoromalonate feeding). 
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whole-cell acidolysis in sulfuric acid to depolymerize 
PHAs [31] followed by LC-MS quantitation of monomer-
derived species, or isolated and purified PHA by removing 
other cellular components with concentrated bleach and 
detergent, [4] followed by extensive washing. Expression 
of PhaC lead to robust formation of polymer and we found 
that fluorinated monomers were incorporated when 
fluoromalonate was fed (Figure 3.17). However, 
fluoromonomer content was relatively low (< 20%), and 3-
hydroxybutyrate, which presumably arises from the 
endogenous pool of malonyl-CoA (ca. 35 µM [32]) 
supplying pathway enzymes with their native substrates, 
comprised the bulk of the polymer. We also found that 
overall polymer yields were reduced by 2-fold when 
fluoromalonate was included, and that only 34% of the total 
2-fluoro-3-hydroxybutyryl-CoA produced was polymerized 
(in contrast to 88% of the 3-hydroxybutyryl-CoA 
polymerized when no fluoromalonate was fed). This 
reduction could be due either to preferential hydrolysis of 
the fluorinated acyl-CoAs by PhaC or an endogenous 
thioesterase, or to slower incorporation of fluorinated 
monomers by PhaC. Overall 2-fluoro-3-hydroxybutyrate 
production was similar whether PhaC was included in the pathway or not (compare Figure 3.17 
and Figure 3.13, pPOL1-nb), suggesting that PhaC itself does not contribute substantially to 
hydrolysis.  
To verify fluorinated monomer incorporation, we purified polymer and analyzed it by NMR. 
The 1H, 19F and 13C spectra all show peaks corresponding to fluorinated monomers, with 
characteristically large JH-F and JC-F coupling constants (Figure 3.18). Comparison of the 1H 
Figure 3.21. Full COSY spectrum of poly(2-fluoro-3-hydroxybutyrate-co-3-hydroxybutyrate) and expansion showing evidence of co-
polymerization. 
Figure 3.20. Diastereomers of 2-fluoro-(R)-3-
hydroxybutyrate from the in vitro reactions of 
NphT7 and PhaB (as the acyl-CoAs; 
reproduced from [3]), culture medium and 
polymer. The peak positions of the 
diastereomers are inverted in culture medium 
(note ppm scales), but since the peak ratios are 
identical, this is likely due to CoA 
thioesterification and/or differences in pH and 
ionic strength. 
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spectrum of polymer isolated from cells cultured with (Figure 3.18) and without fluoromalonate 
(Figure 3.19) show identical poly(3-hydroxybutyrate) peaks. Notably, both diastereomers of 2-
fluoro-(R)-3-hydroxybutyryl-CoA appear to be incorporated into polymer, with a ratio similar to 
that observed in culture medium and in the in vitro reactions of NphT7 and PhaB (Figure 3.20), 
suggesting that PhaC does not distinguish the stereochemistry of the 2-fluoro substituent. 
Because acetofluoroacetyl-CoA is expected to epimerize rapidly under biological conditions, 
resulting in a nearly 1:1 mixture of diastereomers (since the nearest stereocenter is 12 bonds 
away), the observed diastereomeric ratio presumably represents the substrate selectivity of PhaB. 
It is unlikely to be the result of epimerization of 2-fluoro-3-hydroxybutyryl-CoA or 2-fluoro-3-
hydroxybutyrate, because the diastereomers of 2-fluoro-3-hydroxybutyric acid (two syn 
enantiomers and two anti enantiomers) are resolved under our LC conditions, and we observe a 
different ratio in polymer acidolysate (1.5 ± 0.2, mean ± standard deviation) compared to culture 
medium (3.1 ± 0.4) (which matches the ratio observed by 19F NMR of 2.8 ± 0.4, suggesting that 
ionization and fragmentation efficiency is similar between the two diastereomers), and this 
would not be expected if epimerization is facile. 
The fluoromonomer content is too low to show 1D 1H or 13C peaks corresponding to non-
fluorinated monomers adjacent to fluorinated ones, but the COSY spectrum does have one such 
crosspeak (Figure 3.21), which indicates a fluorinated monomer used to extend a non-fluorinated 
chain. The 1H-19F HMBC spectrum also shows crosspeaks at 1H chemical shifts very close to 
those of nonfluorinated monomers (Figure 3.22). Finally, the 19F[1H] spectrum (Figure 3.18), 
which shows every unique fluorine as a singlet, makes it clear that fluoromonomers exist in 
many distinct chemical environments within the polymer. 
Runs of fluoromonomers seem unlikely, but the possibility exists that fluorinated monomers 
are chain-terminating, due either to slowness of subsequent extensions or the lability of the α-
fluoro (thio)ester. To investigate this possibility, we tested the molecular weight of polymers 
Figure 3.22. 1H-19F HMBC spectrum of poly(2-fluoro-3-hydroxybutyrate-co-3-
hydroxybutyrate). 
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produced by our system that contained either 
no fluorinated monomers or 7% fluorinated 
monomers using GPC (Table 3.1). The 
molecular weights and dispersity indices were 
essentially identical, which given the 
considerable fluoromonomer content implies 
that chain termination is not significantly 
more likely following fluoromonomer 
incorporation. This is promising for the 
potential to synthesize higher fluoromonomer 
content materials. However, all other 
properties that we examined (Table 3.1) also 
showed no differences between the polymers 
(including thermal properties determined by 
DSC, data not shown), so higher 
fluoromonomer content is apparently required 
to assess whether poly(2-fluoro-3-
hydroxybutyrate) has any characteristics of interest. 
To attempt to improve fluoromonomer incorporation, we synthesized genes for alternative 
polymerases, two PhaC homologs from organisms that had previously been reported to 
polymerize 2-substituted monomers [18]. However, neither performed better than the original 
PhaC from Ralstonia eutropha (Figure 3.23). We also added ligases in an operon after RpamatB 
on pXHB1: two homologs of AlkK, an enzyme reported to ligate medium chain length 3-
hydroxy acids to CoA in Ralstonia and related PHA-producing organisms [33], from 
Streptomyces coelicolor and Pseudomonas oleovorans; and acetyl-CoA synthetase (ACS) and 
propionyl-CoA synthetase (PrpE) from E. coli. Although some of these enzymes reduced media 
titers of 2-fluoro-3-hydroxybutyrate, a possible result of its reattachment to CoA, all of them 
reduced the fluoromonomer content of intracellular polymer, suggesting a deleterious effect on 
overall organofluorine production (data not shown). 
  
Figure 3.23. Monomer content of polymer and growth medium 
using alternative polymerases. Error bars show sample standard 
deviation, n=3. 
Table 3.1. Properties of polymers produced using the NphT7-based pathway. 
 Poly((R)-3-hydroxybutyrate) 
Poly(2-fluoro-(R)-3-
hydroxybutyrate-co-(R)-
3-hydroxybutyrate) 
Mol % fluoromonomer - 7 
Number average 
molecular weight (Mn, Da)* 
5.4 × 105 6.0 × 105 
Dispersity (Mn/Mw) 1.62 1.69 
Decomposition 
temperature (°C) 260 260 
 * Bleach exposure during purification is known to slightly reduce polymer molecular weight [4]. 
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3.4 Conclusions 
The model system we have developed is capable of supporting mM flux of organofluorine 
biosynthesis in E. coli. We used it to identify functional fluoromalonate transporters that should 
be portable to other organisms. We found that toxicity from the synthetic pathway is minimal, 
and can be attributed to fluoroacetyl-CoA formation. This metabolite can either be detoxified 
using FlK or potentially redirected to the pathway using e.g. an engineered ACCase. Endogenous 
metabolism still competes favorably with the organofluorine pathway, underlining the need for 
developing enzymes with improved fluorine tolerance and specificity. These results set the stage 
for biosynthesis of fluorinated analogues of complex, high-value compounds such as bioactive 
natural products. 
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Chapter 4: Engineered trans-acting acyl transferases: a strategy 
for efficient, regioselective fluorine incorporation into 
polyketides 
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4.1. Introduction 
Trans-ATs are enzymes homologous to fatty acid synthase ATs that have evolved to act in 
trans as part of so-called trans-AT PKS clusters, [4] which are much less well-characterized than 
cis-AT clusters such as DEBS. In these type I systems, cis-AT function within each module has 
been lost (although fragments of the cis-AT domain may still be distinguishable), and all ACPs 
within the cluster are acylated with extender units by one or more trans-ATs. Trans-AT PKSs 
are also distinguished by other fascinating characteristics: modules sometimes possess tandem 
ACPs, which may or may not be essential for function; the order of chain extension events often 
diverges from the sequence of modules; and ketosynthase domains are more closely related by 
substrate specificity than by cluster of origin [5,6]. In addition, trans-AT clusters often include a 
domain (fused to a trans-AT or as a separate protein) homologous to cis-ATs, which is thought 
to function not as an acyl transferase but as an editing protein, hydrolyzing stalled or incorrect 
intermediates from the assembly line [8]. Trans-ATs may also be fused to a trans-acting enoyl-
reductase domain, phylogenetically unrelated to cis-ERs, which functions analogously to trans-
ATs [10]. 
Since trans-ATs have evolved to act in trans, they have compensated for loss of the high 
effective concentration that comes with physical tethering to their ACP substrates. These 
enzymes have catalytic efficiencies on the order of 103 to 104 M-1 s-1. [9,11] while cis-ATs range 
from 101 to 102 M-1 s-1 when acting in trans [9,12]. This high efficiency makes them attractive 
targets for evolution: mutations that alter specificity often compromise catalytic activity, but 
trans-ATs can accommodate considerable activity loss while still remaining effective. Trans-
ATs have been shown to efficiently acylate ACPs (or thiolation domains, the analogous 
component of non-ribosomal peptide synthetases) from other clusters, including cis-AT ACPs, 
and have been used to complement AT0 modules [11-14]. We therefore aim to use trans-ATs to 
accomplish our goal of regioselective fluorinated extender incorporation by polyketide synthases 
(Figure 4.1). 
Almost all known trans-ATs are malonyl-CoA specific. The exceptions are single examples 
of ATs that load rare extender units, ethylmalonyl [15] or methoxymalonyl [16]; no 
methylmalonyl-specific ATs have been characterized. KirCII, which loads ethylmalonyl units, 
does in fact have relaxed extender specificity that has been used in polyketide synthesis, but its 
kinetics are poor, especially compared to other trans-ATs, and its lack of specificity may actually 
be problematic [17-19]. Fortunately, our positive results using DszAT to load fluoromalonyl 
units onto DEBS ACPs (Section 2.3), compared to the lack of activity of methylmalonyl-specific 
DEBS cis-ATs on fluoromalonyl-CoA, suggest that malonyl-specific ATs are a promising area 
to explore. 
Figure 4.1. Trans-AT complementation in the context of a full PKS assembly line. Cis-ATs load their native extender units, while 
modules with inactivated cis-ATs are loaded with fluoromalonyl extenders by the trans-AT. 
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Rather than pursuing directed evolution studies on the first trans-AT we tested, we hope to 
explore existing sequence diversity in this enzyme family, which may result in differences in 
activity. By testing a small library of trans-ATs, we hope to find ATs with improved activity on 
fluoromalonyl-CoA, or a reduced preference for malonyl-CoA over fluoromalonyl-CoA, which 
may be more promising candidates for evolution than DszAT. 
Only a handful of trans-ATs have been characterized biochemically. DszAT can acylate 
diverse ACPs, including those from DEBS, as described by our group and others [9,14,17]. 
FenF, which acts in mycosubtilin biosynthesis in Bacillus, can efficiently acylate ACPs and even 
peptidyl carrier proteins with Km values on the order of 1 mM [11]. BryP-AT1 is a slower 
enzyme but it can also acylate heterologous ACPs, e.g. from bryostatin and pikromycin 
synthases [7]. KirCI-AT2 has been established as an active enzyme; it acylates all ACPs within 
its biosynthetic cluster except the one served by KirCII [3]. Finally, the AT from fatty acid 
synthesis in Streptomyces coelicolor, FabD, has also been shown to acylate DEBS ACPs [20]. 
Additional trans-ATs have not been characterized individually but have been confirmed to be 
part of an active trans-AT PKS. These include DifA [21], PedD [22], LkcD [23], VirI [24], 
LnmG [25], TaV-AT2 [26,27], MmpC [28], RhiG [29], OzmM [16], ChiA [30], PksE [10] and 
MlnA [31]. Metagenomic sequencing of environmental DNA has furnished a wealth of new 
secondary metabolite clusters, including trans-AT PKSs. These sequences are another source for 
library members, although their positive classification as PKS ATs is dependent on genetic 
context from correct cluster assembly, since they are homologous to fatty acid synthase ATs. 
Our screening strategy for a trans-AT library could encompass both in vitro and in vivo 
testing. An in vivo approach requires more initial investment but has the advantages of being 
both more scalable and much more relevant, since it is essentially the situation in which these 
enzymes will be used. The work described in Chapter 3 should make it possible to generate 
sufficient fluoromalonyl-CoA for in vivo fluorinated extender use. For in vivo complementation 
assays, trans-ATs from the library will be expressed along with a full PKS that has AT active 
site mutation(s). DEBS again provides a convenient model system, since its efficient expression 
has been achieved in both the native producer [32] and a more easily genetically manipulated 
heterologous Streptomyces host, S. coelicolor [1]. We envision establishing 6-dEB production in 
such a host – strains of S. lividans [33], S. coelicolor [34] and S. avermitilis [35] have been 
developed that lack most biosynthetic clusters and therefore have enhanced secondary metabolite 
production potential and reduced background – and constructing all six possible AT mutants of 
DEBS (Figure 4.2). Expression of library members in all six backgrounds should provide a 
stringent test of in vivo complementation and reveal any differences in efficiency in forming the 
six fluorinated 6-dEB regioisomers arising from module, backbone position or adjacent site 
chemistry. These may include complementation of AT0 mutant modules by other cis-ATs within 
DEBS [13], acylation at 
undesired positions [17], lack 
of trans-AT activity on 
specific ACPs, occlusion of 
ACPs by the full PKS 
homodimeric complex, or 
interference from native 
metabolism. 
Figure 4.2. In vivo library expression and combinatorial complementation scheme for 
fluorinated 6-dEB production and trans-AT screening. 
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4.2 Materials and methods 
Commercial materials. Luria-Bertani (LB) Broth Miller, LB Agar Miller, Terrific Broth 
(TB), yeast extract, malt extract and glycerol were purchased from EMD Biosciences 
(Darmstadt, Germany). Carbenicillin (Cb), isopropyl-β-D-thiogalactopyranoside (IPTG), 
tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl), sodium chloride, dithiothreitol 
(DTT), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), magnesium chloride 
hexahydrate, kanamycin (Km), acetonitrile and ethylene diamine tetraacetic acid disodium 
dihydrate (EDTA), were purchased from Fisher Scientific (Pittsburgh, PA). Coenzyme A 
trilithium salt (CoA), diethylfluoromalonate, malonic acid, methylmalonic acid, tris(2-
carboxyethyl)phosphine (TCEP) hydrochloride, phosphoenolpyruvate (PEP), adenosine 
triphosphate sodium salt (ATP), myokinase, pyruvate kinase, lactate dehydrogenase, 
poly(ethyleneimine) solution (PEI), β-mercaptoethanol, sodium phosphate dibasic hepthydrate 
and N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) were purchased from Sigma-Aldrich 
(St. Louis, MO). Formic acid was purchased from Acros Organics (Morris Plains, NJ). 
Acrylamide/Bis-acrylamide (30%, 37.5:1), electrophoresis grade sodium dodecyl sulfate (SDS), 
Bio-Rad protein assay dye reagent concentrate and ammonium persulfate were purchased from 
Bio-Rad Laboratories (Hercules, CA). Restriction enzymes, T4 DNA ligase, Antarctic 
phosphatase, Phusion DNA polymerase, T5 exonuclease, and Taq DNA ligase were purchased 
from New England Biolabs (Ipswich, MA). Deoxynucleotides (dNTPs) and Platinum Taq High-
Fidelity polymerase (Pt Taq HF) were purchased from Invitrogen (Carlsbad, CA). PageRuler™ 
Plus prestained protein ladder was purchased from Fermentas (Glen Burnie, Maryland). 
Oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA), 
resuspended at a stock concentration of 100 µM in 10 mM Tris-HCl, pH 8.5, and at 4°C. DNA 
purification kits and Ni-NTA agarose were purchased from Qiagen (Valencia, CA). Complete 
EDTA-free protease inhibitor was purchased from Roche Applied Science (Penzberg, Germany). 
Amicon 5,000 MWCO regenerated cellulose ultrafiltration membranes were purchased from 
EMD Millipore (Billerica, MA). 
Bacterial strains. E. coli DH10B-T1R and BL21(de3)T1R were used for DNA construction 
and heterologous protein production, respectively, except for DEBS modules, which were 
heterologously expressed in E. coli BAP1 [36]. 
Gene and plasmid construction. Standard molecular biology techniques were used to carry 
out plasmid construction. All PCR amplifications were carried out with Phusion or Platinum Taq 
High Fidelity DNA polymerases. For amplification of GC-rich sequences, PCR reactions were 
supplemented with DMSO (5%) using the standard buffer rather than GC buffer with primer 
annealing temperatures 8-10°C below the Tm. All constructs were verified by sequencing 
(Quintara Biosciences; Berkeley, CA). 
Assembly of cloning vectors. To construct pCDF-pUWL-shuttle, a cassette encoding pTet.rfp 
was amplified from pWCD0941 (a gift from Will DeLoache, UC Berkeley) using primers 
pUWL-sgg CF1/CR1 and cloned into pCDF2.P(tac.tac)(gg) (a BsaI-acceptor vector) by BsaI 
Golden Gate (following the protocol below). To construct pSET152(gg), the same cassette was 
PCR amplified using primers pSET152gg CF1/CR2 and inserted between the EcoRV/BamHI 
sites of pSET152 [37] by Gibson assembly [38], resulting in a BsaI Golden Gate acceptor vector. 
To construct pSET152r(gg), rop was amplified from pET28a using primers pSET152-ROP-
F1/R1 and inserted into the NheI site of pSET152(gg) by Gibson assembly. An analogous 
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procedure was used to convert pSET152-pc13 into pSET152r-pc13. To construct 
pET28a.HisN(sgg), the single backbone SapI site was first removed by SapI digestion and 
Gibson assembly insertion of the oligos pET.SapI_del F1/R1. The resulting vector, 
pET28a*SapI, was digested with NdeI/EcoRI and the NdeI/EcoRI fragment of pCDF-pUWL-
shuttle, containing the SapI-acceptor RFP cassette, was inserted by ligation.  
Assembly of trans-AT library. Genes were reverse-translated using IDT’s codon optimization 
for Streptomyces coelicolor. Hairpins and high-G+C runs were removed manually as necessary 
to pass pre-synthesis QC. gBlocks (Appendix Table 3, C) were assembled by Golden Gate 
cloning into pCDF-pUWL-shuttle and pET28a.HisN(sgg) in parallel using SapI according to the 
J5 Manual protocol (j5.jbei.org). Reaction mixtures (15 µL scale) contained 10X NEB T4 DNA 
ligase buffer (1.5 µL), BSA (1 mg/mL, 1.5 µL), NEB SapI (10 U, 1 µL), NEB T4 DNA ligase 
(2,000 U, 1 µL) and ~30 ng/kb of each assembly piece. Reactions were routinely carried out at 
7.5 µL scale. The assembly program was 20-40 cycles of (37ºC for 3 min and 16ºC for 4 min), 
followed by 50ºC for 5 min and 80ºC for 5 min. The entire mixture was transformed into KCM 
chemically competent cells. 
ATs cloned into pCDF-pUWL-shuttle were sequence verified, then digested with XbaI, 
which mobilizes the AT with 25 bp homology to pUWL201PW [39] at both termini. The 
resulting fragments were inserted between the NdeI/HindIII sites of pUWL201PW by Gibson 
assembly. 
ScofabD was PCR amplified from Streptomyces coelicolor A3(2) M13 genomic DNA using 
primers FabD.GF1/GR1 and inserted between the NdeI/BamHI sites of pET16b by Gibson 
assembly. 
Assembly of vectors for cloning eryAI-II-III. Initial attempts at a 4-piece Golden Gate 
assembly to build pSET152r-preEryAI+TE were unsuccessful, so pSET152-pc13, which lacks 
the cat-sacB cassette, was assembled first. PCR amplification of peryAI and the 5’ end of the 
eryAI gene failed, probably because of the short length of the fragment, so it was instead ordered 
as a gBlock. This fragment was assembled together with the 3’ homology region to eryAIII, 
which was PCR amplified from pRSG64 using primers pSETEryAI F3b/R3, into pSET152(gg) 
by BsaI Golden Gate cloning. The cat-sacB cassette contained a single internal BsaI site, so this 
was removed by SOE PCR amplification from a colony of E. coli TUC01 [2] using primer pairs 
cat-sacB SOE F1/R1 (internal) and pSETEryAI F2b/R2b (external). The resulting fragment was 
inserted into the NheI site of pSET152r-pc13 by Gibson assembly, giving pSET152r-
preEryAI+TE. Sucrose sensitivity conferred by the vector was verified during cloning; only 
about half of the candidates that incorporated the amplified cat-sacB cassette retained the 
phenotype. 
Expression and purification of proteins. RpaMatB, DszAT, DEBS-Mod6AT0+TE and 
methylmalonyl-CoA epimerase were expressed and purified as described above (Section 2.2). 
Expression of trans-ATs in E. coli. TB (1 L) containing kanamycin (50 µg/mL) in a 2.8 L 
Fernbach baffled shake flask was inoculated to OD600 = 0.05 with an overnight TB culture of 
freshly transformed E. coli containing the appropriate overexpression plasmid. The cultures were 
grown at 37°C to OD600 = 0.6 to 0.8 at which point cultures were cooled on ice for 20 min, 
followed by induction of protein expression with IPTG (0.4 mM) and overnight growth at 16°C. 
Cell pellets were harvested by centrifugation at 9,800 × g for 7 min at 4ºC and stored at -80ºC. 
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Purification of FenF and PksC. FenF and PksC were purified essentially as described for 
DszAT (Section 2.2). Concentrations were estimated using extinction coefficients calculated 
using ExPASY ProtParam (reduced form). 
Trans-AT lysate assays. Frozen cell pellets were thawed and resuspended at 500 µL/100 
mg cell paste in 400 mM sodium phosphate, pH 7.5. The mixture was resuspended by pipetting 
and transferred to a screw-top vial. Glass beads (1 mM) were added (~250 µL) and the cells were 
lysed by bead beating for 2 x 30 s at maximum speed using a Mini-Beadbeater-24 (Biospec 
Products, Bartlesville, OK). The lysate was clarified by centrifugation at 23,000  × g for 20 min 
at 4°C. The clarified lysate constituted 50% of each reaction mixture. Assay mixtures (60-100 
µL) contained 400 mM sodium phosphate (total concentration), pH 7.5, phosphoenolpyruvate 
(25 mM), TCEP (5 mM), magnesium chloride (10 mM), ATP (2.5 mM), pyruvate kinase (27 
U/mL), myokinase (10 U/mL), CoA (1 mM), methylmalonyl-CoA epimerase (5 µM), RpaMatB 
(20 µM) and fluoromalonate or malonate (10 mM). Purified trans-AT was added (5-10 µM) as 
indicated. Mixtures were incubated at 37°C for 15-30 min and then initiated by addition of the 
N-acetylcysteamine thioester of (2S,3R)-2-methyl-3-hydroxypentanoic acid (NDK-SNAC, 5 
mM) and DEBS-Mod6AT0+TE (5 µM). After incubation at 37°C for 18-22 h, aliquots (35 µL) 
were removed and quenched by addition of 70% perchloric acid (1.75 µL). Samples were 
centrifuged at 18,000 × g to pellet the precipitated protein. The supernatant (33 µL) was removed 
and added to 1 M sodium bicarbonate (6.6 µL) bringing the final pH to 4-5. Excess salts were 
precipitated by freezing in liquid nitrogen and centrifuging at 18,000 × g until thawed. The 
supernatant was removed and analyzed on a Zorbax Eclipse XDB C-18 column as described 
above (Section 2.2). Fluoro-triketide and desmethyl-triketide were detected using an Agilent 
single quadrupole mass spectrometer operating in single ion monitoring mode (negative ion 
mode) and quantified by comparison to external standard curves using standards prepared as 
described (Section 2.2). 
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4.3 Results and discussion 
Trans-AT construct design and cloning. As a preliminary step to construction of a full 
library of trans-ATs, we began with the set of trans-ATs from verified PKS clusters. Gene 
synthesis and cloning of these proteins is simplified by isolating the active AT domains – 
especially in cases where tandem ATs are of the proofreading type. We truncated the sequences 
to remove trans-ER domains and tandem AT domains based on a multiple sequence alignment 
(Figure 4.3), maintaining native termini where appropriate and following experimentally verified 
truncations when available. These proteins have percent identity ranging from 31 to 67% across 
their malonyl-specific AT domains and likely encompass a variety of activities. 
Streptomyces genomes have high G+C content, which leads to extreme codon bias, especially 
at the wobble position. To make our library compatible with Streptomyces expression, we chose 
codons optimized for S. coelicolor. This introduced some difficulties for gene synthesis of these 
often repetitive, G+C-rich sequences. When needed, automated reverse translations were 
Figure 4.3. Alignment of trans-AT sequences from verified PKS clusters produced using PRALINE with ClustalW coloring. The 
source protein architecture (e.g. stand-alone AT, AT-trans-ER fusion, tandem-AT) is indicated after the protein name and source 
organism, but only the FabD-homologous AT regions are shown. Experimentally characterized truncations are shown for KirCI [3], 
BryP [7] and DszD (DszAT) [9]. The start and end points of synthesized genes, where different from the regions shown, are 
indicated with vertical black bars.  
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adjusted manually to remove long GC runs and stable predicted hairpins. The next most common 
codons were chosen when possible. 
To clone the library, a two-stage pipeline was developed. Synthetic DNA fragments were 
first assembled into a shuttle vector by Golden Gate cloning. Most type IIs restriction enzymes 
(necessary for the Golden Gate method) have high G+C recognition sequences that are common 
in Streptomyces DNA, which includes both our back-translated genes and many available 
expression plasmids. Therefore we used SapI, which has a 7-nt recognition site that is also 43% 
T and therefore relatively rare in G+C rich DNA, for cloning. Its overhangs are only 3 nt long, 
but this potential drawback seems to be compensated for by higher enzyme activity than the 
traditional BsaI. Reaction mixtures on 7 µL scale containing ~25 nmol of each DNA fragment 
routinely gave hundreds of positive colonies. 
Our destination vector, a replicating Streptomyces plasmid, did however contain >5 SapI 
sites. Therefore we designed the shuttle vector so that cloned inserts could be cut out by XbaI 
digest with 25 bp of homology to the destination vector appended on either end. These restriction 
fragments were then assembled with the cut destination vector using the Gibson method [38] 
without the need for PCR. For further characterization, AT genes were also cloned in parallel 
directly from synthetic DNA into a version of the pET28a expression vector adapted for SapI 
Golden Gate. 
In vitro triketide 
assays. We expressed a 
selection of library 
members in E. coli and 
tested complementation of 
a single DEBS AT0 module 
in cell lysate (Figure 4.4). 
No AT purification is 
needed to see activity in cases where expression level and solubility are adequate (although this 
was not true for all ATs). Triketide formation is minimal in the cis-AT0 background without a 
trans-AT, but adding pure trans-AT or cell lysate containing trans-AT, along with the 
fluoromalonyl-CoA regeneration system described in Scheme 2.1, allows fluoro-triketide 
formation (Figure 4.5). 
Figure 4.4. Workflow for in vitro trans-AT triketide formation assay in cell lysate. 
Figure 4.5. Example chromatograms showing LC-MS detection 
(single ion monitoring, m/z -173) of fluorotriketide lactone in cell 
lysate by complementation of DEBS-Mod6AT0. 
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Expression of most of the library members we tested was robust despite the use of rare (in E. 
coli) codons, but in the E. coli host background many ATs were highly insoluble (Figure 4.6); 
this result may or may not carry over to a Streptomyces host. Even in cases of poor solubility, we 
were able to easily purify enough His-tagged trans-AT to assess activity (e.g. for FenF, Figure 
4.7 and Figure 4.8). 
We used AT expression cell lysate to complement DEBS-Mod6AT0 in a triketide-forming 
assay and compared fluoro-triketide and desmethyl-triketide (H-TKL) levels (Figure 4.8). 
Several trans-ATs were inactive above background, probably due to low solubility; purification 
of FenF allowed activity to be determined. PksC and BryP 
showed high activity on fluoromalonyl-CoA. Fluoro-triketide 
yields were apparently higher using these trans-ATs than 
desmethyl-triketide yields, a surprising observation given the 
native malonyl-CoA specificity of these enzymes. However, this 
assay data is complicated by the formation of additional products 
in the malonyl-CoA condition that were not quantified. When 
trans-AT activity is very high, a PKS module can catalyze two 
chain extensions on the diketide starter, which in the absence of 
NADPH results in a tetraketide pyrone (Scheme 4.1; Omer Ad, 
unpublished results). The exact mechanism for this process is as 
yet unknown, but modules have been made to iterate by replacement of interaction domains [40] 
presumably by intermolecular chain 
transfer to another copy of the module 
after the first elongation event. 
Intramolecular back-transfer of the 
chain to the ketosynthase Cys residue 
after elongation also cannot be ruled 
out. Regardless of its origin, formation 
of this tetraketide pyrone will need to 
be accounted for in future assays, 
since it represents two incorporations 
of malonyl extender. The data in 
Figure 4.8 still provide a relative 
comparison of the ATs, but the 
fluoromalonyl/malonyl product ratio is 
not meaningful. 
Figure 4.6. SDS-PAGE gels showing trans-AT expression and solubility in cell lysate. Lanes: 1 pre-induction 2 post-induction 3 
insoluble 4 soluble. Boxes indicate the band corresponding to each AT. 
Figure 4.8. Cell lysate assay for selected trans-ATs expressed in E. coli 
complementing DEBS-Mod6AT0. Triketides were formed from either 
malonyl- or fluoromalonyl-CoA in separate reaction mixtures. DszAT 
acts as a positive control. The selectivity for malonyl-derived vs. 
fluoromalonyl-derived triketides (R = H vs. R = F) cannot be inferred 
from these data because multiple chain elongation cycles with malonyl-
CoA (tetraketide formation) were observed but could not be quantified. 
Figure 4.7. SDS-PAGE gel for FenF 
purification. Lanes: 1 pre-induction 2 
post-induction 3 insoluble 4 soluble 5 
post-DNA precipitation 6 purified 
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Design and plasmid 
construction for in vivo DEBS 
complementation. Construction of 
vectors for PKS expression, 
particularly of a full, multimodular 
assembly line, is an involved process 
because of the size of the genes 
involved (~30 kb for DEBS, which is 
encoded by eryAI-II-III) and their 
aforementioned high G+C content, 
which can make PCR amplification 
and even Sanger sequencing inefficient and/or error-prone. A vector with a Streptomyces 
replicative origin and resistance marker encoding DEBS was previously reported [1] and we took 
advantage of this for our design. This vector, pCK7, could itself be used for complementation, 
but it has some disadvantages: it is larger than necessary, with the backbone alone being over 10 
kb due mostly to the SCP2* origin, making it difficult to handle and manipulate; it uses a 
heterologous promoter – pactI, which is positively regulated by transcription factor actII-ORF4 
during the onset of stationary phase – rather than the native peryAI; and it has a replicative origin 
(albeit with low copy number), which may complicate adjusting the stoichiometry of DEBS to 
trans-ATs in our system. We therefore set out to create the integrative vector pSET152r-EryAI-
II-III using a recombination-based strategy (Figure 4.9) that avoids PCR and the need for full 
sequencing of the 30 kb DEBS genes. Similar techniques have recently been reported to 
assemble large biosynthetic clusters [41,42]. 
We selected pSET152 as a minimal vector with site-specific integration capability (the øC31-
phage-derived integrase catalyzes insertion of the complete vector backbone at one or more attB 
sites in a Streptomyces chromosome). To make E. coli passage of pSET152 derivatives with 
large inserts more reliable, we first reduced the copy number of the pUC origin by inserting the 
rop gene [43]. We next cloned pSET152r-preEryAI+TE by inserting long (50-800 bp) sequences 
homologous to the 5' and 3' ends of the eryAI-II-III cluster (including the native promoter), 
flanking a positive (chloramphenicol resistance) and negative (sucrose sensitivity) selectable 
cassette [2] which can be excised by NdeI digest. This should allow insertion of the PacI/NsiI 
restriction fragment of pCK7 by either in vivo λ-red recombination or in vitro Gibson assembly 
Figure 4.9. Diagram showing recombination-based strategy for construction of an integrative DEBS 
expression plasmid for Streptomyces expression. Recombination (via λ-red, Gibson assembly or, with marker 
and origin addition, yeast) allows replacement of the cat-sacB cassette with the EryAI-II-III genes, derived by 
restriction digest from pCK7 [1]. Recombinants can be selected by survival on 5% sucrose plates. 
Scheme 4.1. Triketide lactone and tetraketide pyrone formation resulting 
from one or two chain extension reactions with a malonyl extender. 
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(which may be preferable because repeated sequences in the eryA locus could lead to undesired 
recombination events). 
An analogous strategy can be used to prepare the desired set of AT0 point mutations (Figure 
4.10), which are difficult to produce by typical methods (e.g. QuikChange) for the same reasons 
discussed above. The selection cassette can be inserted at any locus in the ery cluster using PCR-
targeted recombination, without the need for a unique, proximal restriction site [44]. A short, 
easily sequence-verified DNA fragment containing the desired point mutation can then be 
prepared by SOE PCR (with the mutation contained on the internal primers) and exchanged for 
the cassette by the same technique. Because the cassette can be counter selected using sucrose, 
the desired scarless point mutant can be selected for. Since this work was initiated, Cas9-based 
methods have been developed for Streptomyces that make point mutations possible using DNA 
oligos [45], and these provide an attractive alternative strategy. 
4.4 Conclusions 
The work outlined here is only the first steps toward construction of a trans-AT library and 
comprehensive screening. Remaining challenges include optimizing 6-dEB production in a 
heterologous host, including finding reproducible growth conditions, adjusting plasmid elements 
and achieving stable coexpression with trans-AT library members. The enzymes and systems 
identified through E. coli 2-fluoro-3-hydroxybutyrate production will need to be incorporated in 
and adapted to the Streptomyces host to achieve robust fluoromalonyl-CoA production. The 
library inaugurated here should be expanded to better cover trans-AT sequence space and a 
testing pipeline implemented. Finally, promising ATs should be selected and subjected to 
rational and/or random mutagenesis to improve fluoromalonyl selectivity. Testing in vivo with 
the full DEBS system will reveal mutations that improve AT expression, stability, ACP 
recognition and selectivity against endogenous extender units, in addition to fluorinated extender 
use, and can potentially be scaled [32] to accommodate large library sizes. 
  
Figure 4.10. Recombination-based strategy for introducing AT0 mutations to the full DEBS cluster. The cat-sacB cassette can be 
introduced by PCR-targeted recombination[2] – potentially assisted by Cas9-based cleavage at the target site. The desired point 
mutant can then be prepared by 2-piece SOE PCR of a short region around the AT active site, and introduced scarlessly by a 
second recombination event.  
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Table 1. Plasmid constructs (A) and oligonucleotides (B) used in Chapter 2. 
A 
Name No. Primers Restriction sites Method Description 
pET28a-His10-MatB 905 MatB.Sco F/R NdeI/XhoI Ligation 
malonyl-CoA synthetase 
from S. coelicolor 
pET28a-His10-Epi 803 Epi.Sco F/R NdeI/XhoI Ligation 
methylmalonyl-CoA 
epimerase from S. 
coelicolor 
pSV272-MBP- 
DEBSMod2-His6 
1396 MBP-M2 F/R SfoI/HindIII Gibson 
N-terminal MBP fusion 
of DEBSMod2. pBP19 as 
template 
pSV272-MBP-
DEBSMod2AT0-His6 
1341 
MBP-
M2ATnull F/R 
(internal) 
MBP-M2 F/R 
(external) 
 
SfoI/HindIII Gibson 
N-terminal MBP fusion 
of DEBSMod2 with 
S2652A mutation 
(introduced via SOE 
PCR) 
pET16b-His10-NphT7 988 NphT7 G F/R NdeI Gibson 
Synthetic NphT7, 
acetoacetyl-CoA 
synthase from S. sp. 
CL190 (primers for 
assembly are given in 
Table 1, B) 
pRSG54 926    
DEBSMod6+TE from Wu, 
N., et. al., J. Am. Chem. 
Soc. 2000, 122 (20) 
4847-4852. 
pAYC138 1045    
DEBSMod6AT0+TE from 
Wong, F. T., et. al., 
Biochemistry 2009, 49 
(1) 95-102. 
pRSG34 1123    
DEBSMod3+TE from 
Gokhale, R. S., et. al., 
Science 1999, 284 
(5413) 482-485. 
pAYC136 1150    
DEBSMod3AT0+TE from 
Wong, F. T., et. al., 
Biochemistry 2009, 49 
(1) 95-102. 
pFW3 1186    
Disorazole Trans AT 
from Wong, F. T., et. al., 
Biochemistry 2009, 49 
(1) 95-102. 
 
B 
Name Sequence 
nphT7 R1 aaacgaacgtcggtcatggtg 
nphT7 F1 caccatgaccgacgttcgttttcgtatcattggcacgggt 
nphT7 R2 gctccggcacgtacgcacccgtgccaatgatacga 
nphT7 F2 gcgtacgtgccggagcgtattgtgtccaacgacgaggt 
nphT7 R3 accagccggcgcacccacctcgtcgttggacacaatac 
nphT7 F3 gggtgcgccggctggtgttgatgatgactggattacccgt 
nphT7 R4 cgttgacgaatgccggtcttacgggtaatccagtcatcatcaac 
nphT7 F4 aagaccggcattcgtcaacgtcgttgggcggcggac 
nphT7 R5 tcggaggtcgcttggtcgtccgccgcccaacga 
nphT7 F5 gaccaagcgacctccgacctggcaaccgcggcg 
nphT7 R6 tcaacgccgcacgacccgccgcggttgccagg 
nphT7 F6 ggtcgtgcggcgttgaaagcagcgggtattacgcc 
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nphT7 R7 gcaataaccgtcagttgctccggcgtaatacccgctgctt 
nphT7 F7 ggagcaactgacggttattgcggtcgcaacgtccaccc 
nphT7 R8 ggctgcggacggtccggggtggacgttgcgacc 
nphT7 F8 cggaccgtccgcagccgccgacggcggcctac 
nphT7 R9 cgcccagatgatgttgcacgtaggccgccgtcggc 
nphT7 F9 gtgcaacatcatctgggcgcaaccggcaccgcggc 
nphT7 R10 tgcacacagcgttaacatcaaatgccgcggtgccggttg 
nphT7 F10 atttgatgttaacgctgtgtgcagcggcacggtttttgct 
nphT7 R11 ccgccacgctggacagagcaaaaaccgtgccgc 
nphT7 F11 ctgtccagcgtggcgggcacgctggtgtatcgtgg 
nphT7 R12 caatgaccagtgcgtaaccgccacgatacaccagcgtgc 
nphT7 F12 cggttacgcactggtcattggtgccgatctgtattcccgta 
nphT7 R13 ggtccgccggattcagaatacgggaatacagatcggcac 
nphT7 F13 ttctgaatccggcggaccgcaagaccgttgttctgtttgg 
nphT7 R14 cgcacccgcgccgtcaccaaacagaacaacggtcttgc 
nphT7 F14 tgacggcgcgggtgcgatggtgctgggtccgac 
nphT7 R15 acccgtacccgtgctggtcggacccagcaccat 
nphT7 F15 cagcacgggtacgggtccgatcgtccgtcgcg 
nphT7 R16 caaacgtgtgcagggcaacgcgacggacgatcgg 
nphT7 F16 ttgccctgcacacgtttggtggtctgaccgacctgatt 
nphT7 R17 cacccgccggcacacgaatcaggtcggtcagaccac 
nphT7 F17 cgtgtgccggcgggtggcagccgccaaccgct 
nphT7 R18 tccaagccatccgtgtccagcggttggcggctgc 
nphT7 F18 ggacacggatggcttggacgcgggtctgcaatacttcg 
nphT7 R19 cctcgcgaccgtccatagcgaagtattgcagacccgcg 
nphT7 F19 ctatggacggtcgcgaggtgcgtcgttttgttaccgaac 
nphT7 R20 cctttaatcagttgcggcaagtgttcggtaacaaaacgacgca 
nphT7 F20 acttgccgcaactgattaaaggtttcttgcacgaggcggg 
nphT7 R21 gctaatatctgccgcatcgacacccgcctcgtgcaagaaa 
nphT7 F21 tgtcgatgcggcagatattagccattttgtgccgcaccaagc 
nphT7 R22 cgtccagcatgacaccgttcgcttggtgcggcacaaaatg 
nphT7 F22 gaacggtgtcatgctggacgaggtctttggtgaactgcacc 
nphT7 R23 atggtcgcacgcggcaggtgcagttcaccaaagacct 
nphT7 F23 tgccgcgtgcgaccatgcaccgtaccgtcgaaacc 
nphT7 R24 cgcacccgtattgccgtaggtttcgacggtacggtgc 
nphT7 F24 tacggcaatacgggtgcggccagcattccgattacgatg 
nphT7 R25 tgcacggactgctgcatccatcgtaatcggaatgctggc 
nphT7 F25 gatgcagcagtccgtgcaggtagcttccgtccggg 
nphT7 R26 gccagcaggaccagttcacccggacggaagctacc 
nphT7 F26 tgaactggtcctgctggcgggttttggtggtggcatg 
nphT7 R27 gcgcgaagctcgctgccatgccaccaccaaaaccc 
nphT7 F27 gcagcgagcttcgcgctgatcgagtggtaagtcagcc 
nphT7 R28 acccgctctagccgtcaggctgacttaccactcgatca 
nphT7 F28 tgacggctagagcgggt 
NphT7 G F aatttcacacgagctcggtacccgggaggagatataccatgaccgacgttcgttttcg 
NphT7 G R gcgctgggtcattatatatctccttttcttaccactcgatcagcgcgaag 
MatB.SCo F tcgattgcacatatgtcctctctcttcccggccctct 
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MatB.SCo R atcggatagctcgagtcagtcacggttcagcgcccgctt 
Epi.SCo F atcccgaatcatatgctgacgcgaatcgacca 
Epi.SCo R ttagtctggctcgagtcagtgctcaggtgactcaa 
MBP-M2 F gggatcgaggaaaacctgtattttcagggcatgagcggtgacaacggcatgaccgagg 
MBP-M2 R gcttgtcgacggagctcgaattcggggatcctcagtggtggtggtggtggtgctcgagtg 
MBP-M2ATnull F gttatcggtcacgcgcagggtgaaatcgcggccgcggtggtggcgggagcgttgtcgctg 
MBP-M2ATnull R cgcgatttcaccctgcgcgtgaccgataacggccgaaggaacggcaccgcaggcacgcca 
 
Table 2. Plasmid constructs (A), oligonucleotides (B) and gBlocks (C) used in Chapter 3. 
 
A 
Name No. Primers Restriction sites 
Backbone 
source Method Description 
pET16b. 
RpamatB 1192 
r_palu matB 
F1/R1 NdeI  pET16b 
Gibson 
assembly 
ColE1 CbR lacI pT7 His10-
RpamatB T7-term 
pCDF-
Duet1.RpamatB 1490 
pCDFDuet 
R.p_matB F1/R1 NdeI/KpnI pCDF-Duet1 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
RpamatB T7-term 
pET23c.His6-
TEV-NphT7 2041 NphT7 23a F2/R1 EcoRI 
pET23c.His-TEV-
SfoI 
Gibson 
assembly 
ColE1 CbR lacI pT7 His6-
TEV-nphT7 T7-term 
pBAD33.pET-
RBS 1512 
pBAD33-
pET.RBS 
GF1/GR1 
KpnI/XbaI pBAD33 Gibson assembly 
M13 CmR araC pBAD 
rrnB-term 
pXHB.ø. 
RpamatB 1514 
pBAD GF1, 
pBAD-pCDF GR1 
/ lacI GF1, lacI-
pBAD GR1 
XbaI/HindIII pBAD33.pET-RBS 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD rrnB-term pT7 
RpamatB T7-term 
pXHB1 
(pXHB.PflmadL
M.RpamatB) 
1547 Pfl.madLM GF1/GR1 XbaI/HindIII pXHB.ø.RpamatB 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT7 RpamatB T7-
term 
pXHB.ScomatC.
RpamatB 1549 
pCDF-ara-
ScoMatC 
GF1/GR1 
XbaI/HindIII pXHB.ø.RpamatB Gibson assembly 
CloDF13 SpR lacI araC 
pBAD ScomatC rrnB-term 
pT7 RpamatB T7-term 
pXHB.KpnmdcF.
RpamatB 1830 
KpnmdcF 
block1/2 XbaI/HindIII pXHB.ø.RpamatB 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD KpnmdcF rrnB-
term pT7 RpamatB T7-
term 
pXHB1.Ecoacs 1548 pCDF-ACS GF1/GR1 KpnI/XhoI pXHB1 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT7 RpamatB 
Ecoacs T7-term 
pXHB1.EcoprpE 1630 PrpE GF1/GR1 KpnI/XhoI pXHB1 Gibson assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT7 RpamatB 
EcoprpE T7-term 
pXHB1.ScoalkK 1618 ScoAlkK GF1/GR1 KpnI/XhoI pXHB1 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT7 RpamatB 
ScoalkK T7-term 
pXHB1.PolalkK 1616 sPolAlkK GF1, sPolAlkK GR1 KpnI/XhoI pXHB1 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT7 RpamatB 
PolalkK T7-term 
pXHB. 
PflmadLM.ø 1929 n/a KpnI/NdeI pXHB1 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term T7-term 
pXHB3 1694 pXHB3.GF1/GR1 NdeI/NotI pXHB1 Gibson assembly 
CloDF13 SpR lacI araC 
pBAD PflmadLM rrnB-
term pT5 RpamatB T7-
term 
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Name No. Primers Restriction sites 
Backbone 
source Method Description 
pPOL1 (pPOL1-
nbc) 1331 
FPHB-NphT7 
F1/R1 / FPHB-
PHAB F1, FPHB-
PHAC R1 
NcoI/XbaI pTRC99a Gibson assembly 
ColE1 CbR lacIq pTrc 
nphT7 phaB ReuphaC 
rrnB 
pPOL1-nb 1589 NphT7 G F3, PhaB G R1 NcoI/XbaI pTRC99a 
Gibson 
assembly 
ColE1 CbR lacIq pTrc 
nphT7 phaB rrnB 
pPOL1-n 1791 pPol1-n GF1/GR1 EcoRI/XbaI pPOL1-nb 
Gibson 
assembly: 
oligo 
insertion 
ColE1 CbR lacIq pTrc 
nphT7 rrnB 
pPOL4.1 1693 pPOL4.1 block1/2 XbaI/HindIII pPOL1-nb Gibson assembly 
ColE1 CbR lacIq pTrc 
nphT7 phaB RruphaC 
rrnB 
pPOL4.2 1783 pPOL4.2 block1/2 XbaI/HindIII pPOL1-nb Gibson assembly 
ColE1 CbR lacIq pTrc 
nphT7 phaB RopphaC 
rrnB 
pET28a.flK 1927 pET28a flK GF1/GR1 XbaI/NcoI pET28a 
Gibson 
assembly 
ColE1 KmR lacI pT7 flK 
T7-term 
pET28a. 
flK(H76A) 1925 
pET28a flK 
GF1/GR1 XbaI/NcoI pET28a 
Gibson 
assembly 
ColE1 KmR lacI pT7 
flK(H76A) T7-term 
pET28a.pTet.flK 2084 pTet-pET28a.flk GF1/GR1 XbaI/BglI pET28a.flK 
Gibson 
assembly 
ColE1 KmR tetR pTet flK 
T7-term 
pET28a.pTet. 
flK(H76A) 2085 
pTet-pET28a.flk 
GF1/GR1 XbaI/BglI pET28a.flK(H76A) 
Gibson 
assembly 
ColE1 KmR tetR pTet 
flK(H76A) T7-term 
 
B 
Name Sequence 
Rhod_Palu_MatB.R2 CATgtgggcgggagagg 
Rhod_Palu_MatB.F2 cctctcccgcccacATGAACGCGAATCTGTTTGCC 
Rhod_Palu_MatB.R3 TCCAGTTTATCGAACAGGCGGGCGAAAAGATTCGCGTT 
Rhod_Palu_MatB.F3 CGCCTGTTCGATAAACTGGACGATCCGCACAAACTGGC 
Rhod_Palu_MatB.R4 AGCCGCGGTCTCGATGGCCAGTTTGTGCGGATCG 
Rhod_Palu_MatB.F4 CATCGAGACCGCGGCTGGTGATAAGATCAGCTATGCCG 
Rhod_Palu_MatB.R5 GCGCGAGCCACCAGCTCGGCATAGCTGATCTTATCACC 
Rhod_Palu_MatB.F5 AGCTGGTGGCTCGCGCGGGCCGCGTCGCAAAC 
Rhod_Palu_MatB.R6 CACGCGCCACCAGGACGTTTGCGACGCGGCCC 
Rhod_Palu_MatB.F6 GTCCTGGTGGCGCGTGGTCTGCAAGTTGGTGACCG 
Rhod_Palu_MatB.R7 GGTTTGCGCCGCAACACGGTCACCAACTTGCAGAC 
Rhod_Palu_MatB.F7 TGTTGCGGCGCAAACCGAAAAGAGCGTTGAGGCACT 
Rhod_Palu_MatB.R8 GTGGCCAGGTACAGAACCAGTGCCTCAACGCTCTTTTC 
Rhod_Palu_MatB.F8 GGTTCTGTACCTGGCCACGGTTCGCGCTGGCGGC 
Rhod_Palu_MatB.R9 CGTGTTCAGCGGCAGATAAACGCCGCCAGCGCGAACC 
Rhod_Palu_MatB.F9 GTTTATCTGCCGCTGAACACGGCATATACCCTGCACGAACT 
Rhod_Palu_MatB.R10 CGTCGGTGATGAAGTAGTCCAGTTCGTGCAGGGTATATGC 
Rhod_Palu_MatB.F10 GGACTACTTCATCACCGACGCGGAGCCGAAAATTGTTGTC 
Rhod_Palu_MatB.R11 CGTTTGCTCGGATCGCAGACAACAATTTTCGGCTCCG 
Rhod_Palu_MatB.F11 TGCGATCCGAGCAAACGTGATGGCATTGCAGCCA 
Rhod_Palu_MatB.R12 CCGACTTTCGCGGCGATGGCTGCAATGCCATCA 
Rhod_Palu_MatB.F12 TCGCCGCGAAAGTCGGTGCAACCGTCGAGACCC 
Rhod_Palu_MatB.R13 CGGCCATCCGGACCCAGGGTCTCGACGGTTGCA 
Rhod_Palu_MatB.F13 TGGGTCCGGATGGCCGCGGCAGCCTGACGGAT 
Rhod_Palu_MatB.R14 TCGCACCTGCCGCTGCATCCGTCAGGCTGCCG 
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Rhod_Palu_MatB.F14 GCAGCGGCAGGTGCGAGCGAAGCGTTCGCGAC 
Rhod_Palu_MatB.R15 TGCACCGCGATCGATGGTCGCGAACGCTTCGC 
Rhod_Palu_MatB.F15 CATCGATCGCGGTGCAGATGATCTGGCGGCGATT 
Rhod_Palu_MatB.R16 GTGCCGCTGGTGTACAGAATCGCCGCCAGATCATC 
Rhod_Palu_MatB.F16 CTGTACACCAGCGGCACGACGGGCCGCAGCAAA 
Rhod_Palu_MatB.R17 GGCTCAACATCGCGCCTTTGCTGCGGCCCGTC 
Rhod_Palu_MatB.F17 GGCGCGATGTTGAGCCACGACAATCTGGCGTCCA 
Rhod_Palu_MatB.R18 CCACCAGGGTCAAGCTGTTGGACGCCAGATTGTCGT 
Rhod_Palu_MatB.F18 ACAGCTTGACCCTGGTGGACTACTGGCGCTTCACCC 
Rhod_Palu_MatB.R19 TGAATCAGCACATCGTCCGGGGTGAAGCGCCAGTAGT 
Rhod_Palu_MatB.F19 CGGACGATGTGCTGATTCATGCGCTGCCGATCTATCA 
Rhod_Palu_MatB.R20 CGAACAGACCGTGGGTGTGATAGATCGGCAGCGCA 
Rhod_Palu_MatB.F20 CACCCACGGTCTGTTCGTGGCCAGCAACGTCAC 
Rhod_Palu_MatB.R21 GGAGCCACGTGCAAACAAGGTGACGTTGCTGGCCA 
Rhod_Palu_MatB.F21 CTTGTTTGCACGTGGCTCCATGATTTTCCTGCCGAAGTTCG 
Rhod_Palu_MatB.R22 CAGATCCAGAATTTTATCCGGGTCGAACTTCGGCAGGAAAATCAT 
Rhod_Palu_MatB.F22 ACCCGGATAAAATTCTGGATCTGATGGCGCGTGCCACGG 
Rhod_Palu_MatB.R23 TCGGAACACCCATCAGGACCGTGGCACGCGCCAT 
Rhod_Palu_MatB.F23 TCCTGATGGGTGTTCCGACGTTTTACACCCGCCTGC 
Rhod_Palu_MatB.R24 AGGCGCGGGCTTTGCAGCAGGCGGGTGTAAAACG 
Rhod_Palu_MatB.F24 TGCAAAGCCCGCGCCTGACCAAAGAGACCACGGGT 
Rhod_Palu_MatB.R25 GAAATGAACAGGCGCATGTGACCCGTGGTCTCTTTGGTC 
Rhod_Palu_MatB.F25 CACATGCGCCTGTTCATTTCCGGCAGCGCCCCGTTG 
Rhod_Palu_MatB.R26 ACGATGGGTGTCAGCCAACAACGGGGCGCTGCCG 
Rhod_Palu_MatB.F26 TTGGCTGACACCCATCGTGAGTGGAGCGCGAAAACG 
Rhod_Palu_MatB.R27 TCCAGGACGGCGTGGCCCGTTTTCGCGCTCCACTC 
Rhod_Palu_MatB.F27 GGCCACGCCGTCCTGGAACGCTACGGCATGACCGA 
Rhod_Palu_MatB.R28 GGGTTGCTCGTATTCATGTTCGTCTCGGTCATGCCGTAGCGT 
Rhod_Palu_MatB.F28 GACGAACATGAATACGAGCAACCCGTATGACGGCGATCGTGTGC 
Rhod_Palu_MatB.R29 GGGCCGACTGCACCCGGCACACGATCGCCGTCATAC 
Rhod_Palu_MatB.F29 CGGGTGCAGTCGGCCCGGCTCTGCCGGGCGTG 
Rhod_Palu_MatB.R30 TCGGTGACACGGGCGCTCACGCCCGGCAGAGCC 
Rhod_Palu_MatB.F30 AGCGCCCGTGTCACCGACCCGGAGACGGGTAAAGAG 
Rhod_Palu_MatB.R31 ATGTCGCCACGCGGCAACTCTTTACCCGTCTCCGGG 
Rhod_Palu_MatB.F31 TTGCCGCGTGGCGACATTGGTATGATCGAAGTTAAAGGTCC 
Rhod_Palu_MatB.R32 GCCAGTAACCTTTGAAAACGTTCGGACCTTTAACTTCGATCATACCA 
Rhod_Palu_MatB.F32 GAACGTTTTCAAAGGTTACTGGCGTATGCCGGAGAAAACCAAGT 
Rhod_Palu_MatB.R33 CGTCGTCACGAAACTCGGACTTGGTTTTCTCCGGCATAC 
Rhod_Palu_MatB.F33 CCGAGTTTCGTGACGACGGTTTTTTTATTACCGGCGACCTG 
Rhod_Palu_MatB.R34 TAGCCACGTTCATCGATTTTACCCAGGTCGCCGGTAATAAAAAAAC 
Rhod_Palu_MatB.F34 GGTAAAATCGATGAACGTGGCTATGTCCACATCCTGGGTCG 
Rhod_Palu_MatB.R35 GTAATCACCAGGTCTTTGCCACGACCCAGGATGTGGACA 
Rhod_Palu_MatB.F35 TGGCAAAGACCTGGTGATTACGGGTGGCTTCAATGTGTATCC 
Rhod_Palu_MatB.R36 TCGATTTCGCTCTCAATCTCTTTCGGATACACATTGAAGCCACCC 
Rhod_Palu_MatB.F36 GAAAGAGATTGAGAGCGAAATCGATGCCATGCCGGGTGTT 
Rhod_Palu_MatB.R37 TCACGGCGCTTTCCACAACACCCGGCATGGCA 
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Rhod_Palu_MatB.F37 GTGGAAAGCGCCGTGATCGGTGTTCCGCACGC 
Rhod_Palu_MatB.R38 CCGTAACACCCTCACCAAAATCCGCGTGCGGAACACCGA 
Rhod_Palu_MatB.F38 GGATTTTGGTGAGGGTGTTACGGCAGTGGTCGTTCGTGATAAGG 
Rhod_Palu_MatB.R39 GGCTTCATCAATCGTCGCACCCTTATCACGAACGACCACTG 
Rhod_Palu_MatB.F39 GTGCGACGATTGATGAAGCCCAGGTGTTGCACGGTCT 
Rhod_Palu_MatB.R40 TGAATTTTGCCAGTTGACCATCCAGACCGTGCAACACCTG 
Rhod_Palu_MatB.F40 GGATGGTCAACTGGCAAAATTCAAAATGCCGAAGAAAGTGATCTTTG 
Rhod_Palu_MatB.R41 TATTGCGCGGCAGATCATCGACAAAGATCACTTTCTTCGGCATTT 
Rhod_Palu_MatB.F41 TCGATGATCTGCCGCGCAATACGATGGGTAAGGTCCAAAAAAATG 
Rhod_Palu_MatB.R42 GTCTTTATAGGTTTCACGCAGGACATTTTTTTGGACCTTACCCATCG 
Rhod_Palu_MatB.F42 TCCTGCGTGAAACCTATAAAGACATCTATAAGTAAggacgggagca 
Rhod_Palu_MatB.F43 tgctcccgtccTTACTTATAGAT 
r_palu matB F1 CAGCAGCGGCCATATCGAAGGTCGTCATatgaacgcgaatctgtttgcccg 
r_palu matB R1 CTTTGTTAGCAGCCGGATCCTCGAGCATAttacttatagatgtctttataggtttcacgcaggaca 
pCDFDuet R.p_matB F1 ttagttaagtataagaaggagatataCATatgaacgcgaatctgtttgcc 
pCDFDuet R.p_matB R1 cagcggtttctttaccagactcgagggtaccttacttatagatgtctttataggtttcacgc 
NphT7 23a F2 tcatcatcatgagaatctctacttccagggtatgaccgacgttcgttttcgtatcattgg 
NphT7 23a R1 ccggatctcagtggtggtggtggtggtgctcgattaccactcgatcagcgcgaagctc 
pBAD33-pET.RBS GF1 aaggagatatacaatctagAgtcgacctgcaggcatgcaagctt 
pBAD33-pET.RBS GR1 ctagattgtatatctccttCgagctcgaattcgctagcccaaa 
pBAD GF1 ttaccaattatgacaacttgacgg 
pBAD-pCDF GR1 ttcgacttaagcattatgcggccgCgtctcatgagcggatacatatttg 
lacI GF1 tgatcttttctactgaaccgctcaag 
lacI-pBAD GR1 ccgtcaagttgtcataattggtaAgcataagggagagcgtcg 
Pfl.madLM GF1 ttcgagctcgaaggagatatacaaAtgaggagggaagccgc 
Pfl.madLM GR1 cttctctcatccgccaaaacagccaagcttTtagcccaccaggccg 
pCDF-ara-ScoMatC GF1 ttcgagctcgaaggagatatacaatctatgtcccccgaactcatctcga 
pCDF-ara-ScoMatC GR1 cttctctcatccgccaaaacagccaagcctacccgaagccgggca 
pCDF-ACS GF1 aacctataaagacatctataagtaaggtAaagaggagaaaagatctAtgagcc 
pCDF-ACS GR1 tttcgcagcagcggtttctttaccagactcttacgatggcatcgcgat 
PrpE GF1 aagtaaggtaccaaagaggagaaaaGATCTatgTCTTTTAGCGAATTTTATCAGC 
PrpE GR1 gttattgctcagcggtggcagcagcctaggCTACTCTTCCATCGCCTGG 
ScoAlkK GF1 aagtaaggtaccaaagaggagaaaaGATCTatgTCGCCCCGGGAGGAC 
ScoAlkK GR1 gttattgctcagcggtggcagcagcctaggTCAGAGCCGGGTGACGTCG 
sPolAlkK GF1 gacatctataagtaaggtaccaaagCGAATTCGAGCTCGGTACC 
sPolAlkK GR1 gttattgctcagcggtggcagcagcctaggCTTATTCGCAGACGCTGCTG 
FPHB-NphT7 F1 cggataacaatttcacacaggaaacagaccaggagatatataatgaccgacgttcgttttcgtatcattggc 
FPHB-NPHT7 R1 cgctgggtcattatatatctccttgaattcttaccactcgatcagcgcgaagctcgctgc 
FPHB-PHAB F1 gaattcaaggagatatataatgacccagcgcatcgcttacgtaaccggtggcatgggtgg 
FPHB-PHAC R1 aagcttgcatgcctgcaggtcgactctagatcatgccttggctttgacgtatcgcccagg 
NphT7 G F3 aatttcacacgagctcggtacccgggAggagatataccATGACCGACGTTCGTTTTCG 
PhaB G R1 GCCTGCAGGTCGACTCTAGAGGATCttagcccatgtgcaggccac 
pPol1-n GF1 cgcgctgatcgagtggtaagaattctctagagtcgacctgcaggcatgcaa 
pPol1-n GR1 ttgcatgcctgcaggtcgactctagagaattcttaccactcgatcagcgcg 
pET28a flK GF1 gagcggataacaattcccctctagaagaaggagatatacatatgaaagatggtatgcgtgtaggc 
pET28a flK GR1 tgatgatgatggctgctgcccatggttaacccgctggggttttctg 
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Name Sequence 
pTet-pET28a.flk GF1 cacgatcatgcgcacccgtggggccCgctttatgaatctaaagggtgg 
pTet-pET28a.flk GR1 ctttcatatgtatatctccttcttctagaGgatcctgaagacgaaagggcctcg 
pXHB3.GF1 caaatatgtatccgctcatgagacGgttttgcaccattcgatg 
pXHB3.GR1 caggcgggcaaacagattcgcgttcaTatgtatatctccttgagctctgtg 
 
C 
Name Sequence 
pPOL4.1-block1 
GCAGACTTTTCCCTGAACGGTGGCCTGCACATGGGCTAAACTAGTCCGGAGGTATAATTAatgctggatcacg
tgcataaaaaactgaagtcaacactggaccctattggctgggggccagctgttacttccgtagccggtcgcgcagtgcggaatccgcaagcggtcaca
gcagcgaccgccgagtatgccggccgcctggcgaaaatccccgcagcagctacgcgcgtgttcaatgcaaacgatcctgatgctcccatgccagtcg
acccgcgtgatcgtcggttttcggataccgcgtggcaggaaaatcccgcatatttctcactgctccaatcgtacttagccactcgcgcctatgttgaagaact
gaccgaagctggcagcggcgacccgttacaggatggcaaggctcggcagttcgctaacctgatgttcgatgccctcgcaccatccaattttttgtggaatc
cgggtgtattgacgcgcgcatttgaaaccggaggtgcgtcgctgctgcgtggagctcgctacgccgcacatgatattttgaaccgcggtggcctgcctctg
aaggtggattctgacgcgtttacggtaggtgagaacttagccgcgacgccgggcaaagtagtattccgcaatgatctgattgagctcatccaatacgctcc
ccagacggagcaggtgcacgcggtgccgattctggcagctccaccctggatcaacaaatactacattctggacctggcgccggggcgcagcctcgcc
gaatgggctgtgcagcatggtcggaccgtatttatgatttcgtaccgtaaccctgatgaaagtatgcggcatattaccatggatgattactatgtggacggg
attgcaaccgccctggatgtagtcgaagagattaccggcagcccgaagat 
pPOL4.1-block2 
ccctggatgtagtcgaagagattaccggcagcccgaagattgaagtgctgagtatttgcctggggggtgcgatggcggcgatggcagccgcacgtgctt
tcgccgtcggagataaacgtgttagcgcatttacgatgctgaatacgctcctggactacagccaagtgggggagctgggcttactgactgacccggctac
ccttgatctggtagagttccggatgcgccagcagggcttcctttcaggcaaagagatggccggttcctttgacatgattcgtgccaaggatcttgtgtttaact
attgggtatctcgctggatgaaaggggaaaagccggcagcgttcgacattctggcatggaatgaagattctacgagtatgcccgcagagatgcattcac
attatctgcgcagtttgtatggccgcaatgaactggctgaaggtctgtacgttctggatgggcagcctctgaatcttcacgacatcgcttgtgatacgtatgttg
tgggtgcgattaatgaccacatcgtgccttggacctcgtcgtatcaggcagtaaatcttctggggggcgatgtacgttatgttctgaccaacgggggtcacg
tcgccggtgctgtgaatcccccgggtaaacgcgtgtggttcaaagcggttggcgcgccagacgccgagagtggcacgccgttacctgccgatccacaa
gtatgggacgaggcagcgacccgttacgaacatagttggtgggaagattggacggcgtggtctaacaaacgtgccggcgaattagtagcgcctccgg
ccatgggtagcacggcccaccctccgctcgaggatgcccctggtacatacgtttttagcTAAGGATCCAGTCGACCTGCAGGCATGC
AAGCTTGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAG 
pPOL4.2-block1 
GCAGACTTTTCCCTGAACGGTGGCCTGCACATGGGCTAAACTAGTCCGGAGGTATAATTAatgtcagataccc
cgctgccgacgattccggatgaactgaccgccccccttgacctgctgctgacctcaggttcccgctctgtagccgctcgtatgcttccggatagctcctgga
cgcggctgggcgtcgggctggctggccgtccgggcaccgtggcacgtcgtggcggtgcgttggtgcgcgaactgggtgccattgcggcaggtaccagt
gatcgcaccccggcaaaatcagataaacgctttggtgacgccgcctggcaacagaacccagctttgcgccgtgcaatgcaggcgtatctggcaacca
gtcacaccgctgccgcgctgcttgatgatgcggagcttgactggcgcgatcacgagcggatgcggttcgttttagataacttggtggaaggcttatcaccta
cgaataatcctctgctctctccgctgggttggaaagcgatggtagataccggcggcctttcggcggcgcgcggtgtgcgggccttagtacgcgatatgtta
agcaaacctcgggttccagcgatggtagaaccggatgcgttcgcagttggcgaagacgttgccgctaccaagggcgcagtagtgctgcagacccgca
catttgaactgatccactatacacctcaaaccgaaaaagtacatgccactccgttattgatcgtgccaccggtcatcaataaatattatatcttggatattgcg
ccggggcgcagcttaatcgaatatctgctgcaacaaggccagcaagtgttcgcaatctcctggcgcaacccccacgctcgccaccgcgactgggatgc
cgatacctatggctccgctattgtagaagccctcgataccgtacagtgcgttgcc 
pPOL4.2-block2 
cgctattgtagaagccctcgataccgtacagtgcgttgccggcactgattcagcccatgttctgggtacctgcagtggtggtatcctggccgccatggtggc
ggcgcacttaacggagattggagagggggatcgtatcgcggggcttaccttagcggtgacggttctggaccaaactcaagctggcaccgcagcagca
gtgatgtctgaacgggcggctgcggcggcaattcgtgatagcgctgcccgcggttatctggatggtcggaccctggctgaaatgtttgcgtggcttcggcc
gagcgatcttgtgtggcgctactgggtgaacaactatgttcagggtcgcgcgcccgcagcgtttgatgttctgttctggaatagtgacaccacccgtatgac
cgccgcgttgcatcgtgatctggtcctcctggggctgcgcaatgcactgacagctccgggggcagcgacaatgctgggcacaccagtagatctgtctac
agttgccgcagacgcctatgtcgtaggcggtagtgcagatcacttgtgcccgtggcagtctacctatcgcagtgcacgtcttttagggtcgaaagattctcgt
ttcgtcctgtcgagcaacggccatatcgcctcgctggttaacccaccgggcaatccccgcgcgtcctttcgcttcgggcagcccgtgccggaaacgcctg
acgaatggttggctgcagcagagacggctagtgattcatggtggccagactacgcccgttggctggcggaacgtagtggcccggatgtcgatgctccgc
acggcttaggagcgcgccagtttcctccactggctcccgccccgggcacatatgtgcatcactccTAAGGATCCAGTCGACCTGCAGGC
ATGCAAGCTTGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAG 
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Name Sequence 
KpnmdcF-block1 
TGGGCTAGCGAATTCGAGCTCGAAGGAGATATACAAatgacctatgtgattattcatgcgctggcgccaatctttgtaatcatgctg
ttgggattttgggcggggaaagccggaatggtggacaacaaaaatgtttcgctgcttaatatttttgttatggatttcgcactgccagcgaccttgttttcggcg
accgtgcagacaccgtgggcaggcatcgttgctcagagcccgctcgtactcgtactgaccggagccatgtggattacctatgcggcaatctatttcctggc
caccagcgtttttaagcgtaccccgcaggacgccgctgtattgacccttactgtagcattgcccaactatgctgcgctgggcctgccgattctcgggtctgtc
ctgggcgagggcgcgagcacgagcttgtcggtcgcggtctcgattgcttgcgggtcagtccttatgaccccgttctgtct 
KpnmdcF-block2 
cgattgcttgcgggtcagtccttatgaccccgttctgtctgttaatcctggagcgtgaaaaagcgcgggccgccggagaaaattctgggtctacgttagctat
gctgccagtcttgatgtggcgttcagttaaaaaacctattgtgtggggacctctgttaggcgtggttctgagcgccatcgggatcaaaatgcctgagatgctt
ctggcgtccattaaacccttaggcctggcagccactgcggcagctctgtttctcaccggcgtaattctgagcgcccgcaaactgcaactcaatgcgctgat
cgcaaccagtaccattgtaaaactgcttgtgcaaccatttattgcttggggtttagtcatgctgctgggtttgcacgggtcgatcgctattaccgctattttaatg
atcgcactggcggcgggcttttttggcgtggtgttcggcaatcgcttcggagtgcagtcgccggatgctgaagccgtgttgctgttaagcagcgttctctgtatt
cttagcctgccattgttcatctctctgacctccggcctgtagAAGCTTGGCTGTTTTGGCGGATGAGAGAAG 
 
Table 3. Plasmid constructs (A), oligonucleotides (B) and gBlocks (C) used in Chapter 4. 
A 
Name No. Primers Restriction sites 
Backbone 
source Method Description 
pSET152 456     pUC Am
R oriT øC31-int 
Gene (1992) 116, 43–49. 
pSET152(gg) 1422 pSET152gg CF1/R1 EcoRV/BamHI pSET152 
Gibson 
assembly 
pUC AmR oriT øC31-int 
pTet RFP rrnB-term T7-
term. BsaI GG acceptor 
pSET152r(gg) 1423 pSET152-ROP-F1/R1 NheI pSET152(gg) 
Gibson 
assembly 
pMB1 (pUC+rop) AmR 
oriT øC31-int pTet RFP 
rrnB-term T7-term. BsaI 
GG acceptor 
pUWL201PW 1421     
pUC pIJ101 CbR TsR 
ermEp* Mol Gen Genet 
(2000) 264, 477–485. 
pSET152-pc13 - 
pSETpreEryAI-
piece1; 
pSETEryA1 
F3b/R3 
BsaI pSET152(gg) Golden Gate 
pUC AmR oriT øC31-int 
eryAI-Nterm eryAIII-Cterm 
pSET152r-pc13 - pSET152-ROP-F1/R1 NheI pSET152r(gg) 
Gibson 
assembly 
pMB1 (pUC+rop) AmR 
oriT øC31-int eryAI-Nterm 
eryAIII-Cterm 
pSET152r-
preEryAI+TE 1513 
cat-sacB SOE 
F1/R1, 
pSETEryA1 
F2b/R2b 
BglII pSET152r-pc13 
Gibson 
assembly 
pMB1 (pUC+rop) AmR 
oriT øC31-int eryAI-Nterm 
CmR sacB eryAIII-Cterm 
pCK7 2066     
ColE1 SCP2* CbR TsR 
pactI actII-ORF4 eryAI 
eryAII eryAIII Science 
(1994) 265, 509–512. 
pCDF-pUWL-shuttle 2075 pUWL-sgg CF1/CR1 BsaI 
pCDF2. 
P(tac.tac)(gg) 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
pTet RFP rrnB-term T7-
term 
pET28a*SapI 1510 pET.SapI_del F1/R1 SapI pET28a 
Gibson 
assembly 
pMB1 lacI KmR pT7 T7-
term. Backbone SapI site 
removed (G>T) 
pET28a.HisN(sgg) 1511 - NdeI/EcoRI pET28a*SapI Ligation 
pMB1 lacI KmR pT7 pTet 
RFP rrnB-term 2xT7-
term. SapI GG acceptor 
pCDF-pUWL-
shuttle.bryP 1496 BryP-block1/2 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
bryP 
pCDF-pUWL-
shuttle.difA 1497 DifA-block1/2 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
difA 
pCDF-pUWL-
shuttle.fenF 1498 FenF-block1/2 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
fenF 
pCDF-pUWL-
shuttle.pedD 1499 PedD-block1/2 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
pedD 
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Name No. Primers Restriction sites 
Backbone 
source Method Description 
pCDF-pUWL-
shuttle.pksC 1495 PksC-block1/2 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
pksC 
pCDF-pUWL-
shuttle.lkcD 1860 LkcD-block1 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
lkcD 
pCDF-pUWL-
shuttle.virI 1859 VirI-block1 SapI 
pCDF-pUWL-
shuttle 
Golden 
Gate 
CloDF13 SpR lacIq 2xpTac 
virI 
pCDF-pUWL-
shuttle.kirCI 1515 
KirCI-block1/2; 
KirCI.SOEF1/R
1/F2/R2 
SapI pCDF-pUWL-shuttle 
Golden 
Gate, 
Gibson 
assembly 
CloDF13 SpR lacIq 2xpTac 
kirCI 
pUWL201PW.bryP 1506 - XbaI; NdeI/HindIII pUWL201PW 
Gibson 
assembly 
pUC pIJ101 CbR TsR 
ermEp* bryP 
pUWL201PW.difA 1507 - XbaI; NdeI/HindIII pUWL201PW 
Gibson 
assembly 
pUC pIJ101 CbR TsR 
ermEp* difA 
pUWL201PW.fenF 1508 - XbaI; NdeI/HindIII pUWL201PW 
Gibson 
assembly 
pUC pIJ101 CbR TsR 
ermEp* fenF 
pUWL201PW.pedD 1509 - XbaI; NdeI/HindIII pUWL201PW 
Gibson 
assembly 
pUC pIJ101 CbR TsR 
ermEp* pedD 
pUWL201PW.pksC 1505 - XbaI; NdeI/HindIII pUWL201PW 
Gibson 
assembly 
pUC pIJ101 CbR TsR 
ermEp* pksC 
pET28a.HisN.bryP 1501 BryP-block1/2 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 bryP 
T7-term 
pET28a.HisN.difA 1502 DifA-block1/2 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 difA 
T7-term 
pET28a.HisN.fenF 1503 FenF-block1/2 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 fenF 
T7-term 
pET28a.HisN.pedD 1504 PedD-block1/2 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 pedD 
T7-term 
pET28a.HisN.pksC 1500 PksC-block1/2 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 pksC 
T7-term 
pET28a.HisN.lkcD 1862 LkcD-block1 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 lkcD 
T7-term 
pET28a.HisN.virI 1861 VirI-block1 SapI pET28a.HisN (sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 virI 
T7-term 
pET28a.HisN.kirCI 1521 KirCI.GGF2/GGR2 SapI 
pET28a.HisN 
(sgg) 
Golden 
Gate 
pMB1 lacI KmR pT7 kirCI 
T7-term 
pET16b.HisN.ScofabD 1518 FabD.GF1/GR1 NdeI/BamHI pET16b Gibson assembly 
pMB1 lacI CbR pT7 
ScofabD T7-term 
 
B 
Name Sequence 
pSET152gg CF1 tatgacatgattacgaattcgatAtctaagtgagacctTccctatcagtgatagagattg 
pSET152gg CR1 ggctgcaggtcgactctagaggatCcgagacCtataaacgcagaaaggccc 
pSET152-ROP-F1 accgcgacgtatcgggccctggccaGCTAGCcttacacGGAGGcatcaGTG 
pSET152-ROP-R1 cccggggacctgcaggtcgactctaTCAgaggttttcaccgtcatc 
pSETEryA1 F3b ATTATGGTCTCTcaccAgatctCATATGtcttcgaccacccgaac 
pSETEryA1 R3 ATAATGGTCTCAgatCtcatgaattccctccgcc 
cat-sacB SOE F1 Gtctattgctggactcggtac 
cat-sacB SOE R1 gtaccgagtccagcaatagaC 
pSETEryA1 F2b gactgcacaacctggcatatgCaccTgtgacggaagatcacttcg 
pSETEryA1 R2b gcgttcgggtggtcgaagacatatgATCAAAGGGAAAACTGTCCATAT 
pUWL-sgg CF1 ttataCATATGtGAAGAGCtccctatcagtgatagagattg 
pUWL-sgg CR1 aacttAAGCTTaAGCaGAAGAGCtataaacgcagaaaggccc 
pET.SapI_del F1 gaaaataccgcatcaggcGCTatTCcgcttcctcgctcactgactcgctgc 
pET.SapI_del R1 GAatAGCgcctgatgcggtattttctccttacgcatctgtgcggtatttc 
KirCI.SOEF1 cggataacaatttcacacaggaaaca 
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Name Sequence 
KirCI.SOER1 GACGGTGGCGAGCCAG 
KirCI.SOEF2 ctggctcgccaccgtc 
KirCI.SOER2 CCAAGGTAGTCGGCAAATAAAAGCTT 
KirCI.GGF2 CGTATGTAGCTCTTCTatggacgtctacgtgttcccc 
KirCI.GGR2 TTGGATAGCTCTTCAAGCtcacccccgtcccatc 
FabD.GF1 agcggccatatcgaaggtcgtCatATGCTCGTACTCGTCGCTCCC 
FabD.GR1 cgggctttgttagcagccggatccTCAGGCCTGGGTGTGCTCG 
 
C 
Name Sequence 
pSETpreEryAI-
piece1 
ATTATGGTCTCTtaaggacgaggcgatgtcaacctcttgatccttcctatattgttcgcccattgcgtggtcgtcgagtagggggacgcgtggcgga
cctgtcaaagctctccgacagtcggactgcacaacctggcatatgcaccTGAGACCATTAT 
BryP-block1 
cgtatgtagctcttctatgaagaccatctaccttttccccgggcagggctcccagcacaagaagatgggcaaatacctcttcgacaagtaccccgagctg
atccaccaggccgaccagcagctccactattccatcaaggagctctgtttggaggacccggaccagctgctcaacaagacccagttcacccagccgg
cgctctacatcatcaacgccctctccttcctggacaagatcgagctggaatcccacaaaccgtcgtacgtcgccggccacagcctcggcgagtacaatg
cgctgttcgcggccggggccttcgacttcctgacgggcctgaagcttgtgcagaagcggggtctcctcatggaggaggcccccaagggcgcgatggcc
gccatcatcggcatcacgcataaccaggtgaagtgtatcctggaggacatcctgaagagctatccaa 
BryP-block2 
cgtatgtagctcttcttcccccagaagaacatcgacatcgccaacatcaactcggagaagcagttcatcatctcgggcctgtacgacgagatcatcgcgt
gcgagaactcgttcaccaagatgggggccaacttcattccgctcaacgtgtccgccgccttccattcccgctacatgaaggatatcgaaatcaagttcga
gcagtacctgcaaaagttccagctgaaccccctccggaccccggtcatcagcaactactccgcccggccgtaccccaaggagaactaccgggactac
atggtcaagcagatctcgcaccccgtcaagtggtacgagtcgatctcctggctcatccagcaggaccacttcgaattcgaggaagtcggcccggggcgt
gtcctcaccaacctgacgaaccagatcaagcagacgccgctccacatctgagcttgaagagctatccaa 
FenF-block1 
cgtatgtagctcttctatgaacaatctcgccttcctcttcccgggacagggctcgcagttcgtgggcatgggcaagtcgttctggaacgacttcgtgctcgcg
aagcgactcttcgaggaggcctccgacgcgatctcgatggacgtgaagaagctgtgcttcgacggggacatgacggagctgacccgcaccatgaac
gcgcagccggccatcctcaccgtctccgtgatcgcgtaccaggtgtacatgcaggagatcggtatcaagccgcacttcctggcgggtcactcgctgggc
gagtactcggccctggtctgcgccggcgtgctctcgttccaggaagccgtgaaactgatccgccagcggggcatcctcatgcagaacgcggaccccga
acagctgggaacgatggcagccatcacgcaggtctatatccagcccctgcaggatctgtgcacggagatcagcaccgaggacttccccgttggtgtcg
cgtgcatgaactccgaccagcagcacgtgatcagcggtcaccgtcaggcggtagagttcgtcatcaagaaggcggagcgcatgggcgccaaccaca
cgtacctgaatgtgagcgccccgttccactgaagagctatccaa 
FenF-block2 
cgtatgtagctcttctcactcctccatgatgcgaagcgccagtgagcagttccagacggcactgaaccagtactccttccgtgacgcggagtggccgatc
atctccaacgtgacggccatcccctacaacaacggtcactccgtgcgggaacacctgcagacccacatgaccatgcccgtccgctgggccgagtccat
gcactacctgctcctccacggagttaccgaggtcatcgagatgggtcccaagaacgtcctggtcgggctcctgaagaaaatcacgaaccacatcgctg
cgtacccgctggggcagacgtccgacctgcacctcctgtccgactccgcggagcggaacgaaaacatcgtgaacctgcggaagaagcagctgaac
aagatgatgatccagagcatcatcgcccgcaactacaacaaggacgcgaagacctacagcaacctgaccacacccctgttccctcagatccagctcc
tgaaggagcgggtagagcgtaaggaagtggaactgagcgccgaggagctggagcacagcatccacctgtgccagctgatctgcgaggcgaagca
gctgcccacgtgggagcagctcagaatcctgaagtgagcttgaagagctatccaa 
PksC-block1 
cgtatgtagctcttctatgatcacctacgtctttcccggccaggggtcccagaagcagggcatgggctcggggctgttcgatgagttcaaggagctgaccg
accaagcggacgagatcttgggctactcgatcaagcgtctctgcctggagaacccgtactcgaacctgaacaagacccaattcacgcagccggcact
gtacgtcgtgaacgccctctcgtacctcaagaagatccgggacgaggaggtcaagccggacttcgtggcgggccactccctgggcgagtacaacgca
ctgttcgcggccgaggcgttcgactttgagaccggactccaactggtccgcaagcgcggcgagctgatgagccttatctcgaacggaggcatggcggc
cgtcatggggctgaacgaggagcaagtcgccaaggcgctgaaggagtaccacctctgaagagctatccaa 
PksC-block2 
cgtatgtagctcttctctccacgacgtcgacatcgcgaacgtcaacgccccgtaccagatcgtgatctcgggcaagaaggacgagatcgagaaggcgg
cgtccctcttcgaaaccatgaccgaggtcacgatggtcctgcccctgaacgtgtcgggagccttccactctcgctacatgaacaaggccaaggaggagt
tcgaagagttcctccacgccttctacttctcgccgccgtccatccccgtaatctccaacgtgtacgccaagccctacacgtacgagttcatgaagcagacg
ctggctgaccagatcaaccactccgtcaagtggaccgacagcatctcctacctgatgaagaagggtcatatggaattcgaggaggtgggcccgggga
acgtcctcaccggactaatccaccgcatcaaaaaggatgcggaggctatgccgcgttgagcttgaagagctatccaa 
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Name Sequence 
PedD-block1 
CGTATGTAGCTCTTCTatgggcgagcagcttttcgacaggtttcccaacatcatcgaggccgccaacgacatcctcgggtactcgatcaagac
cctgtgcctggaggacccgcagagacagctccgcctcacccagtacacgcaggtggccctctacgtcgtgaacgccctgacctaccgtcagcacctgc
agcagggaggcggtctgcccgacttcgtggcggggcactcgctgggagagtacaacgccctggagtcggccggcgtattttcgttcgaggacggcctc
cggctggtgcagaagcggggcgacctgatgagccaggcgccgcgtggcgcgatggccgcgatcctcggcatcagcgccgactccgtggccgggat
cctggcggagcaaggcctgacgcgcatcgacatcgcaaactacaacgcaccgacccagacgatcatctcgggtctcgaggccgacattcgtgacgc
gcaagccgtgttcgaatcctgccaggcgatgtacgtcccgctcaacaccagcggcgccttccacTGAAGAGCTATCCAA 
PedD-block2 
CGTATGTAGCTCTTCTcactcgcgctatatgcagtccgcacgcgacgagtttgcgcagttcctggaggcgttcgagttccgggacccccagat
ccccgtggtggcgaacgtgaccgcgaagccgtacgtcggcaccgaggtcgtccgcaccctggccgaccagctcacgggtagcgtccgatggctgga
ctccatgcgcttcctgctcgatcagggcgtgacggagttccgtgaactgggacccggggacgtgctgagcaagctcgtggagagcatccgctcgagcg
ccatgtccaagcccgtgtccgagttcgctgcggagaactcccagcagctggtcgacgagtggaaccgcacctgcccgatcggctcgcgcgtccgcgtc
aaggggtacgacgacatactggtcacgaagtcgcgtgccgtgctgctgttcgggcaccgggccgccatctacatggaaaactaccagggttacttcgct
ctgtccgaggtcgagcccctcatcgaacagcagcccctggtggagaaggtatggTGAGCTTGAAGAGCTATCCAA 
DifA-block1 
cgtatgtagctcttctatgttcctgttcctgtgccgctgcctgcaccagtcgatctacgagatccgagacgtcttcgtctggcgctccacctgcgacatccaga
actggaggtgcggcaaggacgaggacaagatgctgacgttcgtcttcccggggcagggttcccagttcaagggcatgggtgcgggcctgttcgacga
gttccaggacctgacccgccaggcggacgacatcctggggtacagcatcgaggagctgtgtctggaggaccccaaccaccagctgggcaagaccc
agttcacccagccggcactgtacaccgtgtcggccctctcgtacctgaagaagatgaaggagagcgggcgtgagcccgactacgcggccggacact
cgctgggcgagtacaatgccctgttcgcagccgggtgctttgatttcgagacaggactgcaacttgtcaagaagcggggagaactgatgtccaaggcg
gcccccggcggatgaagagctatccaa 
DifA-block2 
CGTATGTAGCTCTTCTGGAatggcggccgtgctgggcttcaccgcagagcaggtgaaggaggtgctgtcagactaccacctcacgggtat
cgacatcgccaaccacaacagcccgtcccagatcgtcatcgcggggaccaagcaggacatcgagaaggccggcccggtgttcgaaaaggcgggc
gtgcggatgtacctccccctcaatgtgtcgggggcgttccattcgagatatatgaaggacgccgagaaggagttcgcggactacctggaagagacggc
cttcctgcccctgcgcttccccgtcatctcgaacctgcacgcggccccgtacaagaacgacgagatcaagaccaacctcacgctgcagatgacaaacc
aggtcaagtggacggacacgatccggcgtctcatgggactggagaacaacgagatcgcggaggtgggacccggcgaggtgctgacgaagctgac
gcgtcaaatcaagaaggacgccgtgcccttgTGAGCTTGAAGAGCTATCCAA 
KirCI-block1 
cgtatgtagctcttctatggacgtctacgtgttccccggccagggggcgcaggtcaagggcatggggcgggacctcttcgaccgcttcccggagctcgtg
gagcgggcggacgccgtcctgggctactcgatccgggagctctgcctggaggacccgggccgcaacctgcgcgacacccgctacacgcagccggc
cctgtacgtggtcggggcgctgtcctggctcgccaccgtccaggagggcggtcggctcccggactacctgctgggccacagcctgggcgagttcgcgg
ccctgttcgccgcaggcgtctacgacttcgaaacgggcctccggctggtcgccgagcggggccgcctgatgggccaggtcacgggtggcacgatggc
cgccgtgtccgccgtggactcgagcctcgtgcgcgaggtcctgcgcgacgacgaactcagcggcctgtgaagagctatccaa 
KirCI-block2 
cgtatgtagctcttctctggacatcgccaactacaacgcgcctacccagacggtcgtagccgggccggcggacgctgtcaaccgggccctggcggtctt
caaggacaagggtgcccgctgcgcgccgctgaacgtgagcgccccgttccacagccggtacatggcgcaggccgcggaggaattcggccggctcct
ggatgcgactgccttcgcagcccccaagatcccggtaatctcgaatgtcgacgcgagaccctacgagcccgacgcggtggccgcgaccctccggcg
ccagatcgtgtcgcccgtccgctggacggactccatccggctcctgatgggacgggggtgagcttgaagagctatccaa 
VirI-block1 
CGTATGTAGCTCTTCTatgacccgtatcttcatgttccccggacagggcgcacagcgtgtgggtatgggacggaccctcctcgaccgattccc
ggacctggagcgggaagcctcggacacgctgggctactccctgcgccggctgtgcctcgaagacccggagggacggctgggtaacacgcggtaca
cccagcccgcaatgttcgccgtcaacgccctggcccaccgtgcggcagtggaagacggtgcccgtccggacatcgccatcggtcacagcctcggcga
gtacaacgcgctggaagccgcgggagtgttcggcttcacggacggcctgcgcctggtcgcagcccgtgccgcggctatggcggaagtcggcggagg
cggtatgtcggcagtggtcggactcaccgaaacgaagctgcgcttcctgctgctgcgcgctggcttcgctaccctcgacctggcaaacctgaacaccgc
gtcgcagaccgtcctggccggtcccctcgaagacctggaagaggcgggtcaggtcctggaagacgcgggagcccgcatggtacggcgactggacgt
gtccggtcccttccattcccgttacatggcaccggctgcggccgcactggtacccctggttcggtccgcacggctgcgtccgccggcgttcccagtgatcg
cgaaccggacagcccagccttaccgggccgaactcgctgccgacctcctcctgcagcaaatcgaccacccagtccgctggcacgaaaccgtccgga
ccctgctcgacgaaccggacgcagtgttcacggagatcggtgaatcgacggtcctcacatcgatggtacgccagatcaagcgtgacgctgagcctgcc
cgtgccgcacgccctcggcaggcagtggcaTGAGCTTGAAGAGCTATCCAA 
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Name Sequence 
LkcD-block1 
CGTATGTAGCTCTTCTatggctggcgatgtcgtcatgttccccggccagggttcccagcgcatcgggatgggaaaggaggtcttcgacgcgta
cccccagctgtgcgaccgggccgacgagatcgtgggccactcgctgcgggagctgtgcctcaaggacccggacggtcgcctcaacgagacgagcc
gcacccaggaggccgtctacttcgtcagctgcctgatgtacctggcgtacgccgaggaacacggtgcggagcaggtgcgctgcctgaccggtcactcc
ctgggtctgtaccccgcactgttcgccgcgggagtcttcgacctgttcgagggcctcgagatcgtgtcccgccgcggagcgctgatgcaggaggcacgg
gacggtgccatggtggcagtcctgggaccgcgggcctccgagatcgacgaccacctggcacggctcgagttcttcgacgtggacgtcgcaaactaca
actccccggagcaggtcgtcctcagcgcactcaagcctcgcctggaggagctggtgccgcgcctggaggaaacgggtcaccggtgcgtctggctccc
cgtctccggagccttccactcccgccacatggagccggctcgcctgcgcttcgcacagttcctgcgcgaccggaccttcaccccgccgaccaagccggt
cgtcagcacgaccagcggtcgcaccctgggggctcgccacctcctcgaggagatggtgttccagctcgtcaagcccgtccggtggtggcagacggtg
acccacctgtcccgcaccggacacaagaccttcgacgaggtgggtcccgggcgtgtgctcaccaagctgtccgcggagatcctcggtgacgagccttc
gccgcaggctgagccgcgtaagTGAGCTTGAAGAGCTATCCAA 
 
Table 4. Plasmid constructs (A), oligonucleotides (B) and gBlocks (C) not described in Materials 
& Methods sections. 
A 
Name No. Primers Restriction sites Backbone PCR template Method Description 
pET16b. 
BsuyngE 720 yngE.F1, yngE.R1 NdeI/BamHI pET16b 
B. subtilis 
colony ligation 
B. subtilis putative 
propionyl-CoA 
carboxylase 
carboxytransferase 
subunit 
pET16b. 
BsuyngH 732 yngH.F2, yngH.R1 NdeI/BamHI pET16b 
B. subtilis 
colony ligation 
B. subtilis putative 
propionyl-CoA 
carboxylase biotin 
carboxylase subunit 
pCWori-HisN. 
BsuyngHB. 
EcobirA 
736 yngHB.F1, yngHB.R3 NdeI/SalI pCWOri-AccA2.birA 
B. subtilis 
colony ligation 
B. subtilis putative 
propionyl-CoA 
carboxylase biotin 
carboxy carrier protein 
subunit 
pET16b. 
CgldtsR1 923 
Cg.dtsR1.pET16b.F1, 
Cg.dtsR1.pET16b.R1 NdeI pET16b 
pCDF.P(Tet)-
acs.accBC.dts
R1 
Gibson 
assembly 
Corynebacterium 
glutamicum ACCase 
beta 
(carboxytransferase) 
subunit, synthetic 
pET16b. 
CglaccE 924 
Cg.accE.pET16b.F1, 
Cg.accE.pET16b.R1 NdeI pET16b 
pCDF.P(Tet)-
acs.accBC.dts
R1 
Gibson 
assembly 
Corynebacterium 
glutamicum ACCase 
epsilon subunit, 
synthetic 
pET16b. 
CglaccBC 925 
Cg.accBC.pET16b.F1, 
Cg.AccBC.pET16b.R1 NdeI pET16b 
pCDF.P(Tet)-
acs.accBC.dts
R1 
Gibson 
assembly 
Corynebacterium 
glutamicum ACCase 
alpha (biotin 
carboxylase/biotin 
carboxy carrier protein) 
subunit, synthetic 
pCDFDuet-1-
dszAT-ø 1191 
pCDFDuet_DszsAT.F1, 
pCDFDuet_DszsAT.R1 NcoI/HindIII pCDFDuet-1 pFW3 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
dszAT pT7 T7-term. 
DszAT has C-terminal 
TSLRPHNA 
appended. 
pET16b. 
EcoprpE 1196 prpE F2, prpE R2 NdeI/BamHI pET16b 
E. coli DH10b 
colony 
Gibson 
assembly 
pMB1 CbR lacI pT7 
EcoprpE T7-term 
pCDFDuet-1-
ø-SCo.matB 1199 
pCDF-Duet MatB F1, 
pCDF-Duet MatB R2 NdeI/KpnI pCDFDuet-1 
S. coelicolor 
gDNA 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
pT7 ScomatB T7-term 
pCDFDuet-1-
dszAT-
SCo.matB 
1200 pCDF-Duet MatB F1, pCDF-Duet MatB R2 NdeI/KpnI 
pCDFDuet-1-
dszAT-ø 
S. coelicolor 
gDNA 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
dszAT pT7 ScomatB 
T7-term. DszAT has C-
terminal TSLRPHNA 
appended. 
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Name No. Primers Restriction sites Backbone PCR template Method Description 
pCOLADuet-
1-ScoaccA2-
ScopccBE. 
EcobirA 
1210 PCCase_birA.F1, PCCase_birA.R1 KpnI 
pCOLADuet-
1-accA2-
pccBE 
pBAD33.birA Gibson assembly 
S. coelicolor PCCase: 
pTrc AccA2 pT7 pccB 
pccE EcobirA 
pCDFDuet-1-
RBS500. 
dszAT.ø 
1224 pCDF-DszAT-500-F1, pCDFDuet_DszsAT.R1 NcoI/HindIII pCDFDuet-1 pFW3 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
calc.500-rate RBS 
dszAT pT7 T7-term. 
DszAT has C-terminal 
TSLRPHNA 
appended. 
pET28a. 
ScomatB. 
500dszAT 
1226 
pET28a-matB-DszAT-
R1, pET28a-matB-
500DszAT-F1 
XhoI pET28a. ScomatB 
pCDFDuet-1-
RBS500. 
dszAT.ø 
Gibson 
assembly 
pMB1 KmR lacI pT7 
His6.ScomatB 
calc.500-rate RBS 
dszAT T7-term 
pBAD18-Cb. 
500ScomatC 1254 
MatC F1.474, MatC G 
R2, MatC NF1/ NR1 KpnI/HindIII pBAD18-Cb 
S. coelicolor 
gDNA; 
neighborhood 
PCR 
Neighbor
hood 
PCR, 
Gibson 
assembly 
CbR pBad calc.474-rate 
RBS ScomatC  
pBAD18-Cm. 
500ScomatC 1255 
MatC F1.474, MatC G 
R2, MatC NF1/ NR1 KpnI/HindIII pBAD18-Cm 
S. coelicolor 
gDNA; 
neighborhood 
PCR 
Neighbor
hood 
PCR, 
Gibson 
assembly 
CmR pBad calc.474-
rate RBS ScomatC  
pCDFDuet-
1.nphT7-0 1280 nphT7 pCDF GF1/GR1 NcoI/HindIII pCDFDuet-1 
pTRC33-
npht7-phaB 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
nphT7 pT7 T7-term 
pCDFDuet-1. 
ø-phaB 1281 phaB pCDF GF1/GR1 NdeI/KpnI pCDFDuet-1 
pTRC33-
npht7-phaB 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
pT7 phaB T7-term 
pCDFDuet-1. 
nphT7-phaB 1282 phaB pCDF GF1/GR1 NdeI/KpnI 
pCDFDuet-
1.nphT7-ø 
pTRC33-
npht7-phaB 
Gibson 
assembly 
CloDF13 SpR lacI pT7 
nphT7 pT7 phaB T7-
term 
pSV272.1-
Mod6noTE 1283 
MBP-M6 F1,  
MBP-M6 R1 SfoI pSV272.1 PRSG54 
Gibson 
assembly 
His6-MBP-TEV-DEBS 
module 6 fusion, no 
thioesterase domain 
(cutoff from published 
HisN-ACP6 construct) 
pSV272.1-
Mod6AT0 
noTE 
1284 MBP-M6 F1,  MBP-M6 R1 SfoI pSV272.1 pAYC138 
Gibson 
assembly 
His6-MBP-TEV-DEBS 
module 6 
fusion/Ser>Ala mutant, 
no thioesterase domain 
(cutoff from published 
HisN-ACP6 construct) 
pET28a.HisN. 
PIKS-KR1 1324 
PIKS_KR1 F2, 
PIKS_KR1 R2 BsaI pET28a(gg) 
PIKS-KR1-
block2 
Golden 
Gate / 
Gibson 
assembly 
Pikromycin synthase 
module 1 KR 
(synthetic). To correct 
design error, GG to 
assemble vector, 
blocks 1 and 3; Gibson 
on PCR of block2 
(sequential one pot) 
pET28a.HisN. 
GDH 1325 GDH F1, GDH R1 BsaI pET28a(gg) 
B. subtilis 
colony 
Golden 
Gate 
B. subtilis glucose 1-
dehydrogenase 
pXHB.ø-
RpamatB. 
Ecoacs 
1519 pCDF-ACS GF1/GR1 (Table 2, B) XbaI/HindIII 
pXHB.ø-
matB 
pCDF.P(Tet)-
acs.accBC.dts
R1 
Gibson 
assembly Empty pBAD site 
pXHB-
ScomatC-
RpamatB. 
Ecoacs 
1550 
pCDF-ara-ScoMatC 
GF1/GR1  
(Table 2, B) 
XbaI/HindIII 
pXHB.ø-
RpamatB. 
Ecoacs 
pBAD18-
Cb.500matC 
Gibson 
assembly 
CloDF13 SpR lacI araC 
pBAD ScomatC rrnB-
term pT7 RpamatB 
Ecoacs T7-term 
pPOL1-bc 1590 PhaB GF2 / FPHB PhaC R1 (Table 2, B) NcoI/BamHI pTRC99a pPOL1 
Gibson 
assembly pPOL1 without nphT7 
pPOL3 1627 
TetR-pTet-pPOL GF1, 
TetR-pTet-nphT7 GR1 
/ nphT7 pCDF G F1, 
NphT7 pPOL GR1 
NdeI pPOL1 
pCDF.P(Tet)-
acs.accBC.dts
R1 
Gibson 
assembly 
ColE1 CbR lacIq tetR 
pTet nphT7 pTrc 
phaBC rrnB-term 
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pPOL2 1668 PhaC F10, rrnB R2 AatII/XbaI pPOL1 pBT33-phaABCP-crt 
Gibson 
assembly 
pPOL1 but with 
synthetic phaP1 gene 
after phaC 
pXHB3. 
EcoprpE 1695 
pXHB3.GF1, 
pXHB3.GR1 NdeI/NotI 
pXHB1.Ecop
rpE n/a 
Gibson 
assembly 
pXHB1.EcoprpE but 
replaced T7 promoter 
with T5 
pET21c. 
KSAT03.phaB 1967 
KSAT3-PhaB GF1, 
KSAT3-PhaB GR1 
EcoRI/HindI
II 
pET21c-
KSAT03 pPOL1-nb 
Gibson 
assembly 
pMB1 CbR lacI pT7 
DEBS-KS3AT30 phaB 
T7-term 
pPOL1Cm-bc 2087 n/a 
pPOL1-bc: 
ApaI/HindIII 
pTRC33: 
EcoRV/XbaI 
pPOL1-bc / 
pTRC33 n/a 
Gibson 
assembly 
pPOL1-bc with 
backbone exchanged 
from pTrc99a to pTrc33 
 
B 
Name Sequence 
yngE.F1 attCATATGctgatggattatgaaaagg 
yngE.R1 ggatccctcgagcccggggtcgacgagctcggtactctagttacaccggataaaccgg 
yngH.F2 gaggtgaaCATATGtttacaaaagtactgatcgc 
yngH.R1 attTCTAGAGGATCCtttataggtgctgtttcaaaaag 
yngHB.F1 attCATATGacggttagcatacaaatg 
yngHB.R3 attGTCGACGGATCCCCCGGGCTCGAGGAGCTCcaaattattgagtggaattgctc 
Cg.dtsR1.pET16b.F1 cagcagcggccatatcgaaggtcgtCATATGACCATTTCCAGCCCG 
Cg.dtsR1.pET16b.R1 CTTTGTTAGCAGCCGGATCCTCGAGcataTTACAGCGGCATATTACCATGC 
Cg.accE.pET16b.F1 cagcagcggccatatcgaaggtcgtCATATGtccgaagagaccacgc 
Cg.accE.pET16b.R1 CTTTGTTAGCAGCCGGATCCTCGAGcataTTAGAAAAAGTTCACGTTCTGAAACG 
Cg.accBC.pET16b.F1 cagcagcggccatatcgaaggtcgtCATATGAGCGTTGAAACCCGC 
Cg.AccBC.pET16b.R1 CTTTGTTAGCAGCCGGATCCTCGAGcataTTACTTAATCTCCAGCAGAACGAC 
pCDFDuet_DszsAT.F1 gtttaactttaataaggagatataccATGAAAGCATACATGTTTCCCGGGC 
pCDFDuet_DszsAT.R1 CTTAAGCATTATGCGGCCGCAAGCTTGTTACGACGACGAGGGGCTGGG 
prpE F2 cagcagcggccatatcgaaggtcgtcatATGTCTTTTAGCGAATTTTATCAGCGTTCGATTAACGAA 
prpE R2 ctttgttagcagccggatcctcgagcataCTACTCTTCCATCGCCTGGCGGATCT 
pCDF-Duet MatB F1 ttagttaagtataagaaggagatataCATatgtcctctctcttcccggccctct 
pCDF-Duet MatB R2 gtttctttaccagactcgagggtaccTCAGTCACGGTTCAGCGCCCG 
PCCase_birA.F1 Gggccgcacctactggccgacctgaaggagatatacgatgaaggataacaccgtgccactgaaattg 
PCCase_birA.R1 Cagcggtttctttaccagactcgagggtaccttatttttctgcactacgcagggatatttcaccgccc 
pCDF-DszAT-500-F1 ccctgtagaaataattttgtttaactttaatCTCAAGCGTAAAGTTCCACAAGACGCAatgaaagcatacatgtttcccgggc 
pET28a-matB-DszAT-R1 gatctcagtggtggtggtggtggtgTTACGACGACGAGGGGC 
pET28a-matB-500DszAT-F1 ggcgctgaaccgtgactgactcgagCTCAAGCGTAAAGTTCCACAAG 
MatC F1.474 Ggctagcgaattcgagctcggtaccgttttagccaccagttcgaaaaaatcaactaatatgtcccccgaactcatctc 
MatC G R2 caggctgaaaatcttctctcatccgccaaaacagccaagcttCTACCCGAAGCCGGGCAC 
MatC NF1 gaccccttgacgtgatcc 
MatC NR1 ccgggaagagagaggaca 
nphT7 pCDF G F1 gtttaactttaataaggagatataccATGACCGACGTTCGTTTTCG 
nphT7 pCDF G R1 cttaagcattatgcggccgcaagcttgTTAccactcgatcagcgcg 
phaB pCDF G F1 ttagttaagtataagaaggagatataCATATGacccagcgcatcgcttac 
phaB pCDF G R1 gtttctttaccagactcgagggtaccTTAgcccatgtgcaggccac 
MBP-M6 F1 caacctcgggatcgaggaaaacctgtattttcagggcgccATGAGCGGTGACAACGGC 
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Name Sequence 
MBP-M6 R1 cgtttgatctcgagtgcggccgcAAGCTTtcaGAGCTGCTGTCCTATGTGGTC 
PIKS_KR1 F2 AACGTTGGGCAGGTCTGGTTGATCTgcctgcccagccggatg 
PIKS_KR1 R2 TTGCACGATGTGCACGACGAACCTGttccgctgtcagggtatcaac 
GDH F1 ATTATGGTCTCTTATGTATCCGGATTTAAAAGG 
GDH R1 ATAATGGTCTCAAAGCTTAACCGCGGCCTGCCTGG 
PhaB G F2 cggataacaatttcacacaggaaacagaccaGgagatatataAtgacccagcgcatcgc 
TetR-pTet-pPOL GF1 tacgcatctgtgcggtatttcacaccgcatCGCTTTATGAATCTAAAGGGTGG 
TetR-pTet-nphT7 GR1 GTCATGGTATATCTCCTTATTAAAGggatcCtgaagacgaaagggcctcg 
NphT7 pPOL GR1 TCAGAGCAGATTGTACTGAGAGTGCACCATctcgaGttaccactcgatcagcgcg 
PhaC F10 ggactttgccgacacgg 
rrnB R2 gaccgcttctgcgttctg 
pXHB3.GF1 caaatatgtatccgctcatgagacGgttttgcaccattcgatg 
Name Sequence 
pXHB3.GR1 caggcgggcaaacagattcgcgttcaTatgtatatctccttgagctctgtg 
KSAT3-PhaB GF1 cgagctggcctaccgcgttgcttaaGAATTCAAGGAGATATATAATGACCCAGCG 
KSAT3-PhaB GR1 gtggtggtgctcgagtgcggccgcaagcttTTAGCCCATGTGCAGGCCAC 
 
C 
Name Sequence 
PIKS-KR1-
block1 
ttatggtctcttatggcaaccggtgatgattggcgttatcgtattgattggaaacgtctgcctgcagcagaaggtagcgaacgtaccggtctgagcggtcgtt
ggctggcagttacaccggaagatcatagcgcacaggcagcagcagttctgaccgcactggttgatgccggtgcaaaagttgaagttctgacagccggt
gcagatgatgatcgtgaagcactggcagcacgtctgacagcgctgaccacaggtgatggttttaccggtgttgttagcctgctggatggtctggttccgca
ggttgcatgggttcaggccctgggtgatgcaggtattaaagcaccgctgtggtctgttacccagggtgcagttagcgttggtcgtctggatactccggcaga
tcctgatcgtgcaatgctgtggggtctgggtcgtgttgttgcactggaacatccggaacgttgggcaggtctggttgatctcgaatgagaccatta 
PIKS-KR1-
block2 
Ttatggtctctcgaagcctgcccagccggatgcagcagcactggcccatctggttaccgcactgagcggtgccaccggtgaagatcagattgcaattcg
taccaccggtctgcatgcacgtcgtctggcacgtgcaccgctgcatggtcgtcgtccgacccgtgattggcagccgcatggcaccgttctgattacaggtg
gtacaggtgcactgggtagccatgcagcacgttggatggcacatcatggtgcagaacatctgctgctggttagccgtagcggtgaacaggcaccgggt
gcaacccagctgaccgcagaactgaccgcaagcggtgcccgtgttaccattgcagcatgtgatgttgcagatccgcatgcaatgcgtaccctgctggac
gcaattccggcagaaacaccgctgacagcagttgttcataccgcaggcgctctggatgatggtattgttgataccctgacagcggaattcctgagaccatt
a 
PIKS-KR1-
block3 
Attatggtctctttcccaggttcgtcgtgcacatcgtgcaaaagcagttggtgcaagcgttctggatgaactgacacgtgatctggatctggatgcatttgttct
gtttagcagcgttagcagcacactgggtattccgggtcagggtaattatgcaccgcataatgcatatctggacgccctggcagcccgtcgtcgcgcaaca
ggtcgtagcgcagtgagcgttgcctggggtccgtgggatggtggtggtatggcagccggtgatggtgttgccgaacgtctgcgtaatcatggtgttccggg
tatggacccggaactggcgctggcagcgctggaaagcgcactgggacgtgatgaaaccgcaattaccgttgcagatatcgattgggatcgtttttatctg
gcatatagcagcggtcgtccgcagccgctggttgaagaactgccggaagttcgtcgtattattgatgcacgtgattaagctttgagaccattat 
 
